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Abstract
Hepatitis C virus (HCV) causes acute and chronic liver diseases in humans. Its two 
envelope proteins, E1 and E2, are heavily glycosylated. They interact with host cell 
receptors and provide a target for host immune recognition. The host virus interactions 
determine the pathogenesis and outcome of HCV infection.
L-ficolin is a soluble pattern recognition molecule of importance in innate immune 
defence against microorganisms. It activates the lectin complement pathway upon binding 
to carbohydrate recognition patterns on microorganisms. It was hypothesised that L-ficolin 
could interact with HCV glycoproteins. Both recombinant and serum derived L-ficolin 
were investigated for binding to the envelope glycoprotein E1E2 of HCV. Specific, dose-
dependent binding of L-ficolin to HCV glycoprotein E1E2 was observed. The interaction 
between L-ficolin and HCV particles in infected sera was also demonstrated. Binding of 
L-ficolin to HCV pseudoparticles expressing E1E2 glycoproteins resulted in neutralisation 
of virus infectivity. The serum L-ficolin level was significantly higher in patients with 
mild HCV liver fibrosis compared to patients with severe HCV liver fibrosis. These 
results suggest a potential protective effect of L-ficolin, as an innate immune defence, 
against HCV infection.
To study the role of anti-HCV E1 and E2 (anti-E1E2) in HCV disease, the levels of anti-
E1E2 antibodies were evaluated in 230 sera of patients with chronic hepatitis C by 
enzyme-linked immunosorbent assay. The antigens used were recombinant HCV 
glycoproteins derived from genotype 1 (H77c) and genotype 3 (UKN3A1.28). 
Seroreactivity was greater when sera were tested against antigen derived from their 
homologous genotype than against heterologous antigen. The seroreactivity was inversely 
proportional to the viral load and to the degree of liver ﬁbrosis. These results demonstrate 
that seroreactivity against E1E2 depends upon the genotypic origin of the E1E2 antigens 
and the infecting genotype, and suggest a possible protective effect of anti-E1E2 against 
disease progression.
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1. Introduction
1.1. Hepatitis C Virus  
The Hepatitis C virus (HCV) was first recognised in 1989 as a parenterally 
transmitted agent responsible for most transfusion-acquired non-A, non-B hepatitis 
(NANBH) cases. It was identified by Choo et al., who cloned a complementary 
DNA (cDNA) of the virus from a patient diagnosed with NANBH [1]. The virus 
was termed Hepatitis C virus (HCV), and since then it has become a target for 
painstaking research. HCV infection is a significant global health problem due to 
viral persistence and progression to chronic hepatitis, leading to cirrhosis and 
increased risk of hepatocellular carcinoma (HCC). It is also the leading factor for 
liver transplantation worldwide [2]. 
1.1.1. Epidemiology of HCV Infection
World Health Organisation (WHO) estimates that about 170 million people (3% of 
world population) are infected with HCV around the world [3]. Epidemic 
proportions of HCV infection have been reached and more than one million new 
cases of infection are reported annually, worldwide [4]. The prevalence of HCV in 
the UK is less than 1% and it varies widely in different parts of the world, ranging 
from 0.003% in Sweden up to around 20% in highly endemic areas such as Egypt
[5, 6]. This variation partly reflects different modes of HCV transmission. The 
high prevalence rate reported from Egypt is attributed to the use of non-sterile 
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needles during the Egyptian parenteral antischistosomal therapy mass-treatment 
campaigns in the 1960s-70s [5]. Some worrying data suggest that the silent 
epidemic of HCV will continue to remain a major health hazard in the developing 
world, at least in the near future [6].
HCV is transmitted primarily by parenteral routes such as blood transfusion, 
intravenous drug use (IVDU), tattoos, contaminated medical equipments, and 
rarely by sexual and vertical routes. Although the incidence of transfusion-
associated HCV infection in developed countries has been reduced since the 
1990s, due to improved blood donor screening [3, 7], injecting drug use accounts 
for most newly acquired HCV infections [8, 9]. Blood transfusions from 
unscreened donors and unsafe therapeutic procedures are still the main modes of 
transmission in developing countries [6]. Centers for disease control and 
prevention (CDC) reported that the risk of HCV transmission per needle-stick 
exposure in health care workers is 1.8% [10]. Sexual transmission of HCV can 
occur, especially in long-term partners of HCV-infected patients. However, this 
could be partly due to sharing of sharp kits such as razors and toothbrushes [11, 
12]. HCV infection has also been reported in HIV-positive men who have sex with 
men (MSM) [13] and even, although at a lower prevalence, in MSM who are not 
injecting drug users [14]. The rate of perinatal transmission, which is the 
commonest cause of transmission of HCV infection to children, is 4-7% per 
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pregnancy in women with detectable viraemia [15]. In all cases, a greater risk of 
transmission is associated with HIV co-infection. 
HCV infection is diagnosed serologically by detection of anti-HCV antibodies to 
structural and non-structural proteins or by detection of HCV ribonucleic acid 
(RNA) in the serum [16]. 
Cumulative laboratory reports of HCV infection in the UK show rises in HCV-
related disease (including hospital admissions, transplants and deaths), as well as 
newly confirmed cases (figure 1.1) [17]. Between 1992 and 2007, a total of 62,238 
laboratory-confirmed diagnoses of hepatitis C infection from England were 
reported. About 69% of reported cases were men and 51% of cases were amongst 
individuals aged between 25 and 39 years. The major risk factor for acquisition of 
infection is injecting drug use, accounting for 93% of cases with known risk 
factor. 
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Figure 1.1: Laboratory reports of hepatitis C infection from England.
The Health Protection Agency Centre for Infections receives, electronically, 
confirmed laboratory cases of hepatitis C. A laboratory confirmed case is an 
individual with a positive test for hepatitis C antibody (anti-HCV) or detection of 
hepatitis C viral ribonucleic acid (RNA) in the serum. For infants aged less than 
one year, who may acquire maternal anti-HCV antibodies, diagnosis needs further 
confirmation by hepatitis C RNA testing or by a subsequent positive anti-HCV test 
in the second year of life to be included. This graph shows a consistent rise in the 
number of newly-acquired HCV infection, suggesting an increased disease burden 
on health care services. Adapted from HPA, 2008.
1.1.2. Natural History of HCV Infection
HCV is an important cause of acute and chronic liver disease in humans (figure 
1.2). In most cases, acute HCV infection is mild and asymptomatic. It is estimated 
that only 10-15% of cases present with an acute hepatitis, manifested clinically as 
jaundice, while 10-20% present with non specific symptoms including malaise, 
anorexia, abdominal pain and fatigue [18, 19].
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Although 15-25% of cases spontaneously resolve the infection by clearing the 
virus within 2-6 months, infection persists in up to 80% of infected individuals. 
Persistent HCV infection may progress over decades, resulting in a broad spectrum 
of clinical outcomes including chronic hepatitis and cirrhosis. Cirrhosis results in a 
decompensated end stage liver disease (ESLD) and is a clear risk factor for the 
development of hepatocellular carcinoma (HCC) [2, 20-22]. 
Figure 1.2: HCV disease progression.
This diagram shows person-to-person variability in HCV outcome. The HCV 
disease is usually insidious and subclinical. Acute HCV infection generally causes 
a mild course of disease, and patients are usually asymptomatic. However, 80% of 
patients who contract acute HCV infection will develop persistent infection, which 
often lasts for decades. Chronically infected patients have the risk of serious 
complications of liver disease, such as liver failure and hepatocellular carcinoma 
(HCC). The progression rate is accelerated with alcohol consumption, HIV or 
HBV co-infection. Adapted from Qureshi, 2007.
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The estimated risk for decompensation is about 5% per year in cirrhotic patients
[23] and the 5-year survival rate for decompensated cirrhotics is less than 50% 
[24]. About 3% of patients with cirrhosis will develop HCC per year [25]. Thus, it 
is estimated that HCV is accountable for about 27% of cases of cirrhosis and 25% 
of reported instances of hepatocellular carcinoma, worldwide [26].
As HCV is usually fatal only when it leads to cirrhosis, estimating the rate of 
fibrosis progression is an important parameter to evaluate the vulnerability of
chronic HCV-infected patients. The exact pathogenesis of HCV disease and 
factors that may influence viral clearance are not fully understood [27, 28].
However, several factors have been clearly shown to be associated with the 
fibrosis progression rate, including older age at infection, male gender, 
consumption of alcohol, duration of infection, and human immunodeficiency virus 
(HIV) co-infection [29-31]. 
Poyand and colleagues evaluated the progression of liver fibrosis in 2235 
untreated patients with chronic hepatitis C (figure 1.3). Using the median rate of 
fibrosis progression, they reported that rapid progression from infection to 
cirrhosis was strongly associated with three independent host factors: male sex, 
age at infection older than 40 years, and daily alcohol consumption of 50 g or 
more. The median estimated duration of infection for progression to cirrhosis was 
30 years in intermediate progressors, ranging from 13 years in men infected after 
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the age of 40 (rapid progressors) to 42 years in women who did not drink alcohol 
and were infected before the age of 40 (slow progressors). There was no 
association between HCV genotype and fibrosis progression [23].
Figure 1.3: Modeling of liver fibrosis in chronic hepatitis C.
The diagram shows the rate of fibrosis progression per year [the ratio between 
fibrosis stage in METAVIR units (F0 = no fibrosis, F4 = cirrhosis) and the 
duration of infection, in years]. In untreated patients with chronic hepatitis C, the 
median expected time to cirrhosis was 30 years (intermediate progressors). 
However, 33% of patients had an expected median time to cirrhosis of less than 20 
years (rapid progressors), and 31% will only progress to cirrhosis after more than 
50 years, if ever (slow progressors). Adapted from Poynard et al., 1997.  
The outcome of HCV infection may be related to genetically determined variation 
in the efficiency of presentation of viral peptides to T cells. Several human 
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leucocytic antigen (HLA) alleles have been found associated with HCV disease 
prognosis. Susceptibility to HCV infections was associated with HLA A*28, 
A*29, B*14, DR7 in Egyptians [32]. HLA A11-C*04 was found to be associated 
with HCV persistence in Ireland [33], and HLA DRB1*15-DQB1*0602 were 
associated with increased risk for a higher viral load and more severe HCV disease 
in Irish viraemic females [34]. In contrast, certain class II alleles of HLA; 
DQB1*0301 and DRB1*1101 were more associated with viral clearance in a
cohort of Irish women [35].
One study showed that HCV-infected patients were at increased, though non-
significant, risk of mortality from liver disease in the first decade of infection [36]. 
However, a significant, three-fold, increase in the death rate of patients infected 
with hepatitis C compared to that observed in an age- and sex-matched population
was detected. A worse prognosis was associated with increased disease severity, in 
contrast to an improved outcome that was encountered in responders to treatment 
[37]. The increased risk of fibrosis progression with older age [38], along with the 
poor prognosis (a higher rate of HCC and/or decompensation and a lower survival 
without liver transplantation) associated with severe liver fibrosis (Ishak stage ≥ 4) 
secondary to hepatitis C [39], suggest a future increase in HCV-related disease 
burden.
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Although HCV is a hepatotropic virus, its pathology is not only restricted to the 
liver. About 30 to 40% of patients with chronic hepatitis C may present with an 
extrahepatic manifestation [40], which include B-lymphoproliferative disorder, 
essential mixed cryoglobulinemia, glomerulonephritis, porphyria cutanea tarda and 
licken planus [41-43].
1.1.3. Disease Severity
Scoring systems that utilise the concepts of grading and staging to evaluate liver 
biopsies from patients with chronic hepatitis have been described by Knodell [44], 
Ishak [45] and the METAVIR cooperative study group [46]. Staging measures the 
fibrosis and indicates the structural progression of the disease (table 1.1), while 
grading expresses the intensity of necroinflammatory activity (table 1.2). Staging
grading provide a way of recording the histological characteristics representing
severity and progression of chronic hepatitis. Semi-quantification of grade and 
stage provides a numerical index of histological activity, summarised as minimal, 
mild, moderate or severe chronic hepatitis, thus it can enable comparison across 
different series of patients. However, the application of such grading and staging 
in a single biopsy is limited by potential sampling error, as they may depend on the 
sample size and quality. Thus, a higher degree of accuracy can be accomplished 
using multiple biopsies.
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Table 1.1: Ishak staging. 
Histological changes Score 
No fibrosis  0
Fibrous expansion of some portal areas, with or without short fibrous
septa 
1
Fibrous expansion of most portal areas, with or without short fibrous 
septa
2
Fibrous expansion of most portal areas with occasional portal to portal 
(P-P)  bridging
3
Fibrous expansion of portal areas with marked bridging (portal to 
portal (P-P) as well as portal to central (P-C) 
4
Marked bridging (P-P and/or P-C) with occasional nodules (incomplete  
cirrhosis) 
5
Cirrhosis, probable or definite  6
Histological features included in staging [45].
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Table 1.2: Modified histological activity index (HAI) grading.
Necroinflammatory changes Score
A. Periportal or periseptal interface hepatitis (piecemeal necrosis) 
Absent  
Mild (focal, few portal areas)  
Mild/moderate (focal, most portal areas)  
Moderate (continuous around 50% of tracts or septa)  
Severe (continuous around >50% of tracts or septa)
0
1
2
3
4
B. Confluent necrosis 
Absent  
Focal confluent necrosis  
Zone 3 necrosis in some areas  
Zone 3 necrosis in most areas  
Zone 3 necrosis + occasional portal-central (P-C) bridging 
Zone 3 necrosis + multiple P-C bridging  
Panacinar or multiacinar necrosis  
0
1
2
3
4
5
6
C. Focal (spotty) lytic necrosis, apoptosis and focal inflammation 
Absent  
One focus or less per 10X objective  
Two to four foci per l0X objective  
Five to ten foci per l0X objective  
More than ten foci per 10X objective  
0
1
2
3
4
D. Portal inflammation 
None  
Mild, some or all portal areas   
Moderate, some or all portal areas   
Moderate/marked, all portal areas  
Marked, all portal areas 
0
1
2
3
4
Necroinflammatory features included in grading [45].
Chapter 1                                                                                                 Introduction
12
1.1.4. Genome Organisation
HCV is a small (50 nm), enveloped, RNA virus. It is classified as the sole member 
of the genus Hepacivirus that belongs to the Flaviviridae family [47], which also 
includes flaviviruses and pestiviruses [48]. The HCV genome is a positive-sense 
single-stranded RNA molecule, approximately 9.6 kb in length. It contains a single 
open reading frame (ORF) that encodes a single polyprotein of about 3,000 amino 
acids (figure 1.4). The ORF is flanked by 5’ and 3’ noncoding regions (NCR) of 
approximately 341 and 230 nucleotides in length, respectively. Both 5’ and 3’ 
NCR have highly conserved RNA structures essential for polyprotein translation 
and genome replication [20]. The 5’ NCR directs the translation of the HCV ORF 
by acting as an internal ribosome entry site (IRES) that permits the binding of 
ribosomes proximal to the start of the ORF and directs the translation process [49]. 
The 3’ NCR is important for replication in vivo and it encodes a variable 
sequence, poly U tract and a conserved 98 nucleotide sequence [50]. 
The polyprotein precursor is cleaved by viral and host encoded proteases at the 
endoplasmic reticulum membrane to form the mature viral proteins. These proteins 
can be classified into structural and nonstructural proteins. The structural proteins, 
at the amino (N)-terminus, which include the core protein (C), and the envelope 
glycoproteins E1 and E2 are processed by host signal peptidases. The structural 
proteins are separated from the nonstructural proteins by the short membrane 
peptide (P7). The nonstructural (NS) proteins, at the C-terminus, include NS2, 
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NS3, NS4A, NS4B, NS5A and NS5B. They are cleaved by virus-encoded 
proteases [20, 51].
The core protein (191 aa; 21 kDa) which is the major constituent of the 
nucleocapsid is the first cleavage product of the polyprotein [52]. It is a 
multifunctional protein essential for viral replication maturation as well as 
pathogenesis. It has been shown to modify cellular processes leading to the 
induction of hepatocellular carcinoma [53, 54]. Protein F is a newly discovered
protein with unknown function, produced by ribosomal frame shift mutation 
around codon 11 of core protein [55]. The envelope glycoproteins E1 and E2 are 
glycosylated transmembrane proteins that interact with cellular receptors 
mediating viral entry and represent a target for host immune recognition. E1 and 
E2 are discussed in more detail in section 1.1.6.1.  
The P7 protein is a small (63 aa; 7 kDa) hydrophobic protein, believed to be a 
viroporin, which is known to enhance membrane permeability. It can form an ion 
channel in artificial lipid bilayers. The non-structural viral proteins are not 
incorporated into viral particles but are required for RNA replication [56]. NS2
(217 aa; 21 kDa) and the amino terminal domain of NS3 encode a viral protease 
catalysing cleavage of the NS2/NS3 site [57]. NS3 (631 aa ; 68 kDa) has two
functions; the amino terminus acts as a serine protease catalysing cleavage of 
NS3/NS4A, NS4A/NS4B, NS4B/NS5A and NS5A/NS5B, while the carboxy
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terminus displays NTP-ase and helicase properties essential for genome replication 
and translation [58-60]. NS3 may also function by interfering with host cell signal 
transduction [61].
Figure 1.4: HCV genome organisation and polyprotein product. 
Schematic diagram representing the open reading frame in the HCV genome 
flanked by the 5’ and 3’ noncoding regions (NCR). It also shows the position and 
the main functions of the structural and non structural proteins within the 
polyprotein. The polyprotein of 3000 amino acids is translated as one single 
polypeptide, which is then co- and post-translationally processed by viral and 
cellular proteases. The arrows point at cleavage sites for host signal peptidase (   ), 
NS2 protease (  ), and NS2/NS3 protease (  ) during polyprotein processing. 
Adapted from Suzuki et al., 2007. 
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NS4A (54aa; 6 kDa) is a cofactor of the NS3 protease [51, 60]. NS4B (261 aa; 27
kDa) induces the formation of a specialised membranous web within which viral 
RNA replicates [62]. NS5A (448 aa; 56 kDa) may be involved in RNA replication 
and contain the interferon (INF) sensitivity determining region (ISDR) which is 
thought to influence the resistance to the antiviral effects of IFN. NS5B (591 aa; 
65 kDa) has been identified as the virally encoded RNA-dependent RNA 
polymerase, the catalytic core of the replicative machinery [50]. 
1.1.5. Genotypes
HCV genome shows exceptional sequence variation because of the lack of 
proofreading activity of the NS5B RNA-dependent RNA polymerase, resulting in 
misincorporation of nucleotides during RNA replication [20, 63]. According to the
phylogenetic analysis of nucleotide sequences, HCV is classified into 6 major 
genotypes (1-6) based on evaluation of complete genome sequences and 
subgenomic regions. The genotypes differ in their nucleotide sequences by 31-
34%, and in their amino acid sequences by ～30%. Each genotype is subsequently 
subdivided into more closely associated subtypes numbered alphabetically (a, b, c, 
…) [47, 64]. Moreover, such high mutation rate of the RNA genome of HCV 
results in the presence of multiple isolates, called quasispecies, in the same patient 
[65]. The hypervariable region HVR1 of E2 is the most variable region of the 
genome [66], followed by the p7 gene, and the C-terminal region of NS5A [67], 
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while both the 5’ and 3’ NCR as well as the core have highly conserved RNA 
structures [20, 66].
The HCV genotypes vary in geographical and epidemiological distributions [47]. 
The commonest HCV genotypes in Europe and USA are 1a, 1b, 2a, 2b and 3a, 
type 4 genotypes are common in Northern Africa and the Middle East, while type 
5 is common in South Africa and type 6 in Hong Kong [68, 69]. The commonest 
HCV genotypes in the UK are 3a, 1a, and 1b [70].
The effect of differences between the genotypes of HCV on clinical course and 
disease association has been investigated with varying conclusions. For example, 
the correlation between the infecting HCV genotype and disease severity is still 
debatable. While some studies show that infection with HCV genotype 1b viruses 
may be associated of more severe liver disease with development of HCC [71-74], 
other studies found no specific link between cirrhosis or HCC and infection with 
genotype 1b [69, 75-77]. On the contrary, a higher rate of viral clearance was 
observed with genotype 1 infection [78]. So, it seems that in order to use HCV 
genotyping more effectively in the clinical settings, further studies are required.
However, a significant variation between genotypes in rates of response to 
treatment with interferon has been observed with reduced viral clearance in 
genotype 1 infected patients compared with genotypes 2 or 3 [79-81]. Also, virally 
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induced steatosis linked with liver fibrosis is specifically associated with infection 
by genotype 3 [82-84]. The underlying mechanism for the observed differences 
between genotype is not clear. However, it may be a result of differences in 
sequence of structural components such as E1 and E2 glycoproteins and 
replicative ability of the virus [85].
1.1.6. Structure of HCV Virion
Due to the absence of a competent cell culture system and the limited amount of 
virus that can be recovered from serum, the structural analyses of HCV virions are 
limited. After production of infectious HCV particles in cell culture systems [86, 
87], it was recently shown, by cryo-electron microscopy (cryo EM), that HCV 
virions have a spherical shape with a diameter of approximately 50 to 55 nm [88], 
confirming previous results [89, 90]. 
It is believed to have a classical icosahedral scaffold (figure 1.5) in which its two 
envelope glycoproteins, E1 and E2, are anchored to the host cell-derived double-
layer lipid envelope. Underneath the membrane is the nucleocapsid that is 
composed of multiple molecules of the core protein, forming an internal 
icosahedral viral coat encapsidating the genomic RNA [91, 92]. A spherical 
structure, suggesting the nucleocapsid that harbors the viral genome, with a 
diameter of approximately 30-35 nm has been observed [87]. The core particles 
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exhibit six-fold symmetry and the hexagon side length is approximately 20 nm 
[92]. 
HCV virions exist in the blood of infected individuals in various forms: free 
circulating virions [93], virions bound to very low-density lipoproteins (VLDL) 
[94], virions bound to low-density lipoproteins (LDL) [95], and virions complexed 
with immunoglobulins [96]. The association of a major portion of circulating 
virions with LDL and/or VLDL may facilitate the viral entry to hepatocytes via the 
LDL receptor [97] and protects the virus against neutralisation by HCV-specific 
antibodies. 
Figure 1.5: Structure of HCV virion:
Schematic diagram showing the ichosahedral symmetry of HCV nucleocapsid. 
HCV RNA is encapsidated in the viral core particle, encoded by the core gene. 
The nucleocapsid is surrounded by a lipid bilayer envelope studded with 
complexes of two envelope glycoproteins E1 and E2, as heterodimer.
Envelope glycoprotein, E1
Envelope glycoprotein, E2
Envelope lipid
Nucleic acid, RNA
Core protein
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 1.1.6.1. HCV Glycoproteins
The two envelope glycoproteins, E1 (192 aa; 35 kDa) and E2 (363 aa; 72 kDa) are 
type-I transmembrane glycoproteins, with N-terminal ectodomains of 160 and 334 
amino acids respectively, and a short C-terminal transmembrane domain of 
approximately 30 amino acids (figure 1.6). The ectodomains of E1 and E2 contain 
numerous proline and highly conserved cysteine residues that may form 4 and 9 
intramolecular disulphide bonds respectively. These proteins are expressed as a 
noncovalent E1E2 heterodimer, in the viral envelope. E1 extends from aa 192-383 
and E2 extends from aa 384-746 of the polyprotein [20, 98, 99]. 
E1 and E2 are highly glycosylated proteins, containing up to 5 and 11                   
N-glycosylation sites respectively (figure 1.6). N-linked glycosylation supports the 
correct folding of newly synthesised peptides in the endoplasmic reticulum (ER). 
Both E1 and E2 influence each other’s folding, assisted by host chaperones [99, 
100]. Among the 11 identified potential glycosylation sites of E2, 9 sites are 
strongly conserved. However, there is variant glycosylation pattern across 
genotypes; the site at aa 476 is less conserved in genotype 1 and absent in 
genotype 5. Also, the glycosylation site at 540 does not exist in genotypes 3 and 6
[98]. This altered glycosylation pattern across genotypes may affect protein 
production, folding and the epitopes that interact with cellular receptors and the 
immune system. 
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Figure 1.6: E1E2 heterodimer.
A: Schematic diagram representing the viral glycoproteins E1 (35 kDa) and E2 (72
kDa) in the form of non-covalent heterodimers. It shows the N-linked 
glycosylation sites on the N-terminal ectodomains. Both E1 and E2 have short     
C-terminal transmembrane domains (TMD) of approximately 30 amino acids.         
B: The potential glycosylation sites in E1 and E2. The position of the 
glycosylation sites are indicated above the boxes corresponding to E1 and E2 
proteins, while the percentages of conservation of the glycosylation sites are 
indicated below each site. Adapted from Op De Beeck et al., 2001.
E1 and E2 play crucial roles at different steps of the HCV replication cycle. They 
mediate viral entry by interacting with cellular receptors CD81, scavenger receptor 
class B member 1 (SR-B1) and claudin 1, essential for host-cell entry [101-104]
and inducing fusion with the host-cell membrane. They are also thought to play a 
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role in viral particle assembly [105]. They also provide a target for immune 
recognition [56, 106].
E1 and E2 are encoded by E1 and E2 genomic regions, which are characterised by 
a high variability; especially E2 that contains two hypervariable regions (HVRs). 
When HVRs are subject to immune pressure, they lead to the formation of escape 
mutants (quasispecies) [107, 108]. Increasing complexity of quasispecies is 
associated with failure of the immune system to clear the virus and with a 
relatively low response to interferon treatment [109, 110].
1.1.7. Replication
1.1.7.1. Model systems
Investigation of the HCV life cycle, understanding of HCV pathogenesis and 
development of novel antiviral treatments were hampered by absence of a 
satisfactory cell culture system and small animal models. The development of 
HCV replicon model in a human liver hepatoma cell line (Huh-7) [56] was a major 
breakthrough that offered the opportunity to investigate the molecular biology of 
HCV infection. Another important milestone was achieved when a robust HCV 
cell culture (HCVcc) system, that allowed a relatively efﬁcient ampliﬁcation of 
HCV, was developed [87]. The replicon model was derived from JFH-1, an HCV 
genotype-2a isolate from a Japanese patient with fulminant hepatitis, and capable 
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of producing infectious virions. Subsequent work resulted in improved 
productivity of infectious virus [111]. 
Another approach to the viral entry into cells was the generation of infectious 
HCV pseudotype particles (HCVpp) that were assembled by displaying functional 
HCV E1 and E2 glycoproteins onto retroviral and lentiviral core particles [106]. 
The presence of a marker gene, such as a green fluorescent protein marker gene,
within these HCVpp allowed consistent and swift determination of infectivity 
mediated by the HCV glycoproteins. Alongside in-vitro replication systems 
progress, small animal models of infection are being developed including 
immunotolerised rat model [112] and transgenic mice [113]. 
1.1.7.2. HCV receptors
The first identified putative HCV receptor involved in HCV entry was CD81
[114]. CD81, a member of the tetraspanins, is a widely expressed multifunctional 
cell surface protein that is involved in cell adhesion, cell activation and signal 
transduction [115]. Its role in HCV entry has been confirmed with HCVpp and 
HCVcc studies [116-118]. Although recombinant CD81 and anti-CD81 antibodies
have been reported to neutralise infection in tissue culture [86, 87], CD81 
expression alone is not enough for cell entry of HCVpp as some CD81-positive 
cell lines can not be infected [102], suggesting that CD81 may act as a post-
attachment entry co-receptor.  
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The human scavenger receptor class B type I (SR-BI), concerned with cellular 
lipometabolism, has been identified as a putative receptor recognised by E2 and 
involved in HCV entry [119, 120]. The enhancement of HCVpp infectivity by 
high-density lipoprotein (HDL) which is a ligand to SR-BI suggested a modulating 
effect of SR-BI to HCV entry [121, 122]. LDL receptors can also mediate viral 
entry by binding to lipoprotein that has been shown to associate with HCV 
particles in serum [97]. A recently recognised co-receptor of HCV is the tight 
junction component claudin-1, that mediates a late step viral entry [104].  
Other molecules, including calcium-dependent (C-type) lectins such as 
liver/lymph node-specific intracellular adhesion molecule-3 (ICAM-3)-grabbing 
non-integrin (L-SIGN) and Dendritic cell-specific ICAM-3-grabbing non-integrin
(DC-SIGN), that interact with recombinant HCV envelope proteins have been 
studied as potential HCV receptors [123, 124]. Their possible role, as they are not 
expressed on hepatocytes, is mediated by the capture and transmission of HCV to 
hepatocytes [125, 126]. 
1.1.7.3. Life cycle
The first step in the viral life cycle (figure 1.7) is the viral interaction, via the 
envelope glycoproteins, with attachment and entry receptors [127]. Entry of HCV 
particles to host cells via receptor-mediated endocytosis, followed by viral particle 
fusion with endosome membrane which is catalysed by a reduction in pH in the 
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late endosome. Then, after uncoating, viral RNA is released into the cytoplasm
[128]. The positive-sense RNA is directly translated via an internal ribosome entry 
site (IRES)-mediated process in the cytoplasm. [129]. The IRES allows translation 
of the RNA in a cap-independent manner and also leads to shutting down the 
translation process in the host cell so that the cell's translational machinery will 
operate to translate viral mRNA. The polyprotein is processed by cellular and viral 
proteases to produce mature structural and nonstructural proteins which remain 
associated with the membrane of the endoplasmic reticulum (ER) [130]. 
Complementary negative-sense RNA is synthesised by NS3-5B replicase and acts
as a template for the production of positive stranded RNA. The presence of 
negative stranded HCV RNA indicates replication of the positive stranded RNA 
genome [131]. HCV forms a membrane-associated replication complex, the 
membranous web, composed of viral proteins, replicating RNA and altered 
cellular membranes [62, 132]. Positive stranded RNA associates with core proteins 
to form the nucleocapsid [133]. The virus particles acquire the viral envelope by 
budding from the ER. Viral particles then travel through the Golgi apparatus 
before release at the cell surface [50, 134].
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Figure 1.7: HCV replication cycle.
Schematic model of the HCV replication cycle. After virus binding and 
internalisation (a), the plus-strand RNA genome (+) RNA is uncoated and 
liberated into the cytoplasm (b), followed by IRES-mediated translation and 
polyprotein processing (c). Viral proteins remain tightly associated with 
membranes of the endoplasmic reticulum (ER). Minus-strand RNA (–) is 
synthesised by the NS3–5B replicase continues RNA replication (d) by acting as 
template for production of (+) RNA. Packaging and assembly (e) of (+) RNA via 
encapsidation with the structural proteins. Mature virus particles are enveloped by 
budding into the lumen of the ER and virus particles transit through the Golgi 
apparatus before release (f). IRES-mediated translation and polyprotein 
processing, as well as membranous web formation and RNA replication, which are 
illustrated as separate steps for simplicity, might occur in a tightly coupled fashion. 
Redrawn from Moradpour et al., 2007.
1.1.8. Immune Response
The host immune response is a really important factor in viral clearance. Immune 
responses to viral infection can be divided into innate and adaptive responses.
Although the innate immune responses are less mature then the adaptive immune 
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responses, they represent the first line of defence before the adaptive responses 
eventually come into play and moreover they have a significant effect on the
development of the clonal immune response [135]. Innate responses are mediated 
by complement, antigen presenting cells (APCs) such as dendritic cells and 
macrophages, and natural killer cells. Adaptive responses are mediated by B 
lymphocytes, antibody-producing plasma cells, CD4+ T lymphocytes (helper T 
cells; Th), and CD8+ T lymphocytes (cytotoxic T cells; Tc). These adaptive 
responses have the properties of memory, antigen specificity and diversity [136]. 
The evolution and prognosis of HCV infection is influenced by the interactions 
between the virus and host immune responses in the first weeks after exposure 
[137].
1.1.8.1. Innate (Non-Specific) Immune response
The innate immunity provides a rapid antimicrobial host defence and facilitates the 
initiation of the adaptive immune response [138]. There is growing proof for 
involvement of innate immune responses and interference to HCV infection. It is 
seen in all individuals, regardless of whether they control the virus or develop 
chronic infection [55, 139]. Natural killer (NK) cells and NK-T cells, present in 
high proportions in the liver, provide a rapid immune response to HCV, mediating 
unrestricted Major histocompatability (MHC) cytolysis of virus-infected cells 
[140]. NK cells also suppress HCV replication in hepatic cells through an 
interferon-γ mediated mechanism [141]. Dendritic cells (DCs) are professional 
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APCs that present antigens as processed peptides to T cells in the context of MHC 
and also activate lymphocytes. Both blood and hepatic populations have been 
reported to be significantly higher in patients with resolved HCV infection than in 
patients with chronic HCV infection [140, 142].
The interferon (INF) system represents a powerful antiviral immune response in 
most viral infections [143]. Production of INF-α/ß is induced by viral infection via 
stimulation of pattern-recognition receptors (PRR) such as toll-like receptor 3 
(TLR3) upon binding of vial double stranded RNA (dsRNA). Stimulation of TLR3 
activates intracellular signaling cascades leading to transcription of IFN-α/ß genes
[144]. Induction of IFN- α/ß requires the activation of nuclear factor kappa B   
(NF-kB) and IFN regulatory factor-3 (IRF-3) [145, 146]. The secreted IFN-α/ß 
binds to the IFN-α/ß receptor on neighbouring uninfected cells and results in the 
activation of related signaling pathways, known as the Jak/STAT pathways, 
leading to upregulation of IFN-stimulated genes [147]. The upregulated genes that 
encode enzymes that result in an antiviral state include dsRNA-dependent protein 
kinase R (PKR) [148] and 2’5’-oligoadenylate synthetase (OAS) [149]. Interferon 
has direct antiviral properties and also acts as a cytokine with immunomodulatory 
effect; enhancing expression of MHC proteins and activation of natural killer cells 
and macrophages [150]. Although HCV induces the production of type 1 
interferon, it is resistant to its antiviral activity [151]. Interferon may also induce 
the expression and presentation of HCV antigens on the infected hepatocyte 
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surface to the immune system by stimulating the generation of 
immunoproteosomes [152]. The potential role of mannan binding lectin (MBL) 
and ficolins as innate immune mediators is described later in section 1.2.7.
1.1.8.2. Adaptive (Specific) Immune response
1.1.8.2.1. Cell-mediated immune response
Cell-mediated immune response plays an important role in pathogenesis and 
control of HCV infection [153]. CD4+ Th cells are stimulated when they recognise
viral peptides bound to MHC class II antigens on the surface of APCs. They 
proliferate and provide helper function by producing cytokines that enhance 
humoral and cellular immune responses. Th1 produces IFN-that stimulates 
recruitment of neutrophil and macrophage activation and upregulates inﬂammatory 
responses. On the other hand, Th2 produces cytokines including IL-4 and IL-10 to 
limit Th1-mediated inﬂammatory responses, thus restraining inﬂammation and 
preventing excessive tissue destruction [154]. Subcutaneous administration of 
recombinant IL-10 improved hepatic inﬂammation and ﬁbrosis scores in patients 
with HCV-induced fibrosis [155], without affecting viral load. Patients with potent 
proliferative antiviral CD4+ T-cell response to HCV antigens E2, NS3, NS4, and 
NS5 during acute infection had better resolution and favorable course of infection 
[156].
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Cytotoxic CD8+ T cells (CTLs), MHC class I-restricted peptide-speciﬁc cells, 
represent a significant effector that contend with viral infection. CTLs migrate into 
infected tissues, recognize infected cells presenting viral peptides in association 
with MHC class I, and become activated to reduce viral replication through a 
combination of cytolysis and secretion of antiviral cytokines; such as INF- and 
tumor necrosis factor (TNF) [157]. HCV-speciﬁc CD8+T-cell activity was reported 
to be related to increased histological inﬂammatory activity and lower levels of 
viraemia [158]. However, the lack of ongoing CTLs selection in chronically 
infected patients suggests that CTLs escape occurs early during HCV infection
[159]. It is possible that, during established HCV infection, insufficiently activated 
CD8+ T cells are not able to clear the viral infection, but may still be able to induce 
immunologically-mediated liver injury through cytotoxic effects [140]. In contrast 
to the strong CD4+ T cell response to HCV that is maintained for many years after
clearance, the memory CD8+ T cell response may be maintained with variable 
efficiency [139]. 
Cellular immune responses appear to have a role in the virologic outcome during 
acute infection rooted in strong association of a persistent and multispecific
antiviral CD4+ and CD8+ T cell response with HCV elimination during acute 
infection [139]. On the other hand, in established chronic infection HCV-specific 
T cell response is weak and unable to clear the virus. It provides only a minimal 
selection pressure for T cell escape variants, and even inactivate them through T 
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cell antagonism [139]. The frequency of virus-specific cytotoxic T cells in HCV-
chronically infected patients is much lower than that observed during infection 
with other persistent viruses, such as hepatitis B virus or HIV, which may reflect 
an immunosuppressive effect leading to viral persistence after infection [160].
1.1.8.2.2. Humoral immune response
The humoral immunity to HCV is mediated by antibodies, which target and bind 
epitopes of viral proteins. The proportion of antibodies that target exposed 
epitopes of the viral structural proteins, such as viral envelope glycoproteins, can 
neutralise the virus and thus prevent or control infection [161]. It has been reported 
that early robust antibody response to the HVR1 of the E2 glycoprotein is 
associated with a self-limited infection [162], and an initial complex quasispecies 
evolution is associated with HCV persistence [163]. To evaluate the protective 
nature of antibodies, a prospective study of HCV viraemia in injection-drug users 
has been performed. The results showed that patients who had previously cleared 
HCV (anti-HCV positive and HCV RNA negative) had a significantly lower level 
of viraemia and higher rate of spontaneous clearance when re-infected with HCV,
compared with patients infected for the first time [164]. These results suggest that 
clearance of HCV infection confers anti-HCV immunity and protects against 
persistent infection. The role of the antibodies to E1E2 (anti-E1E2) in the 
pathogenesis of HCV disease has been investigated however, the results are 
controversial [165-167].
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A few studies have suggested that E1E2 antibody may be useful as a serological 
marker of HCV infection, and incorporation of assays for E1E2 antibody may 
improve the sensitivity of currently available HCV antibody assays, which use
recombinant antigens from 3 nonstructural proteins (NS3, NS4, and NS5) and 1 
structural antigen (core) [168, 169]. This may be helpful for detection of HCV 
infection and improving the performance of the assays for anti-HCV screening
[170]. However, this may be applicable for highly viraemic carriers who can be 
efficiently screened by the detection of E1E2 antibody. A considerable proportion 
of low viraemic carriers may not show the E2 antibody response [171].
1.1.8.3. Evasion of the Immune Responses
Although HCV-RNA can be detected in the serum after one-to-two weeks of 
exposure, indicating viral replication [172], there is a reported delay of the 
adaptive cellular and humoral responses [137, 173] suggesting that HCV can 
suppress the adaptive immune response. This hypothesis is supported by the 
paucity of symptomatic HCV infections, knowing that clinical signs, especially 
jaundice, result from liver injuries mediated by T lymphocytes [173]. In addition, 
the high incidence of HCV persistence after infection in many patients who are 
otherwise immune competent suggests that this virus has evolved a mechanism to 
evade the host response, despite high levels of virion production and strong 
induction of innate immune response [151]. This immune evasion may be due to
generation of viral variants during infection that could escape from immune
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recognition. This strategy is in harmony with the high error rate of the viral 
polymerase during viral RNA replication which leads to production of HCV 
quasispecies [174]. 
Another mechanism of immune evasion may be the ability of HCV to encode one 
or more products that inhibit viral clearance leading to progressive or persistent 
viral infection [160]. In vitro studies have shown that NS5A and E2 can interfere 
with PKR which inhibit HCV translation, core protein can inhibit the IFN 
signalling pathway, and NS3/4A can block the accumulation of phosphorylated 
interferon regulatory factor-3 (IRF-3), which inhibits expression of type I IFNs 
and IFN-stimulated genes [55, 175].  
1.1.9. Treatment
1.1.9.1. Objectives
The goals of HCV treatment are to cure HCV infection by achieving a sustained 
virological response (SVR), defined as the absence of detectable HCV RNA 6 
months after cessation of therapy, and also to delay or prevent disease progression
[176, 177].
1.1.9.2. History
Before 1998, interferon alfa monotherapy for chronic HCV resulted in a SVR rate 
of up to 27% [178]. After the introduction of ribavirin, a broad-spectrum antiviral 
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guanosine analogue, the combination therapy enhanced the SVR rate to 40% [179, 
180]. Then, interferon was replaced with pegylated interferon (peginterferons) 
[181], adding a new milestone to the treatment of chronic hepatitis C. Pegylation 
of interferon, by attaching polyethylene glycol polymer, improves the drug 
efficiency by increasing its binding affinity for cell receptors and enhancing its 
half-life, resulting in more efficient antiviral effect [22]. Subsequently, the overall 
SVR to peginterferon/ribavirin combination therapy increased to 54-63% [80, 81, 
182]. Recently, more improved forms of interferon, peginterferon and ribavirin 
have been developed including oral prodrugs of ribavirin; Viramidine [22] and 
taribavarin [183], and albuferon alfa which is a fused form of interferon α2b with 
human serum albumin [184].
1.1.9.3. Current therapy
1.1.9.3.1. Regimen 
The current recommended strategy for the management of chronic HCV infection, 
a combination of peginterferon plus ribavirin [177, 185] has remained stable since 
2001. Recommended dosage and duration of treatment vary with viral genotype. 
Patients with HCV genotype 1 receive peginterferon, 180 mcg subcutaneously 
(SC) once-weekly plus ribavirin, 1000 or 1,200 mg/day, orally in 2 divided doses, 
for 48 weeks, whereas patients infected with genotype 2 or 3 receive peginterferon 
plus a lower dose of ribavirin, 800 mg daily, in 2 divided doses, for 24 weeks 
[185]. 
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1.1.9.3.2. Response to treatment
The timing and magnitude of the virological response to antiviral therapy in HCV-
infected patients is variable. These regimens lead to SVR rates of 50% for patients 
infected with genotype 1 viruses and of approximately 80% for those infected with 
either genotype 2 or 3 [80, 81, 186, 187]. A high SVR rate (97%) can be achieved 
when treating acute HCV infection with peginterferon for 12 months, regardless of 
the infecting genotype [188, 189]. However, the asymptomatic nature and the 
absence of a clear-cut diagnostic approach for diagnosis [190] represent obstacles 
for treating acute HCV infection.
1.1.9.3.3. Prediction of treatment response
On-treatment monitoring of HCV RNA is recommended especially for patients 
with genotype 1. One of the best predictors of end-of-treatment virological 
response and SVR is the rapid virologic response (RVR), deﬁned as an 
undetectable HCV RNA after 4 weeks of therapy. Achievement of RVR was 
associated with a low rate of relapse during follow-up in HCV genotype 1 patients 
[191, 192]. Achievement of RVR can be used as an indicator to shorten the 
duration of treatment to 24 weeks in individuals with HCV genotype 1 infection or 
to 12–16 weeks in patients with HCV genotype 2 or 3 infection [193]. Early 
virologic response (EVR), defined as the achievement of negative HCV RNA or a 
2-log drop in viral load compared with the baseline measure by 12 weeks, is a 
negative predictor of response to treatment. The failure to achieve EVR is an 
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indication to stop therapy. Also, patients with genotype 1 with detectable HCV 
RNA at week 24 will not accomplish SVR and therefore treatment should be 
discontinued. A promising tool for anticipation of response to treatment, even 
before start of treatment is the study of liver gene expression of interferon-
stimulated genes which is different in non-responders and patients with a SVR 
[194]
1.1.9.3.4. Side effects
Interferon-related side effects include bone marrow suppression (neutropenia and 
thrombocytopenia), flu-like symptoms (fever, headache, arthrlagia and myalgia), 
neuropsychological disorders (irritability, apathy and depression), and 
autoimmune syndromes (autoimmune thyroiditis). The main adverse effect of
ribavirin is hemolytic anemia. The side effects associated with peginterferon and 
ribavirin may reduce adherence to therapy and may affect the management of 
patients with chronic hepatitis C, by either premature withdrawal of therapy or 
dose modifications [81, 186]. 
1.1.9.4. Future therapy
As the current regimen is toxic, expensive, requires prolonged compliance, and not 
all patients with chronic HCV infection meet the criteria for treatment [195], there 
is a pressing need for new HCV drug therapies. The development of an in-vitro 
system for neutralising HCV replication will enable screening of agents that 
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inhibit viral RNA replication [87, 196]. Many specifically targeted antiviral 
therapies for hepatitis C (STAT-C) compounds are promising and currently in 
development. The novel drug therapies for HCV include specific antibodies or 
small molecule inhibitors, blocking E1 and E2 [197, 198], protease inhibitors that 
inhibit the viral protease NS3/4B [199, 200], nucleoside analogue NS5B 
polymerase inhibitors [201, 202], non-nucleoside NS5B inhibitors that target and 
bind directly to the RNA-dependent RNA polymerase [203, 204], RNA 
interference therapies [205], and immune modulators [206, 207]. 
1.1.10. Prevention 
1.1.10.1. Vaccines
As a result of continuous spread of HCV infection, several approaches were taken 
to develop vaccines to control the spread of HCV. HCV envelope proteins, E1 and 
E2, were the first choice in vaccine development against HCV infection. The 
choice of the envelope proteins as an attractive target for vaccine development is 
attributed to their role in receptor binding [114], mediating viral entry [208], and 
the presence of multiple neutralising epitopes [209, 210]. Although it is difficult to 
neutralise a wide range of potential infecting strains especially with the rapid 
production of new variants under immune selection, it could be possible to 
overcome that issue with antibody-based vaccines by the generation of broadly 
cross-reactive neutralising antibodies [211]. 
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Experimental studies in mice with a prototype vaccine based on recombinant 
plasmids encoding HCV proteins induced humoral and cellular immune responses 
[212, 213]. A therapeutic vaccine trial for chronic hepatitis C based on the 
repeated administration of the HCV E1 protein revealed an increase in anti-E1 
antibody levels along with decrease in total Ishak score as well as relative 
decreases in both Ishak fibrosis score, despite unchanged plasma HCV-RNA 
levels [214]. Despite some encouraging results that have been achieved by various 
efforts made to develop a vaccine against HCV infection [213-215], there is no 
effective vaccine available so far. 
1.1.10.2. General measures
Due to the absence of an effective vaccine, preventive measures are directed 
towards reducing HCV transmission, by effective screening of blood and blood 
products, proper sterilisation of medical equipment, use of disposable needles, and 
primary prevention of illegal drug injecting [8]. The preventive measures also 
include educating health workers and increasing public awareness about the risk of 
infection from unsafe practices, counseling and testing for HCV for individuals at
risk [6]. Improved identification and treatment of HCV patients with newly-
acquired infection may significantly reduce onward transmission and reduce 
chronicity [190].
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1.2. Ficolins 
Ficolins are related to the collectin family of proteins, which represent major 
effectors of the innate immune defence in mammals [216-218]. They were first 
described as transforming growth factor-β1-binding proteins on pig uterine 
membranes [219]. Their name, ficolins, reflects their unique structure of 
fibrinogen- and collagen-like domains [220]. Depending on the species, different 
types of ficolin family proteins have been identified; ficolins H, L, and M in 
humans [216, 218, 221], ficolins α and ß in pigs [220], ficolins A and B in mice 
[222, 223], and ficolins 1, 2, 3 and 4 in frogs [224]. 
1.2.1. Types
In humans, three types of ficolins have been described to date (table 1.2), L-ficolin
(ficolin-2, ficolin/P35 or Hucolin) [225], H-ficolin (ficolin-3 or Hakata Ag) [216], 
and M-ficolin (ficolin-1 or ficolin/P35-related protein) [221, 225]. L-ficolin is 
synthesised in the liver and found in the blood circulation [218]. Healthy adult 
plasma contains, on average, an L-ficolin level of 4.13 μg/mL [217]. H-ficolin was 
first identified as a serum autoantigen (Hakata Antigen), recognised by antibodies 
in patients diagnosed with systemic lupus erythematosus and other autoimmune 
diseases [216]. It is synthesised in the liver by hepatocytes as well as bile duct 
epithelial cells and is secreted into both blood circulation and bile. It is also 
synthesised by ciliated bronchial and type II alveolar epithelial cells and is 
secreted into the bronchus and the alveolar space [226]. Therefore, it may play an 
Chapter 1                                                                                                 Introduction
39
important role in both systemic and mucosal immune defence systems [227]. The 
mean serum concentration of H-ficolin is 15 μg/mL, with minor variations. The 
serum levels of H-ficolin decrease in liver disease with increasing severity of 
cirrhosis [228]. M-ficolin is a non-serum ficolin expressed on peripheral blood 
leukocytes. It might act as a phagocytic receptor or adaptor on circulating 
monocytes for microorganism recognition [218, 227] and it has been described 
recently as a secretory protein, in the cytoplasmic secretory granules of 
neutrophils, monocytes and type II alveolar epithelial cells [229]. 
1.2.2. Structure
Ficolins, like the collectins, represent a group of multimeric proteins built of 
identical polypeptides [230]. They are composed of four structural subunits. Each 
is composed of three identical polypeptides of 35-KDa linked by disulfide bonds
(figure 1.8). Each polypeptide chain is formed of a short cysteine-rich NH2-
terminal region of 24 aa with two cysteine residues followed by a collagen-like 
domain that consists of tandem repeats of Gly-Xaa-Yaa triplet sequences (where X 
and Y represent any amino acid), then a short link region (neck domain) of 12 aa 
and then the fibrinogen-like sugar-binding domain of 207 aa [231]. The length of 
the collagen-like domain in H-ficolin (33 aa; 11 Gly-Xaa-Yaa repeats) is shorter 
than M-ficolin (57 aa; 19 Gly-Xaa-Yaa repeats) and L-ficolin (45 aa; 15 Gly-Xaa-
Yaa repeats) [232, 233]. These polypeptides form triple helices in the collagen-like 
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region and assemble to form a subunit comprising triple helix 'bundle-of-tulips' 
structures [216, 230].
Figure 1. 8: Structural organisation of MBL and ﬁcolins.
Schematic diagram illustrating the domain and oligomeric structure of MBL and 
ficolins. Both are oligomers of structural subunits, of three identical polypeptides 
(trimer). Each polypeptide chain (monomer) contains: a cysteine rich N-terminal 
domain, a collagen-like domain, a neck region, and a C-terminal carbohydrate-
recognition domain in MBL and a fibrinogen-like domain in ficolins. In this 
figure, the monomers oligomerise into trimers, which further oligomerise into 
tetra-trimers (12-mer) giving an overall bouquet like structure. However, lower 
and higher oligomers, which are more frequent in MBL than in ficolin, have 
similar organization. Adapted from Fujita et al., 2004.
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The collagen domains assemble the subunits into trimers, and each four trimers 
join together at the N-terminal regions into 12-mers [234]. This collagen-like 
multimeric structure is shared with the mannan-binding lectin (MBL), the 
complement protein C1q (the recognition molecule of the first complement 
component) and surfactant proteins A and D (SP-A and SP-D) [106, 235].
It has been shown that the fibrinogen-like domains at the C-terminal end of the 
polypeptide recognize carbohydrate patterns on the outer walls of microorganisms, 
with a general specificity for N-acetylglucosamine (GlcNAc) [216, 227, 236].
1.2.3. Interaction with microorganisms
The fibrinogen-like domains at the C-terminal end of the polypeptide in ficolins, 
like the carbohydrate recognition domains in MBL, recognize carbohydrate 
patterns on the outer walls of microorganisms. The ligands on microorganisms 
differ between each ficolin and MBL, due to the discrete sequences in their 
recognition domains [229]. The difference in binding properties indicates that each 
lectin binds a specific pathogen-associated molecular pattern [237]. Ficolins are 
able to bind to different types of bacteria (table 1.3) with a general specificity for 
N-acetylated groups [230, 237, 238]. The ability of ficolins to bind to various 
bacteria, may indicate that ficolins function in host surveillance against infection 
by recognition of the macropatterns on pathogenic microorganisms.
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L-ficolin has been shown to bind Salmonella typhimurium strains with exposed 
GlcNAc [218, 239] and serotype III group B Streptococci [240]. In addition,        
L-ficolin specifically binds to lipoteichoic acid from Gram-positive bacteria such 
as Staphylococcus aureus, Streptococcus pyogenes and Streptococcus agalactiae
[241] and also binds to Escherichia coli [230]. H-ficolin binds to Aerococcus 
viridans [242, 243]. The cell-associated M-ﬁcolin was able to bind to S. aureus 
and to interact with a smooth-type strain of S. typhimurium [229]. The 
phagocytosis of E. coli by a human-derived monocytic cell line (U937) was 
inhibited by anti-M-ficolin antibody [227]. 
Although MBL has shown inhibition of Influenza virus hemagglutination and 
infectivity [244, 245] as well as binding activity to gp120 of human 
immunodeficiency virus (HIV) [246, 247], it is not known so far if ficolins are 
able to recognize viruses. 
 1.2.4. Functions
The collectins and ficolins cooperate with phagocytes and humoral factors such as 
complement to eliminate microorganisms [231].  
1.2.4.1. Complement Activation
The main biological effects of MBL and ficolins are mediated through activation 
of the complement system, which represents the key humoral component of the 
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innate immune system, upon binding of MBL or ficolins to sugar structures on 
bacterial surfaces [248]. Like MBL, ficolins associate with MBL-associated serine 
proteases (MASPs) and activate complement independently of antibody through a 
third complement activation pathway (other than the classical and the alternative 
pathways) termed the lectin complement pathway [229, 242, 249, 250]. 
Four related proteins have been described; three MASPs; MASP-1, MASP-2 and 
MASP-3, with a C-terminal serine protease domain, and another small (19 kDa) 
MBL-associated protein; MAp19 [251]. MASP-1 is an alternative splice product 
of MASP-3, and MAp19 is an alternative splice variant of MASP-2 [252, 253].
The MASPs circulate in the blood complexed with MBL and also with ficolins. 
They bind to MBL or ficolins via the collagenous region [229, 239, 242]. MASP-
1, MASP-2 and MASP-3 are homologues of the classical pathway proteases, C1r 
and C1s [254, 255]. MBL and L-ficolin function separately and activate the lectin 
complement pathway independently of each other [256]. 
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Table 1.3: Types and characters of ficolins.
Type Synthesis Tissue 
expression 
Genetic 
determinants
Sugar specificity Pathogen interaction
L-ficolin Liver 
(hepatocytes)
Serum    
(4.13 µg/mL)
On chromosome 9 
(eight exons)
N-acetyl-D-glucosamine, N-acetyl-
D-galactosamine, N-acetyl-D-
mannosamine, N-acetyl-L-cysteine,         
N-acetylglycine, elastin, 
acetylcholine, 1,3-b-D-glucan, and 
lipoteichoic acid.
S. aureus1,2, S. pyogenes1,                       
S. pneumoniae1,                 
S. agalactia1, E. coli3, and 
S. typhimurium4,5
H-ficolin Liver 
(hepatocytes 
and bile
epithelium) 
and type II 
alveolar cells
Serum      
(15 µg/mL), 
bile, 
bronchus, 
and alveolus
On chromosome 1 
(eight exons)
N-acetyl-D-glucosamine, N-acetyl-
D-galactosamine, fucose, glucose,                        
and polysaccharide A. viridans.
A. viridans6,7,                      
S. typhimurium8, and                   
S. minnesota8.
M-ficolin Monocytes Monocyte 
surface and a 
secertory 
molecule
On chromosome 9 
(nine exons)
N-acetyl-D-glucosamine, N-acetyl-
D-galactosamine and Sialyl-N-acetyl
lactosamine
S. aureus9 and                   
S. typhimurium9.
Although the three human ficolins; H- L- and M-ficolin share common structural and functional characteristics, this table shows the 
main differences in terms of synthesis, tissue expression, sugar specificity and pathogen interaction. 1[241], 2[237], 3[230], 4[218], 
5[239], 6[243], 7[242], 8[216], 9[229]
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The lectin pathway (figure 1.9) of complement activation is initiated by the 
binding of MBL or ficolins to carbohydrate surfaces on invading pathogens [257, 
258]. This binding promotes the activation of MASPs which convert from an 
inactive proenzyme form of a single polypeptide to an activated form with two 
polypeptides linked by a disulfide bond, thus acquiring proteolytic activities [259].
Figure 1.9: Lectin complement pathway.
The lectin pathway is activated by the binding of either mannose-binding lectin 
(MBL) or ficolin, in association with MBL-associated serine protease 1 (MASP-
1), MASP-2, MASP-3 and small MBL-associated protein (sMAP), to carbohydrate 
moieties on the bacterial cell surface. MASP2, similar to C1s, is responsible for 
the activation of C4 and C2, which results in the production of C3 convertase 
(C4bC2a) as in the classical pathway. Adapted from Fujita, 2002.
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The activated MASPs cleave C4 and C4b-bound C2 components of the 
complement cascade to generate the C3 convertase, C4b2a. Accumulation of C3 
cleavage product, C3b, can result in C5 convertase activity [248, 249]. 
Complement activation may also result in the destruction of the target through the 
formation of the membrane attack complex [217, 240]. 
1.2.4.2. Opsonisation 
Binding of ficolins, via their fibrinogen-like domains, to carbohydrate moieties on 
microorganisms leads to opsonisation of the microorganisms via complement 
activation and deposition of C3b which stimulates phagocytosis and clearance of 
pathogens bearing surface GlcNAc residues [217, 218, 260, 261]. Alternatively, 
ficolins may function directly as opsonins. This mechanism is supported by the 
ability of L-ficolin to enhance phagocytosis of S. typhimurium by neutrophils
[218] and the inhibition of phagocytosis of E. coli, by promonocytic U937 cells, 
by anti-M-ficolin antibody [227]. Also, H-ficolin has been shown recently to bind 
to late apoptotic cells, resulting in enhanced adhesion and uptake by macrophages
[262].
1.2.5. Interaction with host cells
The carbohydrate structures recognised by MBL and other collectins do not 
include galactose and sialic acid, the crucial sugars that are usually present in 
mammalian glycoproteins which also lack the presence of the specific pathogen-
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associated molecular patterns (PAMP) [231]. This characteristic is supposed to be 
one of the main mechanisms for the ability of ficolins and MBL to differentiate 
between self and nonself [229]. However, aberrantly glycosylated cancer cells and 
apoptotic cells represent an important exception. This has been shown by the 
ability of MBL to bind to apoptotic bodies and enhance macropinocytosis of dead 
cell bodies [263] as well as the complement activation after binding of L-ficolin 
and H-ficolin to apoptotic cells [264]
1.2.6. Phylogeny
Collectins and ficolins, as main effectors of non adaptive immune defence, are 
found in all vertebrates as well as in species representing early evolutionary stages. 
The fibrinogen-like domain of the ficolins has been found throughout the animal 
kingdom, e.g. in animals, insects, sea cucumber, and horseshoe crab [265]. In 
humans, the genes of L-ficolin and M-ficolin are close to each other on 
chromosome 9 (9q34), and are 80% homologous at the amino acid level, 
suggesting a late duplication and divergence, whereas the gene for H-ficolin is 
situated on chromosome 1 (1p35.3), and has about 48% homology at the amino 
acid level with both L-ficolin and M-ficolin [216, 221]. The M-ficolin gene 
contains nine exons, whereas L-ficolin and H-ficolin genes are composed of eight 
exons [235]. The first exon encodes the 5’NCR, leader peptide and N-terminal 
amino acids; the second and the third exons encode the collagen-like domain; the 
fourth exon encodes the link region, and the exons five to eight encode the 
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fibrinogen-like domain. The eighth exon also encodes the 3’NCR. The ninth exon 
(M-ficolin) encodes additional segments of Gly-X-Y repeats in the collagen-like 
domain [221, 266].     
1.2.6.1. Polymorphisms 
The ficolin genes are polymorphic, particularly L-ficolin that has functional 
polymorphic sites that regulate both the expression as well as the function of       
L-ficolin, which may have pathophysiological implications for innate immunity. 
L-ficolin polypeptide chains exist in at least three variants, which are named        
L-ficolin-A (wild-type), L-ficolin-B (Thr236Met) and L-ficolin-C (Ala258Ser). 
The L-ficolin genetic system is regulated during transcription through promoter 
and structural polymorphisms. Single nucleotide polymorphisms (SNPs) in the 
promoter region of the L-ﬁcolin gene, like MBL, were associated with changes in 
the serum concentration [235]. Alternatively, SNPs reported in the exon 8, 
encoding the fibrinogen-like domain, were associated with change in GlcNAc 
binding capacity [267].    
The association between these alleles with clinical pathophysiology and/or disease 
susceptibility is under investigation. Low concentrations of L-ficolin have been 
reported with increased frequency in children with recurrent respiratory infections 
[268]. The amino acid changes in L-ficolin are clustered in exon 8 encoding the 
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fibrinogen-like domain, which could indicate that the genetically determined 
variation in the L-ficolin concentration and change in binding affinity or 
specificity may have led to some changes in host-pathogen interactions similar to 
what has been previously suggested for MBL [269, 270]. 
1.2.7. Potential Role in HCV Disease
There is currently no literature describing interaction between ficolins and HCV. 
However, some studies of relationships between MBL and HCV infection report a 
possible correlation between MBL polymorphisms and HCV disease progression 
[271] and response to treatment [272, 273]. These studies differ in the cohorts used 
and the MBL gene mutations investigated. Polymorphisms in the promoter and 
structural regions of functional MBL gene (MBL2) have been reported to affect 
oligomer formation and circulating levels of MBL. The wild type allele of MBL is 
referred to as allele A. Three single point  mutations in  codons 52 (Arg→Cy5,  
allele  D), codon  54  (Gly→Asp,  allele B),  and  codon  57  (Gly→Glu, allele C 
of exon 1 results in amino acid substitution in the collagenous region of MBL
[270, 274-277].  
A Japanese population with mutation in the MBL gene had lower serum levels of 
MBL, which increased the possibility of disease progression from chronic inactive 
hepatitis to chronic active hepatitis or liver cirrhosis compared to those with the 
wild type allele. This result suggest that mutation in the MBL gene may be a risk 
Chapter 1                                                                                                 Introduction
50
factor in the progression of hepatic injury in HCV infection [271]. Moreover, the 
wild type MBL allele was necessary for successful treatment of HCV with INF
and possession of the homozygous B allele predicted unresponsiveness to 
treatment [272]. However, Kilpatrick et al., reported that the MBL concentrations 
were higher in HCV positive patients than in healthy controls with no significant 
correlation between MBL concentration and disease progression or the response to 
antiviral therapy in an European cohort [278]. 
On the other hand, the enzymatic activity of MBL/MASP-1 complexes has been 
found to be directly associated with the severity of fibrosis in HCV-infected 
patients [279]. As MASP-1 has a similar proteolytic activity to thrombin on 
fibrinogen and factor XIII [280-282], this result may suggest contribution of 
MBL/MASP-1 complexes to the pathogenesis of liver fibrosis. Thus, as L-ficolin 
has similar structural characteristics and interacts in a similar fashion to MBL, it 
seems logic to explore the potential role of L-ficolin in the pathogenesis of HCV 
infection. 
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1.3. Aims of the Work
L-ficolin, a component of innate immune system, is a serum opsonin and a pattern 
recognition receptor which activates the lectin complement pathway by interacting 
with the surface of the microorganisms. Based on the structural and functional 
similarities between ficolins and MBL, the main goal of this study was to 
investigate the potential role of L-ficolin, as a humoral innate immune molecule, in 
HCV disease. This study also involved evaluation of the role of anti-E1E2 
antibodies, as mediators of the humoral adaptive responses, in HCV disease. 
The objectives of this study included expression and purification of recombinant 
L-ficolin and purification of serum L-ficolin in order to employ the purified ficolin 
preparations in investigating whether L-ficolin could bind to HCV glycoproteins
E1E2 and studying the effect of L-ficolin binding to HCV particles. To elucidate
the role of L-ficolin in HCV liver disease, it was essential to evaluate the serum   
L-ficolin levels in patients with chronic hepatitis C infection. Another objective 
was to find out the association between the level of anti-E1E2 antibodies in 
patients with chronic hepatitis C infection and the infecting HCV genotype, viral 
load, disease severity, and response to treatment.
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2. Production and Purification of L-ficolin
2.1. Aims
The primary goals of this part of the study were the production and purification of 
recombinant L-ficolin and purification of L-ficolin from human serum. Purified 
preparations of recombinant and serum L-ficolin were required for characterisation 
of the biochemical interactions with HCV glycoproteins. This section also 
included the development of an ELISA-based assay for quantification of purified 
recombinant and native L-ficolin. 
2.2. Materials and Methods
2.2.1. Materials
2.2.1.1. Plasmids and Bacterial Strains
The human L-ficolin gene was amplified from an Integrated Molecular Analysis of 
Genomes and their Expression (IMAGE) clone pPCR-Script Amp SK [clone 
number BCO 69572 (Open Biosystem)]. pENTR™ TOPO®, pcDNA-DEST40 
and pcDNA-DEST26 vectors were purchased from Invitrogen. Plasmids were 
maintained in and harvested from Escherichia coli TOP10 (Invitrogen). 
Transformed bacteria were grown in Luria Bertani (LB) broth (Sigma) overnight 
at 37°C.
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2.2.1.2. Chemicals and Primers
All the reagents were of the highest standard commercially available as follows: 
bovine serum albumin (BSA), Sodium dodecyl sulphate (SDS), 
tetramethylethylenediamine (TEMED), ammonium persulphate (APS) Tween 20, 
ethidium bromide, dithiothreitol (DTT), dimethylsulfoxide (DMSO), polyethelyne 
glycol (PEG) 4,000, Ampicillin, Kanamycin, imidazole, NaCl, CaCl2, N-Acetyl-
D-glucosamine (GlcNAc), divinyl sulfone, p-nitrophenyl phosphate substrate, 
Tris-Acetate EDTA (TAE) buffer and molecular biology water were all obtained 
from Sigma-Aldrich Company Ltd, Poole, UK. PCR reagents were obtained as 
follows: HotStar Taq DNA polymerase kit was obtained from QIAGEN, 
deoxynucleotide triphosphates (100 mM dNTPs) were obtained from Bioline. 
Expand High Fidelity polymerase mix and Expand High Fidelity Buffer were 
obtained from Roche, Pfu DNA Polymerase was purchased from Stratagene, M13 
forward and M13 reverse primers were purchased from Invitrogen, and all 
oligonucleotides used were synthesised by Proligo and kept at a stock 
concentration of 100 µM. Primers were designed by Dr Alexander Tarr, using the 
Primer Select component of DNAStar package (Table 2.1). The underlined 
sequences represent the sequences for the FLAG-peptide. 
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Table 2.1: PCR and sequencing primers.
Primer Sequence (5’-3’) Tm °C
Ficolin forward CACCGGAAGAGATGGAGCTGGACAGA 65
Ficolin reverse CTAGGCAGGTCGCACCTTCATCTCTGACAC 67
FLAG-signal 
antisense
CTTGTCGTCGTCGTCCTTGTAGTCAGCCCAGG  
CCATGCCCAGGAAAGAGA
85
FLAG-ficolin 
sense
GACGACGACGACAAGCTCCAGGCGGCAGAC
ACCTGT
80
M13 forward TGTAAAACGACGGCCAG 52
M13 reverse CAGGAAACAGCTATGACC 54
T7 forward TAATACGACTCACTATAGGGAGAC 55
BGH reverse TAGAAGGCACAGTCGAGG 56
2.2.1.3. Cell Culture 
Dulbecco’s Modified Eagles Medium and Opti-MEM medium were purchased 
from GIBCO BRL, Paisley, UK. Fetal bovine serum (FBS), non-essential amino 
acids (NEAA), Geneticin, trypsin/EDTA, dimethyl sulfoxide (DMSO), phosphate 
buffered saline (PBS [135 mM NaCl, 3 mM KCl, 2 mM KH2PO4, pH 7.4]) were 
all purchased from Sigma-Aldrich Company Ltd, Poole UK. LipofectamineTM
2000 was purchased from Invitrogen. 
2.2.1.4. Antibodies
Mouse monoclonal anti-human L-ficolin antibody (GN5) was purchased from 
Hycult Biotechnology, Penta-his antibody was purchased from QIAGEN, and 
Mouse monoclonal anti-FLAG antibody, M2 was purchased from Sigma. 
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Horseradish peroxidase (HRP)-conjugated anti-mouse IgG secondary antibody 
was purchased from Dako Cytomation (Table 2.2).
Table 2.2: Antibodies used in western blot analysis:
Primary antibody Secondary antibody
His-tagged L-ficolin GN5, Mouse anti human 
L-ficolin monoclonal 
antibody.
Monoclonal Penta-His 
antibody.
Anti-mouse monoclonal 
horseradish peroxidase 
(HRP)-conjugated 
antibody.
FLAG-tagged L-ficolin GN5, Mouse anti human 
L-ficolin monoclonal 
antibody. 
Anti-FLAG, M2 
monoclonal antibody.
Anti-mouse monoclonal 
HRP-conjugated  
antibody. 
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2.2.2. Production of His-tagged L-ficolin
Figure 2.1: Production of recombinant His-tagged L-ficolin
In order to express His-tagged L-ficolin in mammalian cells, 2 main steps were 
followed. The first step was the creation of an entry clone by cloning a purified 
PCR product of the ficolin (FCN) gene insert, from an IMAGE clone, into an entry 
vector, pENTR™ TOPO® vector. The second step was the production of an 
expression clone by performing LR recombination between the entry clone 
(pENTR™ TOPO), containing the ficolin gene flanked by attL sites and a 
destination vector (pcDNA-DEST40), containing the promoter for expression of 
ficolin gene and C-terminal hexa-histidine (6xHis) tag (for further detection and 
purification of the recombinant protein). att site is a defined length of DNA that 
constitutes a recombination site. ccdB is a counterselectable gene that allows for 
negative selection of unwanted by-product plasmids after recombination.
FCN Gene
Cloning into an Entry clone
attL2FCN GeneattL1
Destination Vector
attR2ccdBattR1
+
LR Recombination
attB2FCN GeneattB1
Expression Clone
Entry Clone
Kan R
Amp R
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(pENTR™ TOPO) (pcDNA-DEST40)
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2.2.2.1. Generating an Entry Clone
The entry clone was created by cloning a blunt-ended purified PCR product of the 
ficolin insert into an entry vector, pENTR™ TOPO. The cloning reaction was 
followed by transformation into TOP10 chemically competent E. coli cells and 
analysis of the positive tranformants.
2.2.2.1.1. Miniprep extraction
IMAGE vector plasmids, carrying the full-length human L-ficolin insert, were 
purified using QIAprep Miniprep Spin Kit (QIAGEN). Overnight LB broth culture 
(3 mL) were pelleted at 5,000 x g for 10 min and plasmids were purified according 
to the manufacturer’s instructions. Plasmid DNA was eluted in 10 mM Tris-HCl, 
pH 8.5. DNA was quantified using a Nanodrop spectrophotometer which converts
A260 to concentration in ng/μL. The purity of DNA was also assessed, using a 
Nanodrop spectrophotometer, by measuring A260/A280 ratio. 
2.2.2.1.2. PCR
Purified miniprep extraction of the IMAGE vector was amplified by PCR. A 
typical single PCR reaction was made up with aliquots (1 μl) of 1/100 dilution of 
the miniprep as a template, 0.5 µL (10 pmol/µL) of both the sense primer (ficolin 
forward) and the antisense primer (ficolin reverse), 2.5 µL (10X) PCR buffer, 0.2
µL dNTPs (200 μM each), 0.125 µL (unit) of Expand High Fidelity taq which 
were added in a 25-μl reaction volume in 0.2 mL thin-walled PCR tubes. A 
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negative control was set up by using the same materials as above but substituting 
the DNA template with 1 µL of water. This PCR reaction was designed to amplify 
the whole L-ficolin encoding sequence. PCR was performed in a PTC-200 thermal 
cycler (Bio-Rad) with heated lid. Amplification was carried out with 35 cycles of 
denaturation at 94°C for 30 sec, annealing at 50°C for 30 sec, and extension at 
72°C for 3 min. A final extension step at 72°C for 7 min was performed. 
2.2.2.1.3. Agarose gel electrophoresis   
The PCR products were analysed by agarose gel electrophoresis along with a 
standard DNA marker and a negative control. Gel electrophoresis was conducted 
using 2% (w/v) agarose in TAE buffer (40 mM Tris-Acetate and 1 mM EDTA, pH 
8.0), containing 0.5 µg/mL ethidium bromide, in an electrophoresis tank 
containing running 1x TAE running buffer. An aliquot of PCR product (5 µL) was 
mixed with 2 µL loading buffer (30% glycerol, 0.25% bromophenol blue, 0.25% 
xylene cyanol). Aliquots (5 µL) of a standard DNA marker (Gene Ruler; 
Fermentas) and DNA samples to be run were loaded into each gel well. The 
samples were run at 90 V for 40 min. The DNA bands were visualised using UV 
light transilluminator and captured using the HeroLab video capture printer.
2.2.2.1.4. PCR purification
The PCR product was purified using the QIAquick PCR Purification Kit 
(QIAGEN), according to the manufacturer’s instructions. DNA adsorbed to the 
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silica membrane in the presence of high salt while contaminants passed through 
the column. Impurities were efficiently washed away, and the pure DNA was 
eluted with Tris buffer and then quantified using a Nanodrop Spectrophotometer. 
2.2.2.1.5. Creation of Blunt-ended DNA product
The purified PCR product was made blunt to allow the conversion of DNA 
fragments with 3'- and 5'-protruding ends to DNA fragments with blunt ends. 
Conversion of the two types of protruding ends was accomplished simultaneously 
by the 3'->5' exonuclease and 5'->3' polymerase activities of Pfu DNA 
Polymerase. Production of the blunt-ended DNA product was carried out with 7
µL purified PCR product, 1 µL 10X PCR buffer, 1 µL dNTPs, and 1 µL (2.5 units) 
Pfu DNA polymerase. The mixture was incubated at 72°C for 30 min.
2.2.2.1.6. Cloning 
The resultant blunt-ended DNA was diluted to a concentration of 5 ng/µL, then 
ligated into a pENTR™ TOPO vector to generate an entry clone using the DNA 
Ligation Kit Solutions (Invitrogen). The following 6 µL reaction was set up: 1 µL
blunt-end PCR product, 1 µL salt solution, 3 µL sterile water, and 1 µL pENTR™ 
TOPO® vector. The mixture was incubated at 22°C for 20 min, then placed on ice 
for 20 min and used to transform E. coli.
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2.2.2.1.7. Transformation 
The TOPO cloning reaction was added into a vial of One Shot® TOP10 
chemically competent E. coli cells, that had been thawed in ice, and mixed gently. 
The mixture was incubated on ice for 20 min. The cell suspension was heat-
shocked for 30 seconds in water at 42°C, and then the tubes were immediately 
transferred to ice for 2 min. Then, 250 μl of S.O.C. Medium (2% tryptone, 0.5% 
yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM 
glucose) were added and incubated at 37°C for 1 hr, with shaking. Then 150 μl of 
the transferred cells were spread on a pre-warmed LB agar plate (containing 50 
μg/mL Kanamycin) and incubated overnight at 37°C.
2.2.2.1.8. Analysis of transformants
The positive transformants (colonies that grew on a Kanamycin-containing LB 
agar plate) were analysed by directional PCR and by sequencing.
Directional PCR
The positive transformants were examined by directional PCR, using 2 sets of 
primers; ficolin forward and M13 reverse primers, and M13 forward and ficolin 
reverse primers, to confirm the correct orientation of the insert. The sequence of 
ficolin insert was amplified by HotStar Taq polymerase kit. The PCR programme 
was initially started with a heat activation step at 95°C for 15 min followed by 
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denaturation at 94°C for 45 s, annealing at 50°C for 45 s, and extension at 72°C 
for 3 min. A final extension step at 72°C for 7 min was performed.
Sequencing
Colonies containing correctly orientated inserts were propagated overnight in 3
mL LB cultures, containing 50 µg/mL Kanamycin, and the transformed plasmid 
containing recombinant L-ficolin was purified using QiaPrep plasmid purification 
kit (Qiagen) and quantified using a Nanodrop Spectrophotometer. Sequencing 
reactions were performed using vector-specific insert-flanking primers (M13 
forward or M13 reverse), to ensure maintenance of recombinant L-ficolin ORF. 
A sequencing reaction mix of 2 µL BigDye, 2 µL buffer (v1.1, Applied 
Biosystems), 1 µL of 3.2 pmol primer (M13 forward or M13 reverse), 400 ng 
template DNA was prepared on ice and made up to a total volume of 10 µL with 
ultra pure water. Samples were added to a preheated block (95°C) and subjected to 
the following thermal profile: [denaturation (96°C for 30 sec), annealing (50°C for 
10 sec), elongation (60°C for 4 min)] for 25 cycles. Amplified ssDNA was diluted 
with 10 µL 18 megohm H2O and precipitated by addition of 50 µL 100% ethanol 
and 2 µL 3M sodium acetate (pH 5.2). The mix was then incubated in the dark at 
room temperature, overnight. Samples were then centrifuged at 15,000 x g for 45 
min. Supernatant was removed and the pellet was washed with 250 µL 70% 
ethanol. Centrifugation was repeated for 15 min, supernatant removed and 70% 
wash repeated. Finally, supernatant was removed and the pellets air-dried at 50°C 
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for 15 min. The sequencing reaction was carried out by the ABI PRISM BigDYE 
Terminator cycle Sequencing Ready Reaction Kit (Perkin Elmer Applied 
Biosystems). The resulting DNA sequences were checked for potential PCR errors
using Chromas version 2.23 and aligned using MEGA3.1 software.  
2.2.2.2. Generating an Expression Clone
The production of an expression clone was performed by LR recombination to 
shuttle the ficolin gene from the entry clone (pENTR™ TOPO), containing the 
ficolin gene flanked by attL sites to a destination vector (pcDNA-DEST40), 
containing a CMV promoter for ficolin expression.
2.2.2.2.1. Recombination reaction 
The reaction was mediated by a Gateway® LR Clonase enzyme mixture 
(Invitrogen), which contains a blend of Int (Integrase), IHF (Integration Host 
Factor) and Xis (Excisionase) enzymes that catalyze the in vitro recombination 
between an entry clone (containing the ficolin gene flanked by attL sites) and a 
destination vector (containing attR sites) to generate an expression clone. LR 
recombination reaction was performed, after miniprep extraction of both the entry 
and the destination vectors, as follows: 2 µL (200 ng) entry clone, 1 µL (400 ng) 
destination vector, 4 µL clonase buffer, TE buffer up to 16 µL and then 4 µL LR 
clonase II enzyme were added. The mixture was incubated at 25°C for 1 hr, then   
2 µL proteinase K was added and the mixture was incubated at 37°C for 10 min.
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2.2.2.2.2. Transformation
The recombination reaction was transformed into One Shot® TOP10 chemically 
competent E. coli cells, as described in section 2.2.2.1.7. Then 150 μl of the 
transferred cells were spread on a pre-warmed LB agar plate, containing 100 
μg/mL Ampicillin, and incubated overnight at 37°C
2.2.2.2.3. Analysis of transformants 
The expression constructs in positive transformants (colonies that grew on an 
Ampicillin-containing LB agar plate) were verified by directional PCR (using two
sets of primers; ficolin forward and BGH reverse primers, and T7 forward and 
ficolin reverse primers) and sequencing from both directions to confirm the 
presence and correct orientation of the ficolin insert, as described before in section 
2.2.2.1.8. 
2.2.2.2.4. Midiprep preparation
After confirmation of the ficolin sequence, a Midiprep preparation was performed 
prior to ficolin expression. Single colonies were transferred to 50 mL LB broth 
medium and raised for plasmid preparation using HP Plasmid Midiprep Kit 
(Sigma, Poole, UK). Overnight broth culture was pelleted at 5,000 x g for 10 min 
and plasmids were purified according to the manufacturer’s instructions. Plasmid 
DNA was eluted in 10 mM Tris-HCl, pH 8.5. DNA quantification and purity was 
assessed using a Nanodrop spectrophotometer.
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2.2.3. Production of FLAG-tagged L-ficolin
2.2.3.1. Creation of FLAG-tagged L-ficolin Construct
A recombinant amino (N)-terminal FLAG-tagged ficolin was created by inserting 
a FLAG peptide, composed of 8 amino acids, DYKDDDDK downstream of the 
signal peptide. This N-terminal FLAG tag is recognised by the monoclonal 
antibody M2 (Sigma), which was subsequently utilised for detection and 
purification of the recombinant ficolin.
2.2.3.1.1. Detection of the Cleavage Site
The recombinant L-ficolin is normally cleaved post-translationally. The cleavage 
site of the signal peptide was determined using SignalP-NN Prediction. The
insertion site of the N-terminal FLAG tag was designed to be immediately 
downstream of the cleavage site (between aa 25 and 26), to overcome the effect of 
post-translational processing. The cleavage site was re-evaluated taking in 
consideration the new aa sequence after inserting the FLAG peptide.
2.2.3.1.2. Fusion PCR
After determination of the cleavage site of the signal peptide, the FLAG-tagged 
recombinant L-ficolin was produced by fusion PCR (figure 2.2).
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2.2.3.1.2.1. The First Round PCR
In a first round PCR, 2 fragments were created; fragment A, using ficolin forward
and FLAG-signal antisense primers, and fragment B, using FLAG-ficolin sense 
and ficolin reverse primers (figure 2.2). The PCR reaction was carried out with 5 
pmol sense primer (ficolin forward/FLAG-ficolin sense) and antisense primer
(FLAG-signal antisense/ficolin reverse), 0.5 U of Expand High Fidelity 
polymerase, and 200 μM dNTPs in a 25-μl reaction volume containing 1x Expand 
Buffer. The cycling parameters for PCR amplification consisted of 35 cycles of the 
following conditions: 30 sec at 94°C, 30 sec at 50°C, and 30 sec at 72°C, followed 
by a final step at 72°C for 7 min. PCR products were confirmed by agarose gel 
electrophoresis and purified using QIAQuik columns (Qiagen, UK). 
2.2.3.1.2.2. The second Round PCR 
In the second round PCR, the fragment A amplicon and the fragment B amplicon
were used as primers and templates to each other to produce the N-terminal 
FLAG-tagged ficolins (figure 2.2). The amplification reaction was performed at 
1:1 molar ratio, using 12 µL (150 ng) of fragment A product and 48 µL (1310 ng) 
of fragment B product in a 250 µL reaction. The second round PCR was done
using similar conditions to the first-round ampliﬁcation. Resultant recombinant    
L-Ficolin was again confirmed by agarose gel electrophoresis.
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Figure 2.2: Creation of FLAG-tagged L-ficolin by fusion PCR. 
A schematic diagram illustrating the creation of FLAG-tagged L-ficolin by fusion 
PCR. (a) two sets of primers were used in the first round PCR. P1 (ficolin forward) 
and P2 (FLAG signal antisense) to create fragment A (the signal peptide and part 
of the FLAG tag). P3 (FLAG ficolin sense) and P4 (ficolin reverse) to produce 
fragment B (the proper ficolin chain and a part of the flag tag). Both fragments A 
and B (b) were combined in the second round PCR to produce the full-length      
L-ficolin (c), including the FLAG tag.
2.2.3.2. Generating an Entry Clone
As described in section 2.2.2.1., the final PCR product was column purified using 
QIAquick PCR Purification Kit. The purified recombinant L-ficolin was blunt-
ended. Then, the resulted blunt-ended DNA was diluted to a concentration of 5 
ng/µL and ligated into the pENTR™ D-TOPO vector. The TOPO cloning reaction 
was transformed into TOP10 chemically competent E. coli cells. Finally, the 
correct orientation of the insert was confirmed by analysing the positive 
transformants by directional PCR. 
P1 P2
P3 P4
Fragment A Fragment B
FLAG
(a)
(b)
(c)
First round PCR
Second round PCR
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2.2.3.3. Generating an Expression Clone
As described in section 2.2.2.2, the recombinant L-ficolin gene was transferred 
from the entry vector to the destination vector (pcDNA-DEST26TM, Invitrogen) 
using LR Clonase™ II Enzyme Mix to generate an expression clone. Then, the 
recombinant plasmids were transformed into E. coli One Shot® TOP10 
Competent Cells and the selection of the resistant cells was performed on 
Ampicillin-containing LB-agar plates (100 µg/mL). The recombinant L-ficolin 
insert was verified by directional PCR, using T7 forward and ficolin reverse 
primers and by sequencing using vector primers M13 forward and M13 reverse. 
2.2.4. Cell Culture and Expression of Constructs
2.2.4.1. Cell Lines and Media
The human epithelial kidney (HEK) 293FT cell line (Invitrogen, Paisley, UK) 
stably transfected with pCMVSPORT6TAg.neo plasmid was used for transfection 
with plasmids encoding either His-tagged or FLAG-tagged L-ficolin. The cells 
were thawed and growth medium was added [Dulbecco’s Modified Eagles 
Medium with 2 mM L-glutamine (GIBCO) supplemented with 10% FBS, 0.1 mM 
NEAA, 500 µg/mL Geneticin (to maintain pCMVSPORT6TAg.neo)]. Cells were 
maintained in 75-cm2 polystyrene cell culture flasks fitted with 0.22 µm filter caps 
(Nunc), containing approximately 20 mL growth medium.
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2.2.4.2. Cell Manipulation and Culture
2.2.4.2.1. Manipulation
All cell manipulations described in this chapter were carried out in a class II 
vertical laminar flow cabinet (Envair) which was cleaned with 70% v/v ethanol (in 
water), before and after each manipulation. All cell lines were grown in a LEEC 
CO2 incubator, at a temperature of 37ºC in 5% CO2 humidified atmosphere.
2.2.4.2.2. Cell Storage
2.2.4.2.2.1. Transfer of cells from frozen storage
Frozen cells were removed from liquid nitrogen storage and defrosted rapidly in 
warm water. The resulting suspension was transferred to a 75-cm2 polysterene cell 
culture flask and 20 mL fresh growth medium were added to the cell culture flask. 
The growth medium was changed after approximately 24 hrs, and the cells were 
passaged when confluent (typically after 3 days).
2.2.4.2.2.2. Transfer of cells to frozen storage
The growth medium was removed by aspiration; the remaining cells were washed 
by swirling with 10 mL sterile PBS, pre-warmed to 37ºC. The cell monolayer was 
disrupted with 5 min incubation with 2 mL 10% trypsin/EDTA in PBS, pre-
warmed to 37ºC. Flasks were shaken to help disrupt the cell monolayer. The 
resulting cell suspension was transferred to a sterile tube diluted with 8 mL fresh 
growth medium and centrifuged at 250 x g for 5 min. Following centrifugation, the 
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supernatant layer was removed and the pellet was re-suspended in 8 mL of 10% 
v/v DMSO in FBS. Each mL of the resulting suspension was transferred to a cryo 
vial suitable for storage in liquid nitrogen.
2.2.4.2.3. Cell Passage
The first part of this procedure was identical to that described in section 
2.2.4.2.2.2. Following the centrifugation step, the supernatant was discarded and 
the cell pellet re-suspended in 10 mL fresh growth medium (pre-warmed to 37ºC). 
A small amount (10 µL) of the resulting suspension was pipetted into each 
chamber of a Neubauer haemocytometer, which has 25 central squares, and 
allowed to settle for 1 min before counting. All cells within the 5 X 5 division 
grids of both chambers were counted. The mean count was calculated and the 
numbers of cells was calculated using the following equation: Number of cells/mL 
= Mean cell count X dilution factor (10) X 104. The suspension was diluted with 
fresh growth medium and poured into cell culture plates or cell culture flasks.
2.2.4.3. Transfection of HEK 293FT Cells
HEK 293FT Cells were used for transient expression of the L-ficolin constructs. 
Transfection was carried out using the cationic lipid reagent, LipofectamineTM
2000. Tissue culture plates (9 cm) were seeded at a density of 2x105 cells/mL one 
day prior to transfection and incubated overnight for 90% confluence at 
transfection. Medium was changed with Opti-MEM medium 3 hrs prior to 
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transfection. Two tubes A and B were prepared containing; A: 24 μg of a plasmid 
DNA encoding recombinant L-ficolin in 1.5 mL Opti-MEM and B: 60 μl 
Lipofectamine in 1.5 mL Opti-MEM. Tube B was incubated for 5 min at room 
temperature before addition to tube A. After mixing, the transfection solution was 
incubated for 20 min at room temperature to allow the DNA-Lipofectamine 
complexes to form. Then 3 mL of the transfection solution per plate were added 
drop wise to cells and mixed gently. The cells were incubated at 37ºC, in 5% CO2
incubator. Six hours after transfection, the medium was removed and replaced by 
Dulbecco’s modified Eagle’s medium and reincubated. 
The supernatants containing L-ficolin were harvested 72 hrs after transfection and 
centrifuged at 250 x g for 5 min to remove any cell remnants before adding 
Protease Inhibitor Cocktail (Roche), to inhibit serine and cysteine proteases.           
A proportion of the supernatants was analysed for L-ficolin content by Sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and the 
reminder of the supernatant was stored at -20°C. 
2.2.5. SDS-PAGE, Western Blot Analysis and Silver Stain
2.2.5.1. SDS-PAGE
Separation of proteins was achieved by SDS-PAGE according to the Laemmli 
method [283]. The samples were electrophoresed in 10% SDS-polyacrylamide 
gels. In a discontinuous system, a non-restrictive large pore gel, called a stacking 
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gel, is layered on top of a separating gel called a resolving gel. Each gel is made 
with a different buffer. The stacking gel (2.5 mL per gel) and 10% polyacrylamide 
resolving gel (7.5 mL per gel) were prepared as follow: stacking gel [1.7 mL H2O, 
415 µL 30% acrylamide, 315 µL 1 M Tris (pH 6.8), 12.5 µL 20% SDS, 8.5 µL 
30% APS and 5 µL TEMED] and resolving gel [3 mL H2O, 2.5 mL 30% 
acrylamide, 1.9 mL 1.5 M Tris (pH 8.8), 37.5 µL 20% SDS, 50 µL 30% APS and 
11.25 µL TEMED]. Samples were added to equal volumes of 2 times Laemmli 
Buffer (100 mM Tris-HCl pH 6.6, 4 % SDS, 20 % glycerol, 0.2 % Bromophenol 
blue). Generally, unless mentioned otherwise, the protein samples were loaded 
under non-reduced conditions, as a standard reaction condition. Reduced 
experiments are mentioned wherever used. Dithiothreitol (DTT) [40 mM] was 
added to 2X Laemmli Buffer for reduced samples. The Full-range Rainbow 
Marker Protein Standard (GE Healthcare) was used as a molecular weight 
standard. All samples were heated at 95°C for 5 min. and gels were run at 150V 
for 90 min. 
2.2.5.2. Western Blot Analysis
After electrophoresis, proteins were transferred, as described by Towbin et al., 
1970 [284], to Hybond ECL nitrocellulose membranes (Amersham), using a 
Trans-Blot Semi-Dry Transfer Cell (BioRad). Blotting paper and nitrocellulose 
membrane were soaked in Transfer Buffer (39 mM glycine, 48 mM tris base, 
0.037 % SDS, 20 % methanol, pH 8.3) before addition to the blotter. Proteins were 
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transferred under a current of 1mA/cm2 for 1.5 hr. Membranes were blocked in 50 
mL blocking solution (5 % Marvel in PBS-Tween) with gentle shaking for 1 hour 
or overnight. The blot was washed 3 times for 5 minutes per wash in 100 mL PBS-
Tween (0.05 % Tween 20) and then incubated in primary antibody solution in 
PBS-Tween for 1 hour with gentle rocking. Expression of His-tagged L-ficolin 
was detected by either anti-L-ficolin monoclonal antibody, GN5 or penta-his 
monoclonal antibody. The FLAG-tagged L-ficolin was probed with either anti-   
L-ficolin monoclonal antibody, GN5 or anti-FLAG monoclonal antibody M2 
(table 2.2). After incubation with primary antibody, washes were repeated to 
remove the excess antibody and membranes incubated with HRP-conjugated goat 
anti-mouse secondary antibody diluted in PBS-Tween for 1 hour with gentle 
rocking followed by three washes for 5 minutes per wash. The blots were 
developed using enhanced chemiluminescence detection reagents ECL-Plus (GE 
Healthcare, UK) for 1 min and then removed from the solution and wrapped in 
cling film. The membrane was put into a film case and brought to the dark room. 
A sheet of Kodak film (Kodak Bio Max Film) was overlaid on the blot for 2 
minutes. Then the film was soaked in developer for 2 minutes, fixed in fixing 
solution for 2 minutes, then washed in water for 2 minutes and allowed to dry.
2.2.5.3. Silver Stain
Samples were added to equal volume of Laemmli buffer under non-reducing and 
reduced conditions (with 20 mM DTT), then loaded and gel electrophoresis was 
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performed as in section 2.2.5.1. Staining gel with Silver stain was carried out using 
SilverQuest stain kit (Invitrogen) according to manufacturer’s instruction. After 
staining, the gel was dried using a Dry Ease Gel Drying System (Invitrogen).   
2.2.6. Purification of Expressed Proteins
2.2.6.1. Purification of His-tagged L-ficolin
2.2.6.1.1. Immobilised Metal Affinity Chromatography
Nickel agarose gel was used for purification of the polyhistidine-tagged L-ficolin 
by Immobilised Metal Affinity Chromatography (IMAC) using a 1 mL HisTrap 
Chelating HP column (GE Healthcare). The supernatant containing L-ficolin was 
injected and loaded onto the column. Weakly-bound proteins were then washed off 
with 5 column volumes (CV) wash in Wash Buffer (20 mM sodium phosphate, 
300 mM NaCl, and 20 mM imidazole pH 7.4). Then an eultion step, 5 CV steps of 
50 mM imidazole [0-500 mM imidazole using Elution Buffer (20 mM sodium 
phosphate, 300 mM NaCl, 0.5 M imidazole, pH 7.4)]. A post elution step of 5 CV 
of 0.5M imidazole was used to ensure removal of all proteins. The start material, 
flow-through, wash and eluate were analysed by western blot analysis and ELISA, 
and the peak fractions were kept at 4°C, for further analysis. 
2.2.6.1.2. Ion Exchange Chromatography
A Mono Q 5/50 GL Tricorn column (Amersham) was equilibrated with start buffer 
(20 mM Tris-HCl, pH 8.0) for 10 minutes at a flow rate of 0.5 mL/min. The 
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sample was loaded onto the column at the same flow rate. The bound protein was 
then eluted in a 20 mL linear salt gradient from 50 mM to 1 M NaCl, in 20 mM 
Tris-HCl, pH 8.0. The column flow-through and eluates were collected in 1 mL
batches and analysed for the presence of L-ficolin by western blot analysis and 
ELISA. 
2.2.6.2. Purification of FLAG-tagged L-ficolin
FLAG-tagged L-ficolin was purified by affinity chromatography using anti-FLAG 
M2 affinity gel (Sigma). Prior to loading the L-ficolin sample, the affinity matrix 
was equilibrated with wash buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.4). 
Binding of FLAG-tagged ficolin to the M2 gel was performed by incubation for 3 
hrs at room temperature with gentle mixing to capture the FLAG-tagged ficolin. 
Contaminants were washed off the resin with wash buffer, in a column format, 
until the absorbance of the eluate at 280 nm was less than 0.05 versus a wash 
solution blank. Bound FLAG-tagged L-ficolin was eluted off the column by 
competitive elution with 5 CV of a solution containing 175 ng/µL FLAG peptide 
in wash buffer. One millilitre fractions were collected, and the protein-containing
fractions were pooled and dialysed against TBS buffer. The purity of the expressed 
L-ficolin was monitored by SDS-PAGE. L-ficolin-containing fractions were stored 
at −20 ˚C.
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2.2.7. Purification of Serum L-ficolin
Serum ficolin was isolated from 1 litre of citrated human plasma (HD Supplies) 
using a method adapted from Cseh et al. [285]. 
2.2.7.1. Immobilisation of GlcNAc on Sepharose-4B
Sepharose-4B beads (GE Healthcare) were derivatised with GlcNAc according to 
Krarup et al., 2004 [286]. The beads were activated by incubation with 10% (v/v) 
divinyl sulfone in 0.5 M Na2CO3, pH 11, for 1.5 h at room temperature. Then the
beads were washed with 250 mM Na2CO3, pH 11, and derivatised in 250 mM 
Na2CO3, pH 11 containing 10% (w/v) GlcNAc overnight at room temperature. 
After washing the beads with water, they were incubated with 100 mM 
ethanolamine, pH 9, to block residual active groups, before a final wash with TBS 
buffer (50 mM Tris, 150 mM NaCl, 20 mM CaCl2, pH 7.4).
2.2.7.2. L-ficolin Purification
Plasma was coagulated by addition of 1 M CaCl2 to a final concentration of 20 
mM CaCl2 and incubated at 37 ˚C for 30 min, followed by incubation at 4 ˚C for 3
hrs. The serum was collected from the clot by centrifugation at 3000 X g.
Polyethylene glycol (PEG) 4000 was added to the serum to a final concentration of 
7% (w/v) PEG. After incubation at 4 ˚C for 2 hrs, the PEG precipitate was 
separated by centrifugation for 30 min at 4000 X g at 4 ˚C. The pellet was 
dissolved in 200 mL TBS (50 mM Tris, 0.2 M NaCl, 20 mM CaCl2, pH 7.4), 
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followed by incubation with GlcNAc-Sepharose-4B beads for 2 hrs at 4 ˚C. The 
matrix was washed with TBS until absorbance of flow-through at 280 nm was 
0.001. Bound MBL was eluted by a mannose wash (0.1 M mannose solution in 
TBS), then ficolin was eluted with 0.6 M GlcNAc in TBS. Pooled ficolin fractions 
were dialysed against TBS.
2.2.8. Ficolin quantitation
The levels of recombinant, as well as purified serum L-ficolin were determined by 
ELISA, based on another assay developed by Dr Anders Krarup (MRC 
Immunochemistry Unit, Department of Biochemistry, University of Oxford), using 
biotinylated anti L-ficolin monoclonal antibodies, GN5. A standard L-ficolin 
preparation was kindly provided from Dr Anders Krarup [286].
2.2.8.1. Biotinylation of anti L-ficolin (GN5)
The GN5 antibody was dialysed in 0.1M Sodium Borate Buffer (pH 8.8).             
N-hydroxysuccinimidobiotin (Sigma) was prepared at 10 mg/mL in dimethyl 
sulphoxide (DMSO). The antibody solution was mixed with biotin ester at a ratio 
of 2.5 mg of ester per mg of antibody. After vortexing for 5 min, the mixture was 
incubated at 4°C for overnight on a rotor. Then, 20 µL of 1M NH4Cl were added 
per 250 µg of ester, to inactivate free biotin, and incubated for a further 10 min at 
room temperature. The mixture was then dialysed against PBS at 4°C for 
overnight on a rotor. 
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2.2.8.2. ELISA
MaxiSorb microtiter plate wells (Nunc, Denmark) were coated with 100 µL of 1
mg/mL bovine serum albumin (BSA) in phosphate buffered saline (PBS) (figure 
2.3). After overnight incubation at 4°C, wells were incubated for 2 hrs at room 
temperature with 100 µL 0.1% acetic anhydrid in methanol, to acetylate BSA. 
Wells were thereafter blocked with 200 µL of PBS, 0.05% (v/v) Tween 20 (PBS-
Tween), containing 5% milk powder for 4 hrs at room temperature. The plate was 
washed three times (Denley Well Wash) with TBS (10 mM Tris–Cl, 140 mM 
NaCl, pH 7.4), containing 0.05% Tween 20 and 5 mM CaCl2 (wash buffer). All 
subsequent washes were performed with this buffer. Wells were washed and 
incubated with 100 µL of a source of L-ficolin, diluted in PBS-Tween, overnight 
at 4 ˚C. After this incubation, the plates were washed 3 times as before. For 
detection of L-ficolin, 100 µL of mouse IgG monoclonal biotin-labelled anti-
human L-ficolin antibody (GN5, 0.5 µg/mL) were added to each well. The plates 
were incubated for 2 hrs at room temperature. Wells were washed and incubated 
for 30 min at 37 ˚C with a 1:5000 dilution of a streptavidin-alkaline phosphatase
(streptavidin-AP) conjugate in wash buffer. Following a further three washes with 
TBS-Tween, binding was visualised with 100 µL of p-nitrophenyl phosphate 
substrate (pNPP). The absorbance was measured at 405 nm using a Vmax plate 
reader (Molecular Devices) after 30 min. 
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A two-fold dilution series (1/6.25 to 1/400) of a pooled human serum in PBS-T 
were added to the wells. PBS-Tween was used as a negative control (blank).        
L-ficolin levels were quantified using a standard curve (figure 5.2) generated using
a two-fold serial dilution of a pooled serum, containing 4 µg/mL. This sample was 
quantified by comparison to a standard L-ficolin preparation, as previously 
described [286]. Optical densities of the standard sample were used to determine 
standard curves on a log 10 scale and interpolated X-values were obtained, as 
described in section 5.3.1.
Figure 2.3: Quantitation of L-ficolin by ELISA. 
A schematic diagram shows the components of the ELISA assay used to quantify 
recombinant and serum-derived L-ficolin. The wells were coated with BSA 
followed by acetic anhydride. Ficolin samples were added and the bound ficolin 
was detected by biotinylated monoclonal anti-L ficolin, GN5. Streptavidin-alkaline 
phosphatase (streptavidin-AP) conjugate was added followed by p-ntirophenyl 
phosphate (pNPP) substrate. The OD was determined at 405 nm.
OD 405
pNPP
Streptavidin-AP
Biotinylated GN5
L-ficolin
Acetylated BSA
Chapter 2                                                     Production and Purification of L-ficolin                                                                                                                                                                                                  
79
2.3. Results
2.2.2. Production of His-tagged L-ficolin
2.2.2.1. Generating an Entry Clone
PCR was carried out for the extracted miniprep of the IMAGE vector (pPCR-
Script Amp SK) containing the coding region for the full-length human L-ficolin, 
using ficolin forward and ficolin reverse primers with Expand High Fidelity PCR 
system (figure 2.4). 
Figure 2.4: Detection of ficolin insert in IMAGE vector by PCR. 
PCR amplification of the full-length human L-ficolin insert in IMAGE vector, 
using ficolin forward and ficolin reverse primers. The ficolin insert 942 base pair 
(bp), was detected in lane 1. Lane 2 is a negative control, containing no DNA 
template.
The PCR product was purified then blunt-ended and ligated into a pENTR vector 
to generate an entry clone. The cloning product was transformed into TOP10 
chemically competent E. coli cells that were plated out onto Kanamycin-
M     1     2      
2000 bp
1000 bp
500 bp
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containing LB agar plates for selection of the resistant cells as the pENTR vector 
carries a Kanamycin resistance gene. After overnight incubation, ten colonies were 
selected and screened by PCR (figure 2.5), using the vector primers; M13 forward 
and M13 reverse primers, to confirm the presence of the insert. 
Figure 2.5: Screening of the colonies for positive transformants by 
directional PCR.
After transformation of the L-ficolin DNA ligated to pENTR vector into TOP10 E. 
coli, 10 colonies (1-10) were screened by PCR using M13 forward and M13 
reverse primers for positive transformant colonies containing pENTR. The 
colonies no. 3 (lane 3) and no. 4 (lane 4) are positive transformants, containing the 
ficolin insert. Lane 11 represents a negative control, containing no DNA template.
Two colonies were detected by PCR (figure 2.5; lane 3 and 4) as positive 
transformants with ficolin-carrying pENTR, and directional PCR was carried out 
for them to confirm the correct orientation of the insert (figure 2.6).
Both positive transformants (colonies 3 and 4) contained the ficolin insert with 
correct orientation as confirmed by directional PCR (figure 2.6; A: lane 1 and 2 
and B: lane 4 and 5) and by sequencing.
M   1   2    3   4    5   6   7   8   9 10  11       
2000 bp
1000 bp
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Figure 2.6: Directional PCR for the positive transformants with pENTR.
Directional PCR for positive transformant colonies (no. 3 and 4), using; A: ficolin
forward and M13 reverse primers (lane 1 and 2), B: M13 forward and ficolin
reverse primers (lane 4 and 5). Detection of the ficolin insert in both sets of 
reactions confirms the correct orientation of the insert. Lane 3 and 6 represent 
negative controls, containing no DNA templates.
The sequencing reactions were performed with BigDye 1.1 chemistry using 
vector-specific insert-flanking primers (M13 Forward and M13 Reverse primers) 
for plasmid DNA isolated, from the positive transformant, by miniprep extraction. 
The resulting DNA sequences were checked using Chromas version 2.23 and the 
resulting ORF checked using MEGA3.1 software. Sequence analysis and 
alignment against ficolin sequence database revealed a 100% match with the 
reference ficolin sequence (NCBI data base; accession number: NP_004099). 
Figure 2.7 represents the amino acid sequence of L-ficolin. A glycerol stock was 
made from each colony to be used as a source of entry clone in recombination 
reaction to generate an expression clone.
2000 bp
1000 bp
500 bp
M   1   2    3  M   4   5   6       
A              B
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1 MELDRAVGVLGAATLLLSFLGMAWALQAADTCPEVKMVGL 40
41 EGSDKLTILRGCPGLPGAPGPKGEAGTNGKRGERGPPGPP 80
81 GKAGPPGPNGAPGEPQPCLTGPRTCKDLLDRGHFLSGWHT 120
121 IYLPDCRPLTVLCDMDTDGGGWTVFQRRVDGSVDFYRDWA 160
161 TYKQGFGSRLGEFWLGNDNIHALTAQGTSELRVDLVDFED 200
201 NYQFAKYRSFKVADEAEKYNLVLGAFVEGSAGDSLTFHNN 240
241 QSFSTKDQDNDLNTGNCAVMFQGAWWYKNCHVSNLNGRYL 280
281 RGTHGSFANGINWKSGKGYNYSYKVSEMKVRPA 313
Figure 2.7: Amino acid sequence of L-ficolin.
The figure shows the amino acid sequence of L-ficolin. The different regions 
within the polypeptide chain are highlighted in different colours, as follows: the 
signal peptide (A), the amino terminal region (A), the collagen-like domain (A), 
the neck region (A), and the fibrinogen-like domain (A). The underlined amino 
acid sequences refer to the potential glycosylation sites. This sequence is available 
in UniProtKB database, accession: Q15485.
2.2.2.1. Generating an Expression Clone
LR recombination reaction was carried out between the entry clone pENTR and 
the destination vector pcDNA-DEST40 to generate an expression clone. The 
reaction was performed using LR Clonase enzyme mixture, which contains the 
necessary enzymatic activity to excise the gene of interest from the entry clone and 
integrate it into the destination vector pcDNA-DEST40 which provides the CMV 
promoter for high-level, constitutive expression in mammalian systems. The 
destination vector has the attR1 and attR2 sequences and the counter selectable 
marker ccdB. Upon addition of LR Clonase, the expression clone is produced 
along with a by-product plasmid containing ccdB. The ccdB protein poisons DNA 
gyrase, causing degradation of the host chromosome and cell death. The 
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recombination reaction was transformed into TOP10 chemically competent E. coli
cells. As the destination vector contains an Ampicillin resistance gene, the 
expression clones are selected on Ampicillin-containing plates. Thus, 150 µL of 
the transformed cells were plated out on an Ampicillin-containing LB plate to 
select the positive transformants. 
Then, positive transformants were verified by PCR (figure 2.8), using 2 sets of 
primers; ficolin forward and BGH reverse primers, and T7 forward and ficolin 
reverse primers to confirm the presence and correct orientation of the ficolin 
insert. All the 10 colonies contained the ficolin insert with correct orientation as 
confirmed by directional PCR (figure 2.8) and by sequencing. The correct ficolin 
insertion in all selected colonies represents high recombination efficiency. A 
glycerol stock was made from one colony to be used as a source of expression 
clone and midiprep extraction was done to be used for transfection.
Figure 2.8: Directional PCR for the positive transformants with pcDNA 
DEST40.
Directional PCR for ten positive transformant colonies (1-10), using; A: ficolin
forward and BGH reverse primers, and B: T7 forward and ficolin reverse primers. 
All the selected colonies showed the presence of the ficolin insert in both sets of 
reactions, confirming the correct orientation of the ficolin insert. 
2000 bp
1000 bp
500 bp
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2.2.3. Production of FLAG-tagged L-ficolin
2.2.3.1. Creation of FLAG-tagged ficolin construct
Determination of the signal peptide cleavage site was performed using SignalP-
NN Prediction. The cleavage site was determined to be between aa 25 and 26. 
Thus, the insertion site of the N-terminal FLAG tag was designed to be 
immediately downstream of the cleavage site. Figure 2.11 shows the sequence data
of the insertion site of N-terminal FLAG peptide.
An amino-terminal FLAG-tagged L-ficolin construct was produced by insertion of 
the FLAG peptide downstream of the cleavage site, by fusion PCR (figure 2.9).
The first round PCR products (A amplicon; lane 1 and B amplicon; lane 2) were 
combined in the second round to produce a full-length FLAG-tagged ficolin (lane 
3).
2.2.3.2. Generation of an Entry Clone 
The full-length FLAG-tagged ficolin was cloned into the pENTR™ TOPO entry 
vector and transformed into TOP10 E.coli, which were plated onto Kanamycin-
containing LB agar plates for selection of positive transformants. Ten growing 
colonies of TOP10 E. coli were examined by directional PCR (figure 2.10), using; 
A: ficolin forward and M13 reverse primers, B: M13 forward and ficolin reverse 
primers. The ficolin insert was detected in the colony no. 8 in both sets of 
reactions.
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Figure 2.9: Creation of FLAG-tagged L-ficolin by fusion PCR.
Gel electrophoresis and ethidium bromide staining of the resulting PCR products. 
(a) First round PCR products; fragment A (lane 1), using ficolin forward and 
FLAG-signal antisense primers and fragment B (lane 2), using FLAG-ficolin sense 
and ficolin reverse primers. (b) Second round PCR product: fragment A and 
fragment B were purified and combined in the second round to act as primers and 
templates to each other to produce the final terminal FLAG-tagged ficolin, C (lane 
3). The DNA size marker (M) is shown on the left, in base pairs (bp).
Figure 2.10: Directional PCR for the positive transformants with pENTR.
Directional PCR for 10 colonies (1-10) of transformed TOP10 E. coli growing on 
a Kanamycin-containing LB agar plate, using; A: ficolin forward and M13 reverse 
primers, B: M13 forward and ficolin reverse primers. The ficolin insert can be 
detected in the colony no. 8 in both sets of reactions, confirming the correct 
orientation of the insert.
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Bidirectional sequence analysis was also performed to check the sequence 
integrity of the ficolin insert (figure 2.11), using M13 forward and M13 reverse 
primers. The contiguous DNA sequences were constructed from forward and 
reverse sequencing reactions. The chromatograms showing the sequence data 
generated by Chromas version 2.23 revealed the ficolin sequence including the 
inserted octapeptide FLAG tag, that would enable further ficolin purification, 
downstream of the signal peptide.
Figure 2.11: Sequence data; insertion of N-terminal FLAG peptide.
Chromatograms showing examples of sequence data generated by Chromas 
version 2.23. The upper chromatogram (A) depicts the sequence of the amino-
terminal end of L-ficolin and the black arrow points at the insertion site of the 
FLAG peptide. The lower chromatogram (B) shows the sequence of the upper 
segment after insertion of octapeptide affinity epitope (FLAG) tag (24 bp).
A
B
FLAG (eight amino acid affinity epitope) tag
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2.2.3.3. Generation of an Expression Clone 
The ficolin insert was subsequently transferred from the entry vector to the 
destination vector pcDNA-DEST26 for expression of the recombinant FLAG-
tagged L-ficolin. The expression clone was also verified for the presence and 
orientation of the ficolin insert by directional PCR, then the ficolin sequence was 
confirmed by bidirectional sequence analysis.
2.2.4. Expression of L-ficolin Constructs
Recombinant L-ficolin was produced by transient transfection of His-tagged and 
FLAG-tagged L-ficolin into HEK 293FT cell line using Lipofectamine with 
serum-free media, to eliminate BSA contamination. The ficolin-containing 
supernatants were harvested and the ficolin was separated by SDS-PAGE using
10% polyacrylamide gels, under non-reducing and reducing conditions. Western 
blot was carried out for detection of the expressed ficolin. 
His-tagged ficolin was detected with either 5-His primary antibody or GN5, anti 
L-ficolin monoclonal antibody, then anti-mouse monoclonal HRP-conjugated 
antibody was used as a secondary antibody. SDS-PAGE under non-reducing 
conditions demonstrated that recombinant L-ficolin was a mixture of monomers 
and oligomers (figure 2.12). Besides the monomeric band at 35 kDa, covalent 
oligomers ranged from dimers (70 kDa) to oligomers containing several subunits. 
The presence of two bands at 35 kDa may represent 2 separate polypeptides 
Chapter 2                                                     Production and Purification of L-ficolin                                                                                                                                                                                                  
88
differing in glycosylation. A significant band was observed above the 250 kDa
band of the marker possibly corresponding to the 12-mer consisting of four 
trimeric L-ficolin oligomers. Some weaker bands can be seen above the possible 
12-mer, suggesting that L-ficolin is able to form covalently-linked higher 
molecular weight oligomers. Under reducing conditions (figure 2.12 B), by adding 
DTT to a final concentration of 20 mM, the oligomers were reduced to monomers
with a molecular mass of 35 kDa as a result of disruption of the disulphide bonds 
connecting oligomeric ficolin.
FLAG-tagged L-ficolin was analysed by western blot using M2 anti-FLAG 
antibody or GN5, then anti-mouse monoclonal HRP-conjugated antibody were 
used as a secondary antibody (figure 2.12 A). Similar to His-tagged L-ficolin (H), 
FLAG-tagged L-ficolin (L) separated into a ladder of bands from 35 kDa to the top 
of the gel, suggesting the formation of dimmers (70 kDa) and oligomers of the 35
kDa subunit. The possible L-ficolin oligomers are seen at and above 250 kDa. As a 
negative control, a cell culture supernatenat from untransfected HEK 293FT cells 
(U) was also examined using the same antibodies.
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Figure 2.12: Detection of expressed L-ficolin by western blot analysis.
Both His-tagged (H) and FLAG-tagged (F) L-ficolin were produced by 
transfection in HEK 293FT cells using lipofectamine. Supernatant samples were 
loaded on 10% SDS-PAGE gels, then blotted. Panel A: Detection of L-ficolin (H 
and F) by western blot analysis was carried out with GN5, monoclonal anti-human 
L-ficolin, followed by goat anti-mouse peroxidase conjugated secondary antibody, 
under non-reducing conditions. Ficolin monomer is visible at 35 kDa and 
oligomeric forms are also visible at and above 250 kDa. Cell culture supernatenat 
from untransfected HEK 293FT cells (U) was used as a negative control. Panel B: 
His-tagged L-ficolin subjected to 10% polyacrylamide gel under non-reducing (N) 
and reducing (R) conditions. There are 2 bands at 35 kDa which could represent 2 
separate polypeptides differing in glycosylation. Disruption of disulphide bonds 
under reducing conditions, using DTT at a final concentration of 20 mM, was 
evident by disappearance of the higher oligomeric forms, which were replaced by 
monomeric ficolin visible at 35 kDa. Position of protein size markers are shown 
(in kDa)
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2.2.5. Purification of Expressed L-ficolin
2.2.5.1. Purification of His-tagged L-ficolin
The expressed His-tagged L-ficolin was nickel agarose purified by metal affinity 
chromatography, using 20 mM imidazole in the initial binding stage and thereafter 
a stepwise gradient up to 500 mM to release the bound ficolin. Fractions of 1 mL
were collected and the purification profiles of the recombinant L-ficolin protein 
were studied by SDS-PAGE and immunoblot analysis as well as ELISA. 
Purification of L-ficolin (figure 2.13) revealed an elution profile where some 
putative degradation products of the L-ficolin were seen in the 200 mM imidazole 
fractions, whereas the majority of the multimeric protein eluted at 250 mM 
imidazole, although some putative degradation was visible. L-ficolin quantitation 
of the different fractions was determined by ELISA, previously described in 
section 2.2.8.2. Protein concentrations of more than 10-12 ug purified protein/mL 
elution buffer was achieved using these conditions. A total of 50 ug of purified    
L-ficolin could be obtained from 45 mL of cell culture. The peak fractions were 
pooled and dialysed against PBS then further purified by Mono Q ion exchange 
chromatography using a linear gradient from 50 mM 1 M NaCl. The multimeric  
L-ficolin was eluted at 400-500 mM NaCl. 
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Figure 2.13: Detection of purified His-tagged ficolin.
Supernatants from 3 tissue culture plates (45 mL) were harvested and nickel 
agarose purified using a step gradient (50 mM rises) of imidazole. The start 
material (S), flow-through (F), wash (W) and the eluted fractions (1 to 34, every 
third fraction) were loaded on 10% SDS-PAGE gels (a) and quantified for ficolin 
content by ELISA, previously described in section 2.2.8.2 (b). Ficolin was 
detected by western blot analysis (a) using penta-His primary antibody and anti-
Mouse monoclonal peroxidase conjugated secondary antibody. L-ficolin 
polypeptide is visible as a band ~35 kDa in fractions 19 and 22, at an imidazole 
concentration of 200 mM, representing monomeric L-ficolin. Another peak of 
eluted ficolin is detectable in fraction 25, 28 and 31, at an imidazole concentration 
of 250 mM, representing multimeric L-ficolin. Quantification of ficolin content in 
the eluted fractions by ELISA (b) revealed 2 peaks matching with those detected 
in western blot analysis; one lower peak in fractions 19 and 22, and a second 
higher peak in fractions 25, 28 and 31, containing multimeric L-ficolin.
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The silver stained SDS-PAGE (figure 2.14) after ion exchange chromatography of 
the IMAC-purified His-tagged L-ficolin revealed that the eluted fractions showed 
L-ficolin protein sample of high purity. 
Figure 2.14: Silver stain of purified His-tagged L-ficolin.
After IMAC purification of His-tagged L-ficolin, the peak fractions were pooled 
and further purified by ion exchange chromatography using a linear gradient of 
NaCl. Sliver staining of the eluted fractions was performed to check purity of the 
purified ficolin. By loading 100 ng of L-ficolin, the oligomeric ficolin can be seen 
as higher molecular weight bands under non-reducing conditions (N). The 
monomeric ficolin is not visible in the silver-stained gel as a result of lower 
sensitivity of the silver stain compared to western blot analysis. Under reducing 
conditions (R), the ficolin is visible as monomeric form, at 35 kDa. 
2.2.5.2. Purification of FLAG-tagged L-ficolin
The FLAG-tagged L-ficolin was purified by affinity chromatography using the
anti-FLAG M2 Affinity Gel, as described in section 2.2.6.2. The purified ficolin
was applied to SDS-PAGE gels (10% polyacrylamide) and transferred 
electrophoretically to nitrocellulose membranes which were probed with either
N      R       
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monoclonal anti-human L-ficolin antibody GN5 or anti-FLAG monoclonal 
antibody, M2. The immunoblot shows a large homogenous band corresponding to 
the expected size of L-ficolin, above 250 kDa (figure 2.15). Some higher 
molecular weight complexes as well as some smaller molecular weight proteins 
were also visible. These were speculated to be multimeric L-ficolin complexes and 
breakdown products, respectively, as they are antibody reactive. Quantitation of 
the eluted ficolin was determined by ELISA, indicating elution of 20-25 ug of     
L-ficolin from 30 mL of cell culture supernatant. 
Figure 2.15: Western blot analysis of purified FLAG-tagged L-ficolin. 
FLAG-tagged L-ficolin was expressed in HEK 293FT cells and purified using an 
anti-FLAG M2 affinity gel. The eluted L-ficolin samples were then resolved using 
non-reducing polyacrylamide gel electrophoresis, followed by western blot. The 
membrane was probed with either monoclonal anti L-ficolin antibody, GN5 (A) or 
with anti-FLAG monoclonal antibody, M2 (B). Each blot represents the start 
material (S, supernatant) in lane 1, the flow through (F) in lane 2 and the eluted   
L-ficolin (E) in lane 3. This SDS-PAGE analysis illustrates the monomeric (35
kDa), dimeric (70 kDa), and multimeric (above 250 kDa) forms of L-ficolin. 
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2.2.8. Purification of Serum L-ficolin
Serum L-ficolin was purified by a method adapted from Cseh et al. [285]. Pooled 
citrated human plasma was treated with CaCl2 to remove fibrinogen. Proteins in 
the supernatant were precipitated with PEG and the resulting pellet was 
resuspended in TBS buffer containing calcium ions. The suspension was incubated 
with GlcNac-4B beads, then the beads were washed with TBS and with mannose 
solution to remove bound MBL. Little amount of L-ficolin was observed in the 
flow-through and mannose wash (figure 2.16), indicating that little ficolin protein 
is lost at this stage. Ficolin was then eluted with GlcNAc and showed a banding 
pattern of L-ficolin on western blot analysis. Proteins of 35 kDa, 70 kDa and 
above 250 kDa, were observed using anti-L-ficolin antibody under non-reducing 
conditions, representing ficolin monomers and multimers. These oligomeric forms 
were replaced by a single monomeric form of 35 kDa when subjected to SDS-
PAGE under reducing conditions. Using this strategy in purification of serum      
L-ficolin from 1 litre of human plasma resulted in a ficolin yield of 260 µg and a 
concentration of up to 33 µg/mL in eluted fractions.
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Figure 2.16: Western blot analysis of purified serum L-ficolin. 
L-ficolin was obtained from human serum using GlcNAc-Sepharose beads. (a): 
The flow-through (F), mannose wash (M) and ficolin eluates (1-7) were loaded to 
10% SDS-polyacrylamide gel, under non-reducing conditions (NR). The blot was 
developed using anti-L-ficolin monoclonal antibody, GN5. As expected, the eluted 
ficolin (1-7) showed bands at 35 kDa (momoners), 70 kDa (dimers) and at and 
above 250 kDa (multimers) indicating oligomeric composition. (b): the same 
fractions were applied to 10% SDS-polyacrylamide gel, under reducing conditions 
(R), the oligomers of serum L-ficolin were reduced to a single chain with a 
molecular mass of 35 kDa. Molecular weight markers are indicated on the left.
2.4. Discussion
HCV infection has been recognised as a major worldwide health problem, with 
several host and viral factors contributing to HCV disease progression [29]. HCV 
envelope glycoproteins, E1 and E2, provide a target for host immune recognition. 
L-ficolin is a soluble innate immune effector that acts as a serum opsonin and 
activates complement upon binding to glycosylated targets. It has been shown to 
react with a range of microorganisms [218, 239, 240]. 
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When this project took place in 2005, there was no published description of any 
direct interaction between ficolins and HCV. However, based on some reports
which demonstrated apparent links between MBL, which is structurally and 
functionally similar to ficolins, and HCV infection in terms of HCV disease 
progression [271] and response to treatment [272] as well as a direct association 
between the enzymatic activity of MBL/MASP-1 complexes and the severity of 
fibrosis in HCV patients [279], it appeared worthy to evaluate the possible role of 
L-ficolin, an innate immune defence, in the pathogenesis of HCV infection. The 
hypothesis was based on the ability of L-ficolin to interact with the HCV envelope 
glycoproteins E1 and E2 and that L-ficolin recognition of viral particles may play 
a role in HCV disease outcome. 
There are three types of ficolins in humans, H-, L-, and M-ficolin. The selection of 
L-ficolin to investigate its activity in HCV disease was based on several reasons. 
The first reason was the serum availability of L-ficolin, thus its binding to HCV 
particles may result in either opsonic or neutralising effect, and its serum level can 
be measured to evaluate any potential correlation with HCV disease. The second 
reason was the evident polymorphism affecting either the serum level, as a result 
of single nucleotide polymorphisms in the promoter region of the L-ﬁcolin gene
[235], or the binding activity, as a result of single nucleotide polymorphisms in the 
exon 8, encoding the fibrinogen-like domain [267]. Thus, the L-ficolin 
polymorphism can be studied to find out the implications of the serum levels and 
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functional activity in the context of HCV disease. The third reason was the 
relatively higher scientific interest in characterisation of L-ficolin and its
interaction with many microorganisms [218, 239, 240].  
In order to characterise the biochemical interaction between HCV and L-ficolin, it 
was essential to produce recombinant L-ficolin and to purify serum L-ficolin (and 
also to produce HCV envelope glycoproteins E1E2) to be used in binding assays,
that determine the ability of L-ficolin to bind HCV glycoproteins.
Two types of recombinant L-ficolin were produced; C-terminal His-tagged           
L-ficolin and N-terminal FLAG-tagged L-ficolin, using the Gateway cloning 
technology. The recombinant N-terminal FLAG-tagged ficolin was created by 
fusion PCR where the FLAG peptide was inserted downstream of the signal 
peptide cleavage site (between aa 25 and 26) , allowing further detection and
purification of the recombinant ficolin using anti-FLAG M2 antibody. The aim of 
producing an N-terminal FLAG-tagged L-ficolin was to avoid the potential 
hindering effect of the relatively large C-terminal tag which could interfere with 
the ligand binding through the C-terminal fibrinogen-binding domain as well as 
the polymerisation of the heads in 'bunch-of-tulips' structure. However, although 
the N-terminal end is more flexible, it is a cysteine-rich region where the collagen 
domains assemble the trimers and join together to form 12-mers [234]. This 
oligomerisation is crucial for L-ficolin functionality in terms of ligand binding 
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through its C-terminal ﬁbrinogen domain as a high-avidity binding is essential. 
The biological activity depends on simultaneous multiple bindings accomplished 
through the clustering of fibrinogen-binding domains in oligomeric structures 
[231]. Therefore, the oligomerisation and binding activity of recombinant L-ficolin 
were compared to that of native ficolin purified from serum, as a reference.
L-ficolin was also purified from human serum by passage through a GlcNAc-
Sepharose matrix, using an adaptation from the method developed by Cseh et al., 
[285]. The binding of L-ficolin to GlcNAc-Sepharose ensured the presence of 
ficolin oligomers as the ficolin-GLcNAc interaction requires multiple weakly 
binding fibrinogen-binding domains to provide sufficient binding avidity. 
The His tag and the FLAG tag facilitated the purification of expressed L-ficolin 
from mammalian cell culture supernatants using nickel agarose and anti-FLAG 
agarose, respectively. The His-tagged L-ficolin was eluted using imidazole at 200-
250 mM, in agreement with Hummelshoj et al., who used a 250 mM imidazole-
containing elution buffer to release the bound L-ficolin, in a one-step 
chromatographic purification [287]
Following purification, recombinant L-ficolin expressed in human endothelial 
kidney 293FT cells possessed a similar oligomerisation pattern as serum-derived 
L-ficolin when visualised by non-reducing SDS-PAGE, followed by western blot
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analysis. Both recombinant and serum L-ficolin migrated as a 35 kDa monomer, 
and as higher oligomers including a 400 kDa oligomer, in agreement with 
Hummelshoj et al., who reported a similar mixture of monomeric and oligomeric 
ficolin [287]. Under reducing conditions, the oligomers of both recombinant and 
serum L-ficolin were reduced to monomeric form with a molecular mass of 35 
kDa. This may indicate that the tags had no significant effect on the 
oligomerisation of the recombinant L-ficolin polypeptides and thus would not 
interfere with the ficolin binding activity in subsequent binding assays. Another 
supportive observation in the ELISA assay was the ability of recombinant ficolin 
to bind acetylated BSA, which has been reported as a ligand for ficolin [288].
However, it is not possible to measure the relative quantity of monomers and 
multimers by western blot analysis. The three blot figures (figure 2.13 a, figure 
2.15 and figure 2.16 a) revealed quite different proportions of monomers and 
oligomers. Generally, there was a relatively higher multimeric contents in serum-
derived L-ficolin (figure 2.16 a) than in recombinant FLAG-tagged L-ficolin 
(figure 2.15) and His-tagged L-ficolin (figure 2.13 a). The oligomerisation pattern 
of recombinant L-ficolin could be further investigated by gel ﬁltration, sucrose 
density gradient ultracentrifugation, and mass spectrometry [287].
The ELISA assay described in section 2.2.9.2 provided a good tool to evaluate not 
only the ficolin concentration, but also the oligomerisation pattern of the expressed 
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L-ficolin as the binding activity to acetylated BSA is directly related to the 
presence of correctly oligomerised multimeric ficolin.
In this part of the study, a successful production of two types of recombinant       
L-ficolin was achieved as evident by purification of multimeric His-tagged and 
FLAG-tagged L-ficolin which were comparable to purified serum ficolin in terms 
of oligomerisation and reactivity in ELISA (figure 3.3 b). Having said that, this 
part of the study was challenged by many obstacles that led to a significant delay 
to achieve such results. For example, the occurrence of a point deletion mutation, 
during production of the FLAG-tagged L-ficolin, which led to a premature 
termination of the L-ficolin polypeptide. This missing base was retained by site 
directed mutagenesis. Another obstacle during expression of the His-tagged          
L-ficolin there was a difficulty in obtaining a multimeric L-ficolin which was 
attributed to the presence of C-terminal tagging that could interfere with 
polymerisation. However, some modifications in the post-expression manipulation 
such as addition of protease inhibitors to the harvested cell culture supernatant and 
omitting the addition of Iodoacetamide resulted in better oligomerisation results. 
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3. L-ficolin and HCV Glycoprotein Interaction 
3.1. Aims
In this part of the study viral glycoproteins E1E2 and soluble E2 (sE2) were 
produced and used with purified L-ficolin preparations to characterise the 
interaction of L-ficolin with HCV glycoproteins. Purified L-ficolin preparations 
were also used to pull down HCV particles from serum and to evaluate the 
neutralising activity of L-ficolin to HCV infectivity in a pseudoparticle infectivity 
assay. 
3.2. Materials and Methods
3.2.1. Materials
3.2.1.1. Plasmids and Bacterial Strains
Clones of E1E2 and soluble E2661 (sE2) were previously developed by Dr 
Alexander Tarr. Full length E1E2170–746 constructs (representing amino acid 
residues 170 to 746) and soluble E2661 (sE2) constructs [aa 363-661, including a C-
terminal 6xHis-tag) of genotype 1 isolate H77c were previously cloned into 
pcDNA3.1 (Invitrogen). 
3.2.1.2. Reagents and Antibodies
N Acetyl d-Glucosamine (GlcNAc), N Acetyl L-Cysteine (CysNAc), D-Mannose,
TMB (3,3’,5,5’-tetramethylbenzidine) were all obtained from Sigma-Aldrich 
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Company Ltd, Poole, UK. M-280 tosyl-activated Dynabeads were purchased 
from Dynal Biotech ASA, Oslo, Norway. Polyethylenimine (Exgen 500) was 
purchased from Fermantas. Viral RNA Extraction Kit was purchased from 
QIAGEN. Luciferase assay system (luciferase substrate and lysis buffer), hexamer
oligonucleotides and murine leukemia virus (MLV) RT enzyme were purchased 
from Promega. The primers for 5’ noncoding region (NCR) (Table 3.1) were 
synthesised by Proligo. Two Mouse monoclonal antibodies against HCV 
glycoprotein E2 (ALP98 and AP33) were developed and kindly supplied by Dr 
Arvind Patel (MRC Virology Unit, Glasgow).
Table 3.1: PCR primers for 5’ NCR. 
Primer Sequence (5’-3’) Tm °C Product size (bp)
NCR outer sense AGCGTCTAGCCATGGCGT 58 265
NCR outer anti-
sense
GCACGGCTCACGAGACCT 60 265
NCR inner sense GTGGTCTGCGGAACCGG 58 174
NCR inner anti-
sense
GGGCACTCGGAAGCACCC 62 174
Chapter 3                                              L-ficolin and HCV Glycoprotein Interaction
103
3.2.2. HCV Glycoprotein Expression
Viral glycoproteins (E1E2170–746 or sE2363-661) were subcloned into the eukaryotic 
expression vector pcDNA3.1m prior to transfection into HEK 293FT. Plasmids 
were purified using HP Plasmid Midiprep Kit, as described in section 2.2.2.2.4. 
Transfections of HEK 293FT cells were performed using Lipofectamine, as 
described before in section 2.2.4.3. 
The cell-associated E1E2 was harvested 72 hrs after transfection by lysing the 
cells with lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP40, 20 mM 
Iodoacetamide, pH 7.6). To each plate, 1.5 mL lysis buffer were added and mixed, 
then the lysates were clarified by centrifugation at 8,000 x g for 5 min. The 
supernatant was used as a source of E1E2 after analysing a proportion for E1E2 
content by SDS-PAGE (10% polyacrylamide gel) and the remainder of the 
supernatant was stored frozen at -72°C. Alternatively, for sE2, the supernatants 
were harvested 72 hrs post-transfection and iodoacetamide was added to a final 
concentration of 20 mM, to prevent oligomerisation of monomeric E2. 
Iodoacetamide is an alkylating sulfhydryl reagent that binds covalently with 
cysteine, thus interfere with disulfide bonds formation and further protein 
aggregation. The supernatants were then centrifuged at 250 x g for 5 min to 
remove any cell remnants. A proportion of the supernatants was analysed for sE2 
content by 10% SDS-polyacrylamide gels and the rest of the supernatant was 
stored at -20°C for further purification. 
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3.2.3. SDS-PAGE and Western Blot Analysis
The expressed viral glycoproteins E1E2 and sE2 were characterised by separation 
using gel electrophoresis on 10% SDS polyacrylamide gels, as previously 
described in section 2.2.5.1. Western immunoblot was used to identify the 
expressed E1E2 and sE2. After samples were separated on 10% SDS 
polyacrylamide gels, they were transferred to Hybond ECL nitrocellulose 
membranes, as described earlier in section 2.2.5.2. Non-specific binding was 
blocked with 50 mL blocking solution (5 % Marvel in PBS-Tween) with gentle 
shaking for 1 hour at room temperature. The membranes were then incubated with 
monoclonal antibody against E2, ALP98 [289] (1 µg/mL, in PBS-Tween) for 1 hr, 
followed by HRP-conjugated goat anti-mouse secondary antibody (1 µg/mL, in 
PBS-Tween) for 1 hr. The membranes were washed 3 times for 5 min in PBS-
Tween between each step. The proteins were then visualised using the ECL 
system, as described earlier in section 2.2.5.2.
3.2.4. Nickel Agarose Purification of sE2
His-tagged sE2 glycoprotein were nickel agarose purified by metal affinity 
chromatography using a 1 mL HisTrap HP column, as described for His-tagged    
L-ficolin purification in section 2.2.6.1. The sE2 glycoproteins were bound to the 
nickel agarose, washed with buffer containing 20 mM imidazole and eluted with 
500 mM elution buffer, using 5 CV steps of 50 mM imidazole (0-500 mM 
imidazole). Start material, flow-through, and eluates were stored at 4°C for 
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analysis of the peak fractions using SDS-PAGE electrophoresis and quantification 
using Nanodrop spectrophotometer at 280 nm.
3.2.5. L-Ficolin and HCV Glycoprotein Binding
The binding ability of L-ficolin to HCV glycoproteins (E1E2 and sE2) was first 
examined by an ELISA binding assay (figure 3.1).  
3.2.5.1. L-Ficolin and HCV ELISA Binding Assay
Maxisorp plates were coated (100 µL/well) with 0.5 µg ⁄mL of monoclonal anti-
L-ficolin antibody GN5 in PBS and incubated at 4 oC overnight. Wells were 
blocked with PBS-Tween, 5% milk, 4 hrs at room temperature. After washing 
three times with wash buffer (PBS-Tween, pH 7.4), wells were incubated with 100
µL per well L-ficolin (5 µg⁄mL) overnight at 4°C. L-ficolin was previously 
quantified as described in section 2.2.8. After washing, 100 µL per well of either 
lysates containing HCV glycoproteins E1E2 derived from genotype 1 (H77c), 
diluted 1⁄10 in PBS-Tween or sE2 (4 μg/mL) in PBS-Tween were added. Two-fold 
serial dilutions of E1E2 (from 1/10 to 1/320) or sE2 (4 ug/mL to 0.25 ug/mL) in 
PBS-Tween were used to evaluate the dose-dependent pattern of binding 
interaction and to determine the dynamic range of binding interaction. A cell 
lysate from untransfected 293FT cells was included as negative control. The plates 
were incubated overnight at 4°C. After washing, 100 µL per well biotinylated 
monoclonal anti-E2 antibody AP33 at 1 µg/mL were added and incubated for 1 h 
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at room temperature. After washing three times, wells were incubated for 30 min
at 37°C with 100 µL of 0.5 µg/mL HRP-conjugated streptavidin in PBS-Tween. 
After a further three washes with PBS-Tween, 100 µL/well of 3,3’,5,5’-
tetramethylbenzidine (TMB) were added and the absorbance was measured at 620
nm after 15 min. 
Figure 3.1: L-ficolin and HCV glycoproteins ELISA binding assay. 
A schematic diagram representing the components used in ELISA to determine 
whether binding of L-ficolin to HCV glycoproteins (E1E2 and sE2) was possible.
3.2.5.2. L-ficolin and HCV Binding Inhibition
Inhibition of L-ficolin binding to HCV glycoproteins by competitors was 
performed as described in section 3.2.5.1, with an additional step after L-ficolin 
incubation. The extra step involved adding 100 µL/well PBS containing either
GlcNAc (0.1, 1, 10, 100, or 1000 mM), CysNAc (0.1, 1, 10, 100, or 1000 mM),     
D-Mannose (0.1, 1, 10, 100, or 1000 mM), or no competitor. After 1 hr incubation 
TMB
Streptavidin-HRP
Biotinylated AP33
E1E2/sE2
L-ficolin
Anti L-ficolin, GN5
OD 620 
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at room temperature, 100 µL/well sE2 (1 µg/mL) were added and binding of 
ficolin was detected spectrophotopically as described in section 3.2.5.1.
3.2.6. L-ficolin Binding to Serum-Associated HCV Particles
Another technique to evaluate the L-ficolin/HCV binding interaction, by testing 
the ability of L-ficolin to pull down HCV particles from serum, was approached. 
Briefly, M-280 tosyl-activated Dynabeads, coated with L-ficolin were used to pull 
down HCV particles from serum. The HCV virions were then detected by reverse 
transcription PCR (RT-PCR).
3.2.6.1. HCV Particles Pull-Down Experiment
M-280 tosyl-activated Dynabeads (10 µL) were coated with monoclonal anti-      
L-ficolin antibody, GN5, at a concentration of 3 µg/107 beads, according to the 
manufacturer’s instructions. After washing, the coated beads were then incubated 
in a blocking buffer (0.2 M Tris with 0.1% BSA, pH 8.5), to block free tosyl-
groups. Recombinant L-ficolin diluted in PBS at a molar concentration (assuming 
that 420 kDa is the molecular mass of L-ficolin) equivalent to that of the antibody 
was added to the GN5-coated beads and incubated for 2 hrs at room temperature. 
These ficolin-GN5-coated beads were then used to bind viral E1E2 glycoproteins 
and pull down HCV particles from HCV-infected patient’s serum containing HCV 
at 6,141,619 IU/mL. The beads (10 µL) were incubated with 1 mL of serum, 
diluted 1/50 in PBS-Tween. Alternatively, the diluted serum was spiked with 5
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µg/mL recombinant L-ficolin and incubated for 2 hrs at room temperature to allow 
L-ficolin binding to HCV particles, before mixing with GN5-coated beads for 2 
hrs at room temperature. GN5-coated beads were used also to pull down HCV 
particles. A competition assay was also performed, by incubating L-ficolin-GN5-
coated beads with 0.6 M CysNAc for 1 hr before mixing with sera. In each case,
immunocomplexes were collected via magnetic separation and washed 5 times 
with PBS. Pellets were then resuspended in 140 µL PBS to allow recovery of HCV 
RNA from the immunoprecipitate. Non-coated beads (not coated with either GN5 
or L-ficolin) were incubated with serum under the same conditions as a negative 
control. 
3.2.6.2. Detection of HCV by RT-PCR
HCV RNA was extracted from 140 µL of the immunoprecipitate using a Viral 
RNA Extraction Kit, according to the manufacturer’s instructions. Annealing mix 
was prepared by adding 2.5 µL 5X RT buffer to 10 µL extracted RNA. The mix 
was incubated at 70°C for 5 min, then reverse transcribed by adding 12.5 µL of 
extension mix (2.5 µL 5X RT buffer, 0.5 µL random hexamer oligonucleotides, 
2.4 mM of each dNTP, 0.5 µL MLV RT enzyme, and 5.5 µL water), to generate 
the complementary DNA (cDNA). The mix was incubated at room temperature for 
10 min, and then incubated at 37°C for 1 hr. The resulting cDNA was amplified by 
nested PCR of the 5’ noncoding region (5’ NCR). The first-round PCR was 
performed as follows: 2 µL of cDNA were added to 23 µL of mixture containing 5 
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pmol of primer NCR outer sense and NCR outer anti-sense, 200 µM dNTPs and 
0.625 U of Hot Star Taq polymerase in 1x PCR buffer. One microlitre of the first-
round product was then used as a template in second-round reactions using the
primers NCR inner sense and NCR inner anti-sense. The first round and second 
round nested PCR cycles included 1 cycle of 95°C for 15 min; 35 cycles of (94°C 
for 30 sec, 60°C for 30 sec, and 72°C for 1 min), then a final 7-minute extension at 
72°C. RT-PCR of HCV positive serum was included as a positive control for the 
extraction and PCR.
3.2.7. HCV pseudo-particles (HCVpp) Neutralisation Assay
3.2.7.1. HCVpp Production
HCVpp (retroviral particles pseudotyped with HCV glycoproteins) were generated 
by Dr Alexander Tarr. They were produced by co-transfection of expression 
plasmids encoding the full-length E1E2 glycoproteins from either HCV type 1a 
(H77c) or type 2b (UKN2B1.1), the CMV-Gag-Pol MLV packaging construct, and 
firefly luciferase reporter gene, as a gene marker, under the control of the human 
cytomegalovirus promoter, into the producer cell line, HEK 293-T cells. Briefly, 2
µg of each plasmid were transfected into 1.2 X 106 293-T cells, seeded the day 
before in 9-cm plates, using Polyethylenimine (Exgen 500) as a gene-delivering 
agent. It interacts with DNA to form small, diffusible, readily endocytosed 
complexes. Transfections were followed, after 6 hrs, by changing the medium (10 
mL per plate) to fresh DMEM containing 10% FBS. Supernatants containing the 
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pseudo-particles were harvested 72 hrs post-transfection and filtered through 0.45
µm filters. Purified supernatants were gently loaded onto 1 mL of a 20% sucrose 
cushion, followed by ultracentrifugation in Beckman SW40 ultracentrifuge (at 
40,000 rpm, for 2 hrs at 4°C). Pseudoviral particles pellets were suspended in 500
µL PBS. 
3.2.7.2. Infectivity Neutralisation Assay
The infectivity assay was performed using the Human hepatoma cell line, Huh7. 
Cells were plated on 48-well plate, at a density of 4 x 104 cells per well the day 
before infection. The infection was performed using 50 µL of HCVpp with 200 µL 
fresh DMEM media in each well. For neutralisation assay, 50 µL of HCVpp were 
incubated with 50 µL of a serial dilution of purified recombinant ficolin (at a final 
concentration from 6 µg/mL to 0.1875 µg/mL, in PBS), or PBS as a positive 
control, for 30 min at 37°C before adding to Huh7 cells. On the following day, 
another 250 µL media were added. After 72 hrs of transfection, the ficolin-
mediated neutralisation of HCVpp was evaluated by luciferase assay.
3.2.7.3. Luciferase Assay
The media were removed and the cells were lysed by adding 50 µL of Glo-lysis 
buffer. The plates were kept for 15 min on a rocking platform until the cells were 
lysed. The cell monolayer was scraped and removed with the buffer solution to a 
0.5-mL Eppendorf tube. The tubes were vortexed for 10 sec, then centrifuged at 
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12,000 x g for 2 min. From each tube, 35 µL were transferred to a cuvette 
followed by 90 µL luciferin substrate. The luciferase activity was measured 
immediately and the OD was determined at 420 nm, using Turner TD-20 
luminometer.
3.3. Results
3.3.1. Expression of HCV glycoproteins
Clones representing the entire E1 and E2 coding regions (aa170-746) or a soluble 
fragment of the ectodomain of the E2 protein (aa 363-661; sE2661) were both
expressed in HEK 293FT cells. Cell lysates were used as a source of E1E2, while 
the C-terminal His-tagged sE2 was purified from the culture supernatants by metal 
affinity chromatography.  
3.3.2. Purification of sE2
Metal affinity chromatography, using 20 mM imidazole in the initial binding stage 
followed by a step elution of imidazole (50 mM rises from 0 to 500 mM 
imidazole), was used to purify the expressed His-tagged E2661 and enable 
separation of monomer and aggregated material. Fractions of 1 mL were collected 
and the eluted fractions were studied by SDS-PAGE and western blot analysis 
(Figure 3.2). Monomeric E2 was eluted at 150 mM imidazole and the majority of 
the aggregated material was eluted at 200 mM imidazole. Quantification of 
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purified E2661 was performed by measuring the protein content at A280 using a 
Nanodrop spectrophotometer.
3.3.3. Confirmation of Expressed Glycoproteins
Both the E1E2 lysate and the sE2 eluates were analysed by western blot analysis
using monoclonal anti-E2 antibody ALP98. This revealed E2 monomers (70 kDa)
of E1E2 and sE2 (figure 3.2). E2 omonomers represent correctly-folded E2. 
Disulfide-linked aggregates may represent misfolded complexes [290]. The E1E2 
heterodimers (105 kDa) were dissociated by the denaturing nature of the gel 
revealing the E2 monomers (70 kDa), which were detected with monoclonal anti-
E2 antibody ALP98. These protein models were used as surrogates of the surface 
of HCV virions in ficolin binding assays.
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Figure 3.2: SDS-PAGE analysis of HCV glycoproteins E1E2 and sE2. 
HEK 293FT cells were transfected with a plasmid encoding viral glycoproteins 
E1E2 or soluble E2 of genotype 1 (H77c). E1E2 lysates and IMAC-purified sE2 
were analysed by SDS-PAGE. The immunoblot analysis was performed using 
monoclonal anti-E2 antibody (ALP98). The blots show bands relating to E2 
monomers (70 kDa) of E1E2 and sE2 and aggregates. Untransfected 293FT cell 
lysate was used as a negative control (N). Positions of protein size markers are 
shown (in kDa) on the left.
3.3.4. L-ficolin Interaction with HCV Glycoproteins
The binding of L-ficolin to HCV glycoproteins (E1E2 and sE2) was assessed in
ELISA. Two-fold serial dilution series of E1E2 from cell lysate (1/10 to 1/320) or 
purified sE2 (4 ug/mL to 0.25 ug/mL) was incubated with L-ficolin, captured by 
monoclonal anti-L-ficolin antibody, GN5. A dose-dependent binding of both E1E2
and sE2 to L-ficolin was observed (figure 3.3). The specificity of this binding 
interaction was shown by low background when mock-transfected HEK 293FT 
cellular proteins were used. This is evidence that HCV glycoproteins possess 
Pathogen Associated Molecular Patterns (PAMPs) recognised by L-ficolin.  
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Figure 3.3: L-ficolin and HCV glycoproteins binding assay. 
The ability of L-ficolin to bind to HCV glycoproteins (E1E2 and sE2) was 
evaluated by ELISA, using L-ficolin (5 µg/mL), that was captured by anti            
L-ficolin antibody (GN5), and a serial dilution of E1E2 or sE2 was added. Bound 
E1E2 and sE2 were detected by monoclonal anti-E2 antibody, AP33, at OD405. (a) 
E1E2 binding to L-ficolin was directly related to E1E2 concentration in the cell 
lysate. A negative control lysate from untransfected cells was used to show the 
specificity of interaction. (b) A dose-dependent pattern of binding interaction 
between sE2 and both recombinant ficolin (r ficolin) and purified serum ficolin (s 
ficolin), illustrating a close level of both recombinant ficolin and serum ficolin (at 
the same concentration). The dotted line represents the OD of a negative control 
reaction in which no ficolin was added, to exclude the possibility of non specific 
binding between sE2 (at a concentration of 4 µg/mL) and GN5.  
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To investigate the ability of known L-ficolin ligands to interfere with the
interaction between L-ficolin and HCV glycoproteins, L-ficolin was pre-incubated 
with varying concentrations of either ficolin ligands (GlcNAc or CysNAc), or a 
control sugar specific only for MBL (D-Mannose) for 1 hr prior to addition of sE2 
to the ficolin-containing microtitre plate (figure 3.4). 
Figure 3.4: Effect of competitors on the binding of L-ficolin to sE2. 
The effect of pre-incubating L-ficolin with the indicated concentrations of 2        
L-ficolin ligands, GlcNAc and CysNAc; or a non-ficolin ligand, D-Mannose, prior 
to adding purified sE2. sE2 binding to L-ficolin was examined and percentage
binding was evaluated compared to a binding assay without inhibitor. Both 
GlcNAc and CysNAc inhibited binding of L-ficolin, with IC50 values of 260, and 
1.8 mM, respectively. D-Mannose did not inhibit the interaction at a concentration 
of 1M.
The effect of these ligands on binding to sE2 was compared to uninhibited binding 
of recombinant L-ficolin. Both CysNAc and GlcNAc inhibited the binding 
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interaction between recombinant L-ficolin and the sE2 protein. The inhibition of 
binding of L-ficolin to sE2 was dose-dependent (figure 3.4). The concentration 
that resulted in 50% binding inhibition (IC50) was 1.8 mM and 260 mM of 
CysNAc and GlcNAc respectively. Even at a concentration of 1 M, D-Mannose 
had no effect on the binding interaction, demonstrating a specific inhibition of the 
ligand binding domain of L-ficolin.
3.3.5. L-ficolin binding to HCV Virions
To further confirm the ability of L-ficolin to bind HCV glycoproteins, the ability 
of purified L-ficolin to bind to HCV particles in patients’ sera was evaluated.        
L-ficolin-GN5-coated magnetic beads were incubated with sera from patients with 
chronic HCV infection, isolating authentic HCV particles. In a parallel 
experiment, the patient’s serum was spiked with recombinant L-ficolin at a 
concentration of 5 µg/mL and GN5-coated magnetic beads used to pull down the 
immune complexes. Complexes containing L-ficolin were also isolated with GN5-
coated magnetic beads. HCV RNA associated with Dynabeads after 
immunoprecipitation was detected by RT-PCR of the 5’ NCR (figure 3.5 a). The 
resulting PCR products of GN5-coated Dynabeads incubated with serum 
previously spiked with recombinant L-ficolin (lane 4) and recombinant L-ficolin-
GN5-coated Dynabeads incubated with serum (lane 5) were of the same size as the 
positive control (HCV RNA positive serum; lane 2). 
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Figure 3.5: Detection of HCV RNA by RT-PCR. 
(a) HCV RNA was recovered from the L-ficolin-GN5-coated Dynabeads that had
been incubated with serum from HCV-infected patient (RNA-positive), by RT-
PCR. The PCR products were detected by agarose gel electrophoresis. Positive
bands are detectable from the following immunocomplexes: recombinant              
L-ficolin-GN5-coated Dynabeads incubated with serum (lane 5) and GN5-coated 
Dynabeads incubated with serum previously spiked with recombinant L-ficolin 
(lane 4) which provided a result similar to that detected from RNA positive serum 
(lane 2). Lane 3 represents the non-coated beads (not coated with either GN5 or   
L-ficolin) and lane 1 represents the RT-PCR negative control.
(b) Effect of CysNAc on L-ficolin binding to HCV virions was performed by pre-
incubating L-ficlion-GN5-coated beads with 0.6M CysNAc before mixing with 
serum. A lower yield of HCV RNA was detected in CysNAc-treated L-ficolin-
GN5-coated Dynabeads (lane 1) compared to non-treated L-ficolin-GN5-coated 
Dynabeads (lane 2) and that detected from RNA positive serum (lane 6). A similar 
yield was observed using either GN5-coated Dynabeads incubated with serum 
(lane 3), or GN5-coated Dynabeads incubated with serum previously spiked with 
recombinant L-ficolin (lane 4). Lane 5 represents the non-coated beads.
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Viral RNA was not detected when using uncoated beads (not coated with either 
GN5 or L-ficolin), which were used as a negative control, demonstrating the 
requirement for L-ficolin to mediate immunoprecipitation. This fact was further 
confirmed by the ability of GN5-coated beads to immunoprecipitate HCV RNA 
(figure 3.5 b; lane 3). CysNAc, known to interact strongly with L-ficolin, was pre-
incubated with L-ficolin-GN5-coated beads, at 0.6M, prior to mixing with serum 
to inhibit the L-ficolin binding to HCV virions. As expected, CysNAc, which was 
shown to inhibit L-ficolin binding to sE2, reduced the ability of L-ficolin to bind 
to HCV virions (figure 3.5 b; lane 1).
3.3.6. HCVpp Neutralisation Assay
A retroviral-based psesudoparticle assay was performed to examine the 
neutralising effect of L-ficolin on HCVpp infectivity in Huh7 cells. A serial 
dilution of L-ficolin from 6 µg/mL to 0.1875 µg/mL, in triplicates, was pre-
incubated with HCVpp for 30 min at 37°C. The HCVpp display E1E2 
glycoproteins from two HCV genotypes, type 1a (H77c) or type 2b (UKN2B1.1) 
and contain a luciferase gene as a marker. The neutralising activity was expressed 
as percentage of inhibition compared to a control HCVpp which was not incubated 
with L-ficolin. Measurement of the luciferase activity demonstrated a reduction in 
the infectivity of two pseudoparticles expressing E1E2 glycoproteins from two 
HCV genotypes, type 1a (H77c) or type 2b (UKN2B1.1). The infectivity was 
inhibited to different degrees by L-ficolin in a dose-dependent pattern (figure 3.6). 
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The concentration of L-ficolin required to achieve 50% inhibition of infection
(IC50) for type 1a (H77c) and type 2b (UKN2B1.1) pseudoparticles was 1.5 and 
0.7 µg/mL, respectively.
Figure 3.6: Neutralisation of HCV pseudoparticles by L-ficolin. 
The L-ficolin was pre-incubated with HCVpp for 30 min at 37°C in 2-fold serial 
dilution down from 6 µg/mL to 0.1875 µg/mL and then the HCVpp were used to 
infect the Huh-7 cells. Inhibition of infectivity was determined by reduction in the 
luciferase activity. Infectivity of the HCVpp derived from 2 genotypes type 1a 
(H77c) or type 2b (UKN2B1.1) was inhibited in a dose-dependent manner.          
L-ficolin completely abrogated infection of UKN2B1.1 at a concentration of         
6 μg/mL.
3.4. Discussion
L-ficolin, through its fibrinogen-like domains, recognises carbohydrate patterns on 
the outer walls of microorganisms, with a general specificity for N-acetylated 
groups [236]. The binding of ficolins to sugar structures leads to complement 
activation and deposition of C3b and thus results in phagocytosis and clearance of 
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pathogens [217, 218]. In such a way, L-ficolin has been suggested to have a role as 
an innate immune mediator against a range of infectious diseases [218, 239, 240]. 
HCV possesses two envelope glycoproteins; E1 and E2 expressed as non-covalent 
E1E2 heterodimers in the viral envelope [98]. These are glycosylated 
transmembrane proteins, containing up to 5 and 11 N-linked glycosylation sites 
respectively [20]. As that pattern of glycans might serve as ligands for L-ficolin, 
the potential ability of L-ficolin to interact with HCV glycoproteins and the 
potential binding implications, in terms of neutralising infectivity, were 
investigated.
Two recombinant glycoprotein constructs of the HCV genotype 1a infectious 
clone H77c (E1E2 and sE2) were expressed for analysis of the interaction between 
L-ficolin and HCV. The expressed E1E2 proteins were further evaluated for 
function using a retroviral pseudoparticle model of infectivity [291]. Using an 
ELISA assay, binding curves were created in order to demonstrate the ability of 
purified recombinant L-ficolin to bind to E1E2 and sE2 in a dose-dependent
manner. Further characterisation of L-ficolin binding to HCV glycoproteins was 
achieved by sugar competition assays to confirm binding via sugar residues. 
Consistent with previous reports demonstrating binding of L-ficolin to GlcNAc 
[218] and CysNAc [286], this study demonstrated that recombinant L-ficolin 
binding to HCV glycoprotein E2 (sE2) could be specifically inhibited by pre-
incubation of L-ficolin with either GlcNAc or CysNAc (figure 3.4). The ability of 
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these ficolin ligands to compete with the binding of L-ficolin to a soluble form of 
E2 suggests that the binding is mediated by the L-ficolin fibrinogen-like domain
and the N-linked glycans of E1 and E2. However, the inhibitory effect of CycNac
(IC50 = 260) is much greater than the inhibitory effect of GlcNAc (IC50 =1.8 mM),
in contrast to Krarup et al., [286] who reported a higher inhibitory effect of 
GlcNAc on L-ficolin binding to A. viridans or S. pneumoniae than that of CycNac. 
Thus, the marked reduction of L-ficolin to E2 using 100 mM CycNac could be a 
result of its reducing effect that dissociates the multimeric ficolin. This possible 
effect could be excluded by alkylating the sulfhydryl group of CycNac before 
incubation with L-ficolin.
To determine if the interaction between L-ficolin and HCV glycoproteins extended 
to authentic viral particles, the ability of L-ficolin to associate with HCV particles 
from infected patients’ sera was next demonstrated. HCV particles containing viral 
RNA were immunoprecipitated with either L-ficolin-anti L-ficolin GN5-coated 
beads or even anti L-ficolin GN5-coated beads, confirming not only the               
L-ficolin/HCV glycoproteins binding interaction observed by ELISA, but also the 
ability of L-ficolin to from complexes with the circulating viral particles. This     
ex vivo interaction demonstrates that the HCV particles circulating during infection 
must present glycans with GlcNAc moieties in the correct conformation to be 
accessible to ficolins [238] and suggests that circulating HCV may form 
complexes with this soluble innate effector molecule in vivo. 
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As the HCV glycoproteins mediate viral entry by interacting with multiple cellular 
receptors [102-104], the potential function of L-ficolin in HCV infection was 
addressed by analysing the ability of L-ficolin to inhibit virus infectivity of Huh7 
cells by HCV pseudo-particles. The inhibition of infectivity was evaluated by a 
luciferase assay. Interestingly, binding of L-ficolin to HCV glycoproteins resulted 
in neutralisation of virus infectivity in this in vitro model, using HCVpp
expressing E1E2 glycoproteins from HCV genotype 1a (H77c) and 2b 
(UKN2B1.1). These two clones are able to form functional glycoproteins, 
previously determined by the pseudotype infectivity assay [101]. The 
neutralisation was almost 100% for genotype 2b-derived pseudoparticles at a 
concentration of 6 µg/mL, which is slightly higher than the reported average 
physiological level of L-ficolin, 4.13 µg/mL [217]. Thus, L-ficolin binding to 
HCV glycoproteins may have a blocking effect on entry of virions into host cells, 
which is mediated by binding of E1E2 to cellular receptors [102-104]. Blocking 
this interaction might have a clinically relevant neutralising effect, suggesting a 
ficolin activity as a biotherapeutic. The variation in the magnitude of neutralisation 
of infectivity between the 2 clones of HCV may be related to the genotypic 
differences in glycosylation sites. E1 glycoprotein of genotype 2b (UKN2B1.1) 
has an additional glycosylation site at aa 300, that is absent in genotype 1a (H77c).
This neutralising effect is in agreement with a recent study which revealed the 
ability of porcine ficolin alpha to bind and neutralise porcine reproductive and 
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respiratory syndrome virus (PRRSV) evident by reducing cytopathic effect of 
PRRSV and inhibiting replication of infectious viral particles, determined by 
plaque assay [292]. 
As the main biological effects of the ficolins are mediated through complement 
activation upon binding to sugar structures on bacterial surfaces [248], L-ficolin 
binding to HCV might activate the complement system via L-ficolin associated 
MASPs. In such a pathway, L-ficolin may assist in viral clearance through 
activation of serine proteases that activate the lectin complement pathway.   
MASP-1 activation is another potential functional consequence of L-ficolin 
binding to HCV glycoprotein. MASP-1 has a thrombin like spectrum of activity on 
fibrinogen and factor XIII [280-282], thus, stimulates fibrin deposition and 
supports the development of fibrosis during HCV diseases. L-ficolin/MASP-1 
activation may demonstrate the ability of L-ficolin to play a role in chronic HCV 
infection, by contributing to the pathogenesis of liver fibrosis. 
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4. Role of Anti-E1E2 in HCV Liver Disease
4.1. Aims 
HCV envelope glycoproteins, E1 and E2, associate as a non-covalent heterodimers 
[20]. They are thought to play crucial roles at different steps of the HCV 
replication cycle. They are essential for host-cell entry, binding to cellular 
receptors and inducing fusion with the host-cell membrane [101, 102]. The 
humoral immunity to HCV is mediated by antibodies which bind viral proteins 
including E1 and E2, leading to the clearance of circulating virus particles. 
However, this may be essentially ineffective despite evidence for neutralising 
antibody response, possibly due to rapid selection of antibody escape mutants 
[139].
The aim of this section was to investigate the role of antibodies to HCV 
glycoproteins E1 and E2 (anti-E1E2) in HCV disease by evaluating the serum 
levels of anti-E1E2 in sera of patients with chronic HCV infection. The anti-E1E2 
assay was performed using unique recombinant HCV glycoproteins, derived from 
genotype 1 (H77c) and genotype 3 (UKN3A1.28), as antigens. The assay was 
employed to find out the correlation between the levels of anti-E1E2 and viral 
load, viral genotype, disease severity and responsiveness to treatment. The 
seroreactivity to E1E2 was estimated in 230 sera from 180 patients with chronic 
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HCV infection obtained from the Trent HCV cohort study. Production of HCV 
glycoproteins E1E2 was required for use as antigens in ELISA assays. 
4.2. Materials and Methods
4.2.1. Plasmid Constructs
Full length E1E2170–746 constructs (aa 170-746) from HCV genotype 1 strain H77c 
and genotype 3 strain UKN3A1.28 were generated and cloned into pcDNA3.1 
(Invitrogen) by Dr Alexander Tarr as previously described [101]. Briefly, viral 
RNA was extracted from the sera of patients with different genotypes of HCV and 
virus-specific cDNA sequences of the viral glycoproteins was made using 
genotype-specific primers. Nested PCR was used to generate PCR products 
corresponding to the sequence including amino acids 170-764 of the E1E2 
polyprotein. cDNA was sequenced using Big Dye and API Prism 3100 sequencer 
and the sequences were analysed using ClustalX, MEGA version 2.2, against 
reference strains; genotype 1a (AF011752) and 3a (D17763) [101]. Fragments 
were then cloned into pcDNA3.1, for E1E2 expression. The quality of the 
expressed E1E2 proteins was previously evaluated with retroviral pseudoparticle 
infectivity, in which both types conferred infectivity [101, 293].
4.2.2. Reagents and Antibodies
Maxisorp ELISA plates were purchased from Nunc, Kamstrup, Denmark. GNA 
lectin, carbonate-bicarbonate buffer, phosphate-buffered saline (PBS),                  
Chapter 4                                                   Role of Anti-E1E2 in HCV Liver disease
126
p-nitrophenyl phosphate (pNPP) substrate, normal human serum, and alkaline 
phosphatase-conjugated anti-human IgG antibody were purchased from Sigma-
Aldrich Company Ltd, Poole, UK. Mouse anti-E2 monoclonal antibody, ALP98
was developed and kindly supplied by Dr Arvind Patel (MRC Virology Unit, 
Glasgow). Horseradish peroxidase (HRP)-conjugated anti-mouse IgG secondary 
antibody was purchased from Dako Cytomation.
4.2.3. Cell culture and Glycoprotein Expression
Transfection of plasmids encoding the viral glycoproteins E1E2170-746 of genotype 
1 (H77c) and genotype 3 (UKN3A1.28) was carried out in the HEK 293FT cell 
line (Invitrogen) stably transfected with pCMVSPORT6TAg.neo plasmid. The 
cells were cultured in Dulbecco’s Modified Eagles Medium with glutamine 
(GIBCO) supplemented with 10% fetal calf serum and non-essential amino acids 
at 37ºC, in a 5% CO2 incubator. Transfection was carried out using the cationic 
lipid reagent, Lipofectamine 2000, as previously described in section 2.2.4.3. The 
growth medium was changed 24 hrs after transfection. E1E2 glycoproteins were 
harvested 72 hrs post-transfection by lysing the cells with lysis buffer (50 mM 
Tris-HCl, 150 mM NaCl, 1% NP40, 20 mM Iodoacetamide, pH 7.6). To each 
plate, 1.5 mL lysis buffer were added and mixed, then the lysates were clarified by 
centrifugation at 8,000 x g for 5 min. The supernatant was used as a source of 
E1E2 after analysing a proportion for E1E2 content by SDS-PAGE (10% 
polyacrylamide gel) and the remainder of the supernatant was stored at -72°C.
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4.2.4. Confirmation of Expressed Protein
Separation of proteins was achieved by 10% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transfer to nitrocellulose 
using a Trans-Blot Semi-Dry Transfer Cell (Bio Rad). Expression of E2 protein 
was detected by western blot analysis using mouse anti-E2 monoclonal antibody 
ALP98 primary antibody (1 µg/mL in PBS-Tween), and horseradish peroxidase 
(HRP)-conjugated goat anti-mouse secondary antibody (1 µg/mL in PBS-Tween). 
Western blots were developed using enhanced chemiluminescence detection 
reagents ECL-Plus and exposure to a photographic film, as previously described in 
section 2.2.5.2.
4.2.5. Patients and Samples
The levels of anti-HCV E1 and E2 antibodies were evaluated in 230 sera from 180 
patients with chronic hepatitis C obtained from the Trent HCV Cohort. All 
samples were collected prior to treatment, except in the sub-study examining the 
effect of treatment on anti-E1E2 reactivity. This cohort includes HCV positive 
patients from five centres within the Trent region [294]. All patients are defined as 
chronically infected with HCV by testing positive for HCV antibody using a third 
generation immunoassay (ELISA, Ortho Vitros ECI) and for HCV RNA using a 
commercially available genome amplification technique (Roche Amplicor). HCV 
genotypes are determined using the Bayer line probe assay (Bayer HealthCare 
LLC). Liver biopsies are assessed by a single pathologist, and scored according to
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the criteria of Ishak et al [45]. In a sub-study examining a possible correlation 
between anti-E1E2 reactivity and liver disease activity, sera were specifically 
chosen from patients with either mild (defined as Ishak fibrosis stage 0-2) or 
severe (Ishak stage 5-6) disease. Sera were taken within 6 months of biopsy, or in 
an interbiopsy period where both pre- and post-sample biopsies had the same 
stage. Response to treatment was defined on the basis of serum HCV-RNA 
clearance by PCR. Sustained virologic response was defined as the absence of 
detectable HCV RNA 6 months after cessation of therapy (peg-interferon plus 
ribavirin). Serum samples were stored at -72°C.
4.2.6. Anti-E1E2 Assay
The level of anti-E1E2 in patients’ sera was determined using an ELISA-based 
assay (figure 4.1). Maxisorp ELISA plate wells were coated (50 µL/well) with 5 
µg/mL of Galanthus nivalis agglutinin (GNA) [211] in carbonate-bicarbonate 
buffer (pH 8.9) for 2 hrs at 37°C. Wells were blocked with blocking buffer 
[phosphate-buffered saline (PBS) 0.05 % (v/v) Tween-20, 5% milk powder] (200
µL/well) overnight at 4°C, then washed 3 times with wash buffer [PBS 0.05% 
Tween 20 in, pH 7.4], using the Denly WellWash plate washer. Lysates containing 
HCV glycoproteins E1E2 derived from genotype 1 (H77c) or genotype 3 
(UKN3A1.28) (50 µL/well) were diluted 1/80 in PBS-Tween-Milk prior to 
addition to the plates and incubated for 2 hrs at room temperature. After washing, 
50 µL serum diluted 1/50 in PBS-Tween-Milk was added and incubated for 2 hrs 
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at room temperature. After washing 3 times, 50 µL of anti-human IgG-alkaline 
phosphatase (anti-human IgG-AP) conjugate, diluted 1/1,000 in TBS 
supplemented with 0.05% Tween 20 and 5% milk, was added for 1 hr at room 
temperature. Following a further 3 washes, with TBS-Tween, binding was 
visualised with 50 µL of p-nitrophenyl phosphate (pNPP) substrate. The OD at 
405 nm was determined using a Vmax plate reader (Molecular Devices) after 30 
min. Un-transfected 293FT cell lysates and normal human serum were included as 
negative controls. Manipulation of patient sera during the ELISA assay, including 
washing steps, was carried out in a class I biological safety cabinet (LEEC) which 
was cleaned with 70% v/v ethanol and 2% Trigene, before and after each 
manipulation.
Figure 4.1: Evaluation of anti-E1E2 antibodies by ELISA. 
A schematic diagram representing the components used in ELISA to evaluate the 
levels of anti-E1E2 in sera from patients with chronic hepatitis C. Two full length 
E1E2 constructs from HCV genotype 1 strain H77c and genotype 3 strain 
UKN3A1.28 generated and expressed in HEK 293FT cells, were used as antigens.
pNPP
Anti-human IgG-AP conjugate
Anti-E1E2
E1E2
GNA
OD 405 
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4.2.7. Statistical analysis
Statistical analyses were performed using Prism version 4.03 (Graph Pad, San 
Diego, CA, USA). Comparison between groups was carried out by Mann Whitney 
test or t test. The association between seroreactivity to E1E2 and viral load was 
analysed using the linear regression test. In all tests, a probability level (p) of 0.05 
or smaller denoted a statistical significance. 
4.3. Results
4.3.1. Confirmation of Expressed E1E2
HEK 293FT cells were used for transfection of the plasmids encoding the 
genotype 1 (H77c) and genotype 3 (UKN3A1.28) viral glycoproteins E1E2, using 
Lipofectamine. The expressed HCV glycoproteins were separated by SDS-PAGE 
(10% polyacrylamide gel) and detected by western blot analysis using monoclonal 
anti-E2 primary antibody, ALP98 and goat anti-mouse HRP-conjugated secondary 
antibody. 
The western blot showed several bands indicating the presence of E2 monomers 
(70 kDa) and oligomers of H77c and UKN3A1.28 (figure 4.2). The monomer is 
considered to represent correctly folded E2. As expected, the E1E2 heterodimers 
(105 kDa) were dissociated by the denaturing nature of the gel, and the E2 
monomer (70 kDa) was detected using an anti-E2 antibody (ALP98) that 
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recognises an epitope identical in both genotype 1 and 3 proteins (amino acids 
644-651; referenced to H77c). 
Figure 4.2: Detection of monomeric E1E2 in lysate by western blot.
The proteins were subjected to 10% SDS-PAGE; and after transfer, immunoblot
analysis was performed using monoclonal antibody ALP98. Antibody binding was 
detected with HRP-conjugated anti-mouse immunoglobulin as a secondary 
antibody. Bands were visualised using the ECL plus system. The blot showed two 
bands relating to E2 monomers of H77c (lane 1) and UKN3A1.28 (lane 2). 
Untransfected 293FT cell lysate was loaded in lane 3 as a negative control. The 
position of E2 monomer (70 kDa) is shown with an arrow to the right.
4.3.2. Anti-E1E2 Assay
The seroreactivity of the tested sera (diluted 1/50 in PBS-Tween) to H77c and to 
UKN3A1.28, at OD 405, as an indication for the levels of anti-E1E2, was 
evaluated by ELISA in 230 sera from 180 patients with chronic hepatitis C. The 
H77c and UKN3A1.28 antigens used in this assay represented two functional 
E1E2 glycoproteins from genotype 1 and genotype 3 viruses, respectively. The 
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reactivity of each serum to E1E2 was determined after exclusion of the 
background reactivity to untransfected HEK 293TF cell lysate (figure 4.3). 
Figure 4.3: Serum reactivity to E1E2.
The serum reactivity to E1E2 was determined at different concentrations of serum 
and E1E2 (expressed in HEK 293 cells). A set of 4-fold serial dilution (from 1/50 
to 1/204,800 in PBS-Tween) of the serum (from HCV genotype 1 infected patient) 
was examined for reactivity to another 2-fold series of E1E2 dilution (from 1/10 to 
1/80, in PBS-Tween). The background was determined by evaluating the serum 
reactivity to an untranfected HEK cell lysate. The seroreactivity was considered as 
the signal above the background. Further evaluation of the reactivity was 
performed using sera, diluted 1/50, to E1E2, diluted 1/80. 
In order to determine the pattern of anti-E1E2 reactivity over time, the antibody 
reactivity to E1E2 in 10 patients over 2-5 years was evaluated. The levels of 
reactivity in each patient were fairly constant and did not show variability (figure 
4.4), suggesting that the level of reactivity can be considered as a true 
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representative for the level of anti-E1E2 during the course of chronic HCV 
disease.
Figure 4.4: Pattern of anti-E1E2 reactivity over time.
The seroreactivity of 10 sera to E1E2 was examined over a time period of 2-5 
years, from the start point (Y0), to year 2 (Y2) through year 5 (Y5). The reactivity 
of the examined sera showed little or no variation over the time period, indicating 
that the seroreactivity at a single time point can represent the level of anti-E1E2 
during the course of chronic HCV disease.
4.3.3. Correlation with HCV Genotype
The reactivity of 67 sera (36 sera from patients infected with HCV genotype 1 and 
31 sera from patients infected with HCV genotype 3) was assessed by comparing 
the reactivity of each serum to both HCV E1E2 derived from genotype 1 (H77c) 
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and genotype 3 (UKN3A1.28). The results revealed that the reactivity of sera from 
patients infected with HCV genotype 1 was significantly higher when tested 
against H77c E1E2 (Median: 1.002, Range: 0.0005-2.848) than against 
UKN3A1.28 E1E2 (Median: 0.715, Range: 0.062-2.035), p=0.045 (figure 4.5 A). 
Similarly, the reactivity of sera from patients infected with HCV genotype 3 was 
significantly higher when tested against UKN3A1.28 E1E2 (Median: 1.661, 
Range: 0.0115-2.401) than against H77c E1E2 (Median: 0.8535, Range: 0.048-
2.456), p=0.0007 (figure 4.5 B). 
Figure 4.5: Comparison of reactivity of sera to H77c and UKN3A1.28. 
The reactivity (signal above background) of 36 sera of patients infected with HCV 
genotype 1 and 31 sera of patients infected with HCV genotype 3 (all sera were 
diluted 1/50) to either H77c or UKN3A1.28 was compared, at OD405, as an 
indication for the levels of anti-E1E2. The reactivity of sera infected with HCV 
genotype 1 (A) was significantly higher to H77c than to UKN3A1.28 (p=0.045). 
The reactivity of sera infected with HCV genotype 3 (B) was significantly higher 
to UKN3A1.28 than to H77c (p=0.0007). The horizontal lines represent the 
median values.
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Furthermore, the reactivity of sera of patients infected with HCV genotype 3 
against their homologous E1E2 construct, UKN3A1.28, was significantly higher 
than that of sera from patients infected with HCV genotype 1 against homologous 
E1E2 construct, H77c, (p=0.01).
To confirm these results, the ratio of reactivity of each serum to H77c and 
UKN3A1.28 was calculated (figure 4.6). For the sera derived from patients 
infected with genotype 1, the average ratio of reactivity to H77c/ UKN3A1.28 was 
2.07 and for the sera derived from patients infected with genotype 3, the average 
ratio of reactivity to H77c/ UKN3A1.28 was 0.716, p<0.0001. 
Figure 4.6: Ratio of reactivity of sera to and UKN3A1.28. 
The ratio of reactivity of each serum to H77c and UKN3A1.28. The ratio of 
reactivity of sera derived from patients infected with genotype 1 was >1 (mean; 
2.07), while the ratio of reactivity of sera derived from patients infected with 
genotype 3 was <1 (mean; 0.716) (p<0.0001). The horizontal lines represent the 
mean values.
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4.3.4. Correlation with Viral Load
The reactivity of 54 sera (34 from patients infected with genotype 1 and 20 from 
patients infected with genotype 3) to E1E2 (both H77c and UKN3A1.28) was 
compared with the viral load (range from 600 - 850,000 IU/mL) of each serum. 
The seroreactivity of all sera infected with either genotype 1 or 3 to the 
corresponding E1E2 construct (H77c or UKN3A1.28) was plotted against the viral 
load of each serum. The seroreactivity of the tested sera was inversely proportional 
to the viral load (figure 4.7). The deviation of the slope from zero was significant 
(p=0.0361). 
Figure 4.7: Correlation between reactivity to E1E2 and viral load.
The reactivity of each serum to E1E2, at OD405, is plotted against viral load in 54 
sera infected with either genotype 1 or 3 (tested against corresponding E1E2 
construct). The reactivity to E1E2 was higher in patients with lower viral load 
(p=0.0361).
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4.3.5. Correlation with Liver Disease Severity
To investigate the correlation between the level of anti-E1E2 and the degree of 
liver fibrosis, the reactivity of 28 sera from patients infected with HCV genotype 1 
(17 patients with mild liver fibrosis and 11 patients with severe liver fibrosis) to 
H77c was examined. Also, the reactivity of 23 sera of patients infected with HCV 
genotype 3 (13 patients with mild liver fibrosis and 10 patients with severe liver 
fibrosis) to UKN3A1.28 was examined (figure 4.8). The overall reactivity of the 
tested sera against their homologous E1E2 proteins was significantly higher in 
patients with mild liver fibrosis (Median: 1.719, Range: 0.901-2.305) than in 
patients with severe liver fibrosis (Median: 1.325, Range: 0.827-2.182) (p=0.025). 
Figure 4.8: Correlation between reactivity to E1E2 and degree of liver 
fibrosis. 
The reactivity of 28 sera of patients infected with HCV genotype 1 to H77c and of 
23 sera of patients infected with HCV genotype 3 to 3A1.28, at OD405, is shown in 
relation to the degree of liver fibrosis, mild or severe. Patients with a mild degree 
of liver fibrosis showed a significantly higher level of seroreactivity compared to 
patients with patients with a severe degree of liver fibrosis (p=0.025). The 
horizontal lines represent the median values.
Mild Severe 
0.0
0.5
1.0
1.5
2.0
2.5
R
ea
ct
iv
it
y 
to
 E
1E
2 
(O
D
40
5
)
Chapter 4                                                   Role of Anti-E1E2 in HCV Liver disease
138
As the above data utilised the OD reading of individual sera all tested at the same 
dilution (1/50), a further experimental assay of anti-E1E2 titre was performed to 
validate the findings (figure 4.9). The anti-E1E2 titre was determined by testing 
sera at serial 10-fold dilutions and the titre defined was assigned as the reciprocal 
of the last dilution at which the OD value was greater than the OD of serum 
against negative lysate.
Figure 4.9: Quantitation of anti-E1E2 antibodies. 
The antibody titre of the tested sera was determined by evaluating the anti-E1E2 
reactivity of a 10-fold serial dilution series of sera (from 1/50 to 1/500,000) against 
their homologous E1E2 proteins. The anti-E1E2 titre was determined as the 
reciprocal of the last dilution at which the OD value was greater than the OD of 
serum against negative lysate. The titration of anti-E1E2 antibodies in 2 sera (A 
and B) with a similar OD, demonstrates a different anti-E1E2 titre (marked by the 
red circle).
The relationship between the OD value at a single dilution, and the titre of anti-
E1E2 reactivity was evaluated. By comparing sera from both groups having a 
similar level of reactivity, there was a trend of a higher anti-E1E2 titre in sera from 
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patients with mild HCV liver disease compared to sera from patients with severe 
HCV liver disease (figure 4.10 A).   
Figure 4.10: Correlation between anti-E1E2 antibodies titres and degree 
of liver fibrosis. 
A: The correlation between the reactivity of 25 sera of patients with a mild degree 
of liver fibrosis and of 14 sera of patients with a severe degree of liver fibrosis to 
homologous E1E2, at OD405, and the anti-E1E2 titre of each serum. B: The 
antibody titre of 25 sera of patients with a mild degree of liver fibrosis and of 14 
sera of patients with a severe degree of liver fibrosis is shown in relation to the 
degree of liver fibrosis. The titre of the tested sera against their homologous E1E2 
proteins was significantly higher in patients with mild liver fibrosis than in patients 
with severe liver fibrosis (p=0.0278).  
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The antibody titre of tested sera was evaluated in relation to the degree of liver 
fibrosis. Lower anti-E1E2 reactivity, when expressed as a titre, correlated with 
more severe liver disease (figure 4.10 B) and showed statistical significance 
(p=0.0278), confirming the result obtained previously using the OD value at a 
single dilution.
Several factors are known to be associated with liver disease severity in chronic 
HCV infection, including male sex, age, and duration of infection. The patients in 
this study with severe HCV liver disease were on average 11 years older than 
those with mild disease. No association between age at infection, duration of 
infection or sex and anti-E1E2 reactivity was found (figure 4.11). 
Figure 4.11: Correlation between anti-E1E2 reactivity and confounding 
factors.
Male gender, older age at infection and duration of infection are factors shown to 
be associated with the rate of fibrosis progression. The correlation between anti-
E1E2 reactivity and confounding factors, gender (A) and estimated duration of
infection (B), was evaluated. Anti-E1E2 reactivity showed no significant 
association with either male gender or estimated duration of infection. 
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The sera of 7 patients who progressed from mild to severe fibrosis were also 
examined, by comparing the seroreactivity of their sera in the severe stage with the 
seroreactivity of their sera whilst in the mild stage. The results showed no 
significant difference between the seroreactivity between the two stages (figure 
4.12).
Figure 4.12: Retrospective evaluation of the anti-E1E2 reactivity.
Retrospective evaluation of the anti-E1E2 reactivity in 7 patients who progressed 
from mild to severe fibrosis. By comparing their seroreactivity in the severe stage 
with their seroreactivity whilst in the mild stage, the level of seroreactivity showed 
minimal variation in both stages.
4.3.6. Correlation with Response to Treatment
In order to investigate the relationship between anti-E1E2 reactivity and response 
to therapy, A retrospective assay of the anti-E1E2 level in 50 patients treated with 
standard doses of pegylated interferon and ribavirin combination therapy; 26 
patients infected with HCV genotype 1 and 24 patients infected with HCV 
genotype 3 was performed. These patients were classified into two groups; 25 
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sustained viral responders (SVR) and 25 relapsers and non responders (R/NR). 
Two samples were examined from each patient; the first sample was taken before 
treatment and the second one was taken six months after termination of treatment. 
The pre-treatment level of reactivity against homologous E1E2 proteins was 
significantly higher in SVR than in R/NR (p=0.0256). The seroreactivity of the 
tested sera in SVR was slightly reduced after treatment. However, this reduction in 
the reactivity after treatment was not significant in either group of patients (figure 
4.13). 
Figure 4.13: Correlation between reactivity to E1E2 and responsiveness to 
treatment. 
The reactivity of each serum to its homologous E1E2, at OD405, as an indication 
for the level of anti-E1E2 is shown before and after treatment for sustained viral 
responders (SVR) and relapsers/non-responders (R/NR). Although the post-
treatment reduction of the anti-E1E2 level was not significant in either group, the 
pre-treatment anti-E1E2 level was significantly higher in sustained responders 
(p=0.0256). 
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4.4. Discussion
The role of the antibodies to E1E2 (anti-E1E2) in the pathogenesis of HCV disease 
has been investigated, however, the results are controversial [165, 166]. In this part 
of the study, the level of anti-E1E2 antibodies were evaluated in chronic HCV-
infected patients. Uniquely, the anti-E1E2 antibodies were evaluated using E1E2 
proteins derived from two genotypes (1 and 3) that conferred infectivity in 
pseudoparticle infectivity assay [101].
The reactivity of each serum was assessed to E1E2 proteins from two different 
genotypes. The reactivity of the tested sera was significantly higher to their 
homologous E1E2 than to heterologous E1E2. This higher reactivity may suggest 
the presence of genotype-specific antigens within E1E2, assuming that the various 
E1E2 preparations have a similar proportion of native and denatured aggregates
which might affect epitope exposure and reactivity. By comparing the level of 
anti-E1E2 to the infecting genotype, the level of anti-E1E2 was significantly lower 
in patients infected with genotype 1 than in patients infected with genotype 3. This 
is in contrast to Zampino et al. (2004) who evaluated the level of anti-E1E2 
against antigens derived from a pool of epitopes of different HCV genotypes and 
reported a similarity in the level of E1E2 antibodies among patients infected with 
diverse HCV genotypes. The ability of sera from patients infected with genotypes 
1, 2, and 3 to neutralise to the same extent the binding of recombinant E2 derived 
from genotype 1 has also been reported [208].
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The results showed a significant correlation between higher anti-E1E2 levels and 
lower viral load (figure 4.7). This result suggests a potential protective effect of 
anti-E1E2 against HCV replication, in agreement with Mehta et al. (2002), who 
reported a lower level of viraemia in anti-HCV positive intravenous drug users, 
who previously cleared HCV, when re-infected with HCV. However, other studies 
reported either the absence of significant correlation between anti-E1E2 levels and 
viral load [165, 166], or even a positive correlation between antibodies to HCV 
envelope proteins with hepatitis C viraemia [295], where it was suggested that the 
production of antibodies to HCV envelope protein is driven by HCV replication.
In light of the recent report describing detection of a 5' end subgenome of HCV 
terminating at nucleotide 384 in patients' plasma and liver tissues [296], viral load
results must be interpreted cautiously as they may not give a true value for full 
length viral genome.
The anti-E1E2 antibody level was assessed before and after treatment. The results 
showed a non-significant reduction in the anti-E1E2 level in sustained viral 
responders after treatment. The pre-treatment level of anti-E1E2 was significantly 
higher in sustained viral responders. These results are in agreement with 
Depraetere et al. (2000) and Zampino et al. (2004) who reported that the anti-E1E2 
levels tend to be higher in patients with a long-term or a transient response to 
interferon treatment than in patients who were absolute non-responders, and their 
level tended to be significantly lower after treatment in long-term responders to 
Chapter 4                                                   Role of Anti-E1E2 in HCV Liver disease
145
therapy with HCV clearance than that observed in relapsers and non-responders 
[165, 166]. 
When exploring a possible correlation between anti-E1E2 reactivity and liver 
disease severity, selected sera were deliberately selected from patients with the 
extremes of disease activity. No samples from patients with Ishak 3-4 were tested, 
due to limited number. Significantly higher median values of seroreactivity to 
E1E2 were associated with patients with a mild degree of liver fibrosis (Ishak 
fibrosis stage: 0-2) compared to patients with severe fibrosis (Ishak fibrosis stage: 
5-6). This was true whether the anti-E1E2 reactivity was expressed as an optical 
density value at a single dilution or as a titre, which was used instead of the 
reactivity to discriminate between sera with similar reactivity, at 1/50 dilution, but 
with different antibodies titres. However, there was overlap in anti-E1E2 reactivity 
between the 2 selected groups of patients, and it is not possible to define a cut-off 
value of anti-E1E2 reactivity which differentiates the 2 groups. The relationship of 
confounding factors that are likely to be associated with disease progression was 
analysed to exclude the possibility of independent association with disease 
severity. In 7 patients, the level of anti-E1E2 did not change during progression 
from mild to severe liver disease, suggesting that the lower level of anti-E1E2 in 
patients with severe liver disease is not a consequence of liver disease.
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These data may implicate a modulating effect of anti-E1E2 on HCV disease 
prognosis i.e. a high level of anti-E1E2 is associated with protection against HCV 
liver disease progression. This finding would support studies reporting the ability 
of E1E2 to elicit production of neutralising antibodies against the virus [85, 208, 
297, 298] and the consideration of E1 or E2 as a major candidate for an anti-HCV 
vaccine [211, 214, 297, 299]. However, to elicit a protective antibody response, 
vaccines will require a rational design, targeting production of specific 
neutralizing antibodies against conformation-sensitive epitopes.
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5. Evaluation of Serum L-ficolin levels
5.1. Aim
The main goal in this section was to evaluate the potential role of L-ficolin in 
HCV infection by estimating the serum L-ficolin levels in patients with chronic 
HCV infection. Correlations of L-ficolin levels with viral genotype, viral load, 
response to therapy, and severity of liver disease were investigated.
5.2. Materials and Methods
5.2.1. Materials
Bovine serum albumin (BSA) and acetic anhydride were obtained from Sigma-
Aldrich Company Ltd, Poole, UK. Mouse monoclonal anti-human L-ficolin 
antibody (GN5) was purchased from Hycult Biotechnology.
5.2.2. Patients
The serum levels of L-ficolin were examined in 160 patients with chronic hepatitis 
C obtained from the HCV Trent Study Cohort. All sera were positive for HCV 
antibody and for HCV RNA with determined HCV genotypes. Liver biopsies were 
assessed and scored according to the criteria of Ishak et al. [45]. In a sub-study 
examining a possible correlation between L-ficolin serum level and liver disease 
activity, as previously described in section 4.2.5, sera were specifically chosen 
from patients with either mild (deﬁned as Ishak ﬁbrosis stage 0–2) or severe (Ishak 
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stage 5–6) disease. Samples from 30 blood donors were used as healthy controls. 
A further control population of 32 patients with alcoholic liver disease or non-
alcoholic fatty liver disease was also analysed. Serum samples were stored at         
-72C.
5.2.3. ELISA Assay
An ELISA assay was employed to examine the ficolin levels in serum samples 
from the HCV-infected chronic hepatitis patients and controls, as previously 
described in section 2.2.9.2 (figure 5.1). In brief, MaxiSorb microtiter plates were 
coated with BSA, which was then acetylated by 0.1% acetic anhydride in 
methanol. Serum samples, diluted 1⁄50 in PBS-Tween (in duplicates), were 
incubated overnight at 4 ˚C and then the serum ficolin was detected by mouse IgG 
monoclonal biotin-labelled anti-human L-ficolin antibody, GN5. GN5 antibody 
was biotinylated as previously described in section 2.2.9.1. The plates were 
washed 3 times with wash buffer after each step, using the Denly WellWash plate 
washer. A streptavidin-alkaline phosphatase conjugate and p-nitrophenyl 
phosphate (pNPP) substrate were used and the OD was measured at 405 nm.       
L-ficolin level was determined using a standard curve with a 2-fold serial dilution 
of a pooled human serum of known L-ficolin concentration (4 µg/mL), as a 
reference. Manipulation of patient sera during the ELISA assay, including washing 
steps, was carried out in a class I biological safety cabinet (LEEC) which was 
cleaned with 70% v/v ethanol and 2% Trigene, before and after each manipulation.
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Figure 5.1: Evaluation of serum L-ficolin by ELISA. 
A schematic diagram shows the components of the ELISA assay used to quantify 
serum L-ficolin. The wells were coated with BSA followed by acetic anhydride. 
Serum samples (diluted 1/50, in PBS-Tween) were added and the bound ficolin 
was detected by biotinylated monoclonal anti-L ficolin, GN5. Streptavidin-alkaline 
phosphatase (streptavidin-AP) conjugate was added followed by p-ntirophenyl 
Phosphate (pNPP) substrate. The OD was determined at 405 nm.
5.2.4. Statistical analysis
Statistical analyses were performed using Graphpad prism version 4.03 (Graph
Pad, San Diego, CA, USA). Optical densities of the standard sample were used to 
determine standard curves on a log 10 scale and interpolated X-values were 
obtained. Comparison between groups (non-normally distributed continuous 
variables) was performed using the Mann-Whitney U-test. The genotype variation 
of serum L-ficolin was analysed by a one-way ANOVA test. The correlation 
between L-ficolin level and viral load was analysed using the linear regression 
model. SPSS statistical software (version 14.0, Chicago, IL, USA) was used for 
binary logistic regression analysis, to assess the effect of age as a confounding 
factor. In all tests, a p value of <0.05 was considered statistically significant.
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5.3. Results
5.3.1. Determination of Serum L-ficolin Level
The level of L-ficolin in serum samples from 160 patients with chronic hepatitis C 
infection, 30 healthy blood donors and 32 patients with non-HCV liver disease 
(NHCV) was examined, using ELISA-based assay. A standard curve was created 
using a two-fold serial dilution of a pooled serum (containing 4 µg/mL L-ficolin),
starting from 1/6.25 down to 1/400, which corresponded to L-ficolin concentration 
of 0.64 µg/mL to 0.01 µg/mL (figure 5.2). 
Figure 5.2: A standard curve used for determination of serum L-ficolin 
concentration.
The serum level of L-ficolin was determined by ELISA and calculated using a 
standard curve. A 2-fold serial dilution of a pooled serum (4 µg/mL), from 1/6.25 
down to 1/400 was used and the OD405 of each dilution was plotted against the 
corresponding ficolin concentration (at a logarithmic scale), to create a standard 
curve. The figure is an example of a standard curve used for further determination 
of serum L-ficolin level, based on the OD405 of each serum in the ELISA assay.  
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The optical density values, at 405nm, were plotted against a logarithmic scale of 
ficolin concentration. To overcome the intra assay variation, the standard and the 
serum samples were assayed in duplicates.
5.3.2. Correlation with Demographic Characters
The correlation between serum L-ficolin level and either gender or age was 
examined in 115 patients. The median L-ficolin level in the male patient samples 
(n = 76) was 3.62 µg/mL (range: 0.50-12.52 µg/mL) and the median L-ficolin 
level in the female patient samples (n = 39) was 4.11 µg/mL (range: 1.36-9.15 
µg/mL) (figure 5.3). There was no statistically significant difference in L-ficolin 
levels between the genders (p = 0.37). 
Figure 5.3: Gender correlation with L-ficolin levels.
L-ficolin level in the male and female HCV-infected patients. The difference in    
L-ficolin levels was not statistically significant (p = 0.37). 
The effect of age of HCV-infected patients on the serum level of L-ficolin was 
investigated (figure 5.4). The age of the studied patients ranged from 22 to 78
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years (median = 45 years). There was a tendency toward a reduction in serum       
L-ficolin level in older age, and the linear regression analysis showed a significant 
association (p = 0.01).
Figure 5.4: Age correlation with L-ficolin levels.
Correlation between the age of HCV-infected patients and serum L-ficolin level 
showed statistically significant association (p = 0.01). The older the age of HCV-
infected patients, the lower the serum L-ficolin level.
5.3.3. Correlation with Viral Genotype
The correlation between the viral genotype and serum L-ficolin level was 
examined in 115 patients; 48 patients with HCV genotype 1 infection, 55 patients 
with HCV genotype 3 infection, 8 patients HCV genotype 2 infection and 4 
patients with HCV genotype 4 infection (figure 5.5). Genotypes 1and 3 represent 
the two major genotype groups, while the number of patients infected with HCV 
genotype 2 or 4 is relatively low. The median L-ficolin level in the HCV genotype 
1 infected patients was 3.95 µg/mL (range: 1.01-9.05 µg/mL). The median          
L-ficolin level in the HCV genotype 3 infected patients was 3.67 µg/mL (range: 
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0.50-9.15 µg/mL). The median L-ficolin level in the HCV genotype 2 infected 
patients was 4.85 µg/mL (range: 1.02-12.52 µg/mL). The median L-ficolin level in 
the HCV genotype 4 infected patients was 4.58 µg/mL (range: 2.75-7.2 µg/mL). 
There was no statistically significant difference in L-ficolin levels seen between 
the genotype groups (p = 0.23).
Figure 5.5: Correlation between serum L-ficolin levels and HCV 
genotype.
L-ficolin level in association with the infecting HCV genotype. There was no 
significant association between the infecting HCV genotype and serum L-ficolin 
levels (p = 0.23). 
5.3.4. Correlation with Viral Load
The serum level of L-ficolin in 115 sera was plotted against the viral load of each 
serum and a linear regression analysis was obtained. There was no significant 
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correlation between the level of serum L-ficolin and viral load, p= 0.95 (figure 
5.6). The serum L-ficolin level in the tested sera was variable in patients with 
similar viral loads. The variation extended throughout the range of viral load 
(1,871-874,457 IU/mL). 
Figure 5.6: Correlation between serum L-ficolin levels and viral load.
Correlation between the viral load and serum L-ficolin level showed no 
statistically significant association (p = 0.95).
5.3.5. Correlation with Treatment Outcome
Forty five HCV-infected patients were divided according to their response to 
treatment, with pegylated interferon plus ribavirin, into two groups; sustained viral 
responders (SVR), and relapsers and non responders (R/NR). A retrospective assay 
of the serum L-ficolin level in 22 sustained viral responders and 23 relapsers and 
non responders was performed, before treatment and after termination of the 
treatment course (figure 5.7). The ficolin levels in the tested sera did not show a 
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significant difference before and after treatment in either sustained viral 
responders (p = 0.77) or in relapsers and no responders (p = 0.32). In addition, the 
pre-treatment level of L-ficolin did not show a significant difference between the 
sustained viral responders (median: 4.93; average: 0.35-7.85 μg/mL) and the 
relapsers and non responders (median: 5.25; average: 2.50-9.01 μg/mL). 
Figure 5.7: Correlation between serum L-ficolin level and response to 
treatment.
Serum L-ficolin level was evaluated before and after termination of treatment in 
22 sustained virologic responders (SVR) or in 23 relapsers and non responders 
(R/NR). No significant correlation was seen between pre- and post-treatment 
levels of L-ficolin and response to treatment in sustained virologic responders or in 
relapsers and non responders. Also, no significant difference was detected between 
the pre-treatment levels of L-ficolin in both groups of patients.
5.3.6. Correlation with Disease Severity
To investigate the correlation between the serum L-ficolin level and the degree of 
HCV liver ﬁbrosis, the L-ficolin level in 36 sera from patients with mild HCV 
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liver ﬁbrosis and 17 patients with severe HCV liver ﬁbrosis was examined (figure 
5.8). The serum L-ficolin level was higher in patients with mild liver ﬁbrosis 
(median: 4.13 µg/mL; range: 2.39–12.52 µg/mL) than in patients with severe liver 
ﬁbrosis (median: 3.23 µg/mL; range: 1.02–6.33 µg/mL) (p = 0.015). This result 
demonstrates an association between serum L-ficolin level and HCV liver disease 
severity.
Figure 5.8: Correlation between L-ficolin serum level and degree of liver 
fibrosis. 
Patients with a mild degree of HCV liver fibrosis showed a significantly higher 
level of L-ficolin compared to patients with a severe degree of HCV liver fibrosis 
(p = 0.015). Although, patients with a mild degree of non-HCV liver fibrosis 
showed a higher level of L-ficolin compared with patients with a severe degree of 
non-HCV liver fibrosis, this difference was not significant. The horizontal bars 
represent the median values.
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Patients with non-HCV (NHCV) liver disease, namely alcoholic liver disease and 
non alcoholic fatty liver disease, were also divided into those with mild fibrosis    
(n = 22) and those with severe fibrosis (n = 10). They showed lower serum          
L-ficolin levels in patients with severe liver disease than in patients with mild liver 
disease. However the difference was not statistically significant (p = 0.32). The 
median L-ficolin level in the healthy control group (n= 30) was 4.4 µg/mL. The 
difference in L-ficolin level between the severe HCV liver cirrhosis (n = 17) and 
the healthy control group was found to be statistically significant with a p value of 
0.01. No such statistical significance was achieved between the severe non-HCV 
liver fibrosis groups and the healthy control group (p = 0.074). 
The age, previously found to be negatively correlated with serum L-ficolin level in 
patients with HCV liver disease (figure 5.4), is one of the host factors that may 
affect the liver fibrosis progression in HCV liver disease. The age of the examined 
HCV-infected patients significantly correlated with disease progression (p = 
0.001). Thus, it could potentially have a confounding effect on the serum L-ficolin 
level and liver fibrosis relationship. Binary logistic regression analysis was 
performed using age as a covariant with L-ficolin concentration. The p value for 
L-ficolin concentration was different in the adjusted model. However, both serum 
L-ficolin level (p = 0.03, OR = 0.491, 95% CI = 0.257-0.935) and age (p = 0.021, 
OR = 1.098, 95% CI = 1.014-1.189) remained significantly associated with liver 
disease severity.      
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The L-ficolin level was also determined in the sera of five patients who had 
biopsy-proven disease progression from mild to severe liver fibrosis (figure 5.9). 
There was a tendency for L-ficolin level to decrease concurrently with progression 
of the liver cirrhosis from mild to severe. However, the values were not 
statistically significant (p = 0.15).
Figure 5.9: Retrospective evaluation of serum L-ficolin level.
 Retrospective evaluation of serum L-ficolin level in 5 HCV-infected patients who 
progressed form mild to severe liver disease. The level of L-ficolin had a 
propensity to decrease as the fibrosis proceeded from mild to severe. However, the 
reduction was not statistically significant, p = 0.15.
5.3.7. Correlation with Anti-E1E2
To examine the correlation between both serum L-ficolin level and the level of 
anti-E1E2, the serum L-ficolin concentration in HCV-infected patients was 
compared to the reactivity against E1E2 proteins (the E1E2 antigen used was 
homologous to the infecting HCV genotype in the tested sera) (figure 5.10). Linear 
regression analysis revealed the absence of correlation between the serum             
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L-ficolin concentration and the level of anti-E1E2 in the examined sera (n = 80), p 
= 0.69. 
Figure 5.10: Correlation between L-ficolin serum level and seroreactivity 
to E1E2.
Linear regression analysis revealed absence of a significant correlation between 
the level of serum L-ficolin and seroreactivity of the tested sera to E1E2 protein, p 
= 0.69.
5.4. Discussion
Serum L-ficolin level in patients with chronic HCV infection was determined by 
an ELISA assay in order to explore the clinical impact of L-ficolin binding to 
HCV and its possible effect on HCV disease outcome. The level of serum             
L-ficolin was correlated with viral load, infecting HCV genotype, disease severity 
and response to treatment, to find out the possible associations.
Starting by correlation with demographic characteristics of the examined patients, 
serum L-ficolin level showed a significant inverse relationship with age with no 
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correlation with gender. Kipatrick et al., reported the absence of relationship 
between L-ficolin serum level and either sex or age in healthy blood donors [300]. 
The significant negative correlation between the age and serum L-ficolin 
concentration in HCV-infected patients could be a reflection of the association 
between age and disease severity. The L-ficolin level did not correlate with the 
infecting HCV genotype or the viral load in the tested sera. As L-ficolin showed a
neutralising effect on HCV pseudoparticle infectivity, it was expected that 
circulating L-ficolin might reduce virus load and diminish the pathogenesis of 
HCV infection. However, the role of L-ficolin as an immunoprotective agent
against viral replication is not evident. It may be possible that a high viral 
replication can overwhelm the L-ficolin in the serum. There was no apparent 
relationship between L-ficolin concentration and the response of HCV-infected 
patients to treatment with ribavarin and pegylated interferon. Similarly, Kilpatrick
et al., reported that MBL concentration had no significant association with
response to antiviral therapy, in HCV-infected patients [278].
The only positive implication of the serum levels of L-ficolin in the context of 
HCV disease was the lower serum L-ficolin levels in patients with a severe degree 
of HCV liver ﬁbrosis (Ishak ﬁbrosis stage: 5–6) compared to patients with mild 
HCV ﬁbrosis (Ishak ﬁbrosis stage: 0–2) and to the healthy controls. The median   
L-ficolin level in the healthy control group (4.4 µg/mL) was comparable to the 
literature. Le et al., reported an average serum L-ficolin level of 4.13 µg/mL [217]
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and Kilpatrick et al. reported a median serum L-ficolin concentration of 3.7 µg/mL 
and most values were below 6.0 µg/mL [300]. There was an overlap in L-ficolin 
levels between the two groups of patients, with no clear cut-off value of L-ficolin 
level to differentiate the two groups. A lower extent of reduction in L-ficolin levels 
was also observed in patients with severe non-HCV liver fibrosis. The L-ficolin 
level retained its significant association with liver disease severity even after 
adjustment using the age, which was associated with liver disease severity in 
chronic HCV infection, as a covariant. 
These data, supported by the ability of L-ficolin to bind HCV glycoproteins 
(shown in sections 3.2.5 and 3.2.6) and to neutralise HCV pseudoparticle 
infectivity (shown in section 3.2.7), may implicate a modulating effect of L-ficolin 
on HCV disease prognosis i.e. a high level of L-ficolin may be associated with 
protection against HCV liver disease progression. A similar observation of 
children with lower levels of L-ficolin being more prone to recurrent respiratory 
infections has been reported [268]. Nevertheless, this finding should be carefully 
interpreted as L-ficolin is synthesised in the liver [218] and thus the reduction in 
the serum L-ficolin level in patients with severe liver fibrosis could be simply a 
result of decreased ficolin production by damaged hepatocytes as a previous study 
has reported a reduction of L-ficolin levels in liver disease with increasing severity 
of liver cirrhosis [228]. This cessation in L-ficolin production by the cirrhotic liver 
explains the relative reduction in serum L-ficolin level found also in non-HCV 
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patients with severe liver fibrosis and the tendency towards reduction in serum     
L-ficolin level in patients who progressed from mild to severe liver disease. 
From another point of view, it is possible that the binding of L-ficolin to HCV 
particles plays a role in liver fibrosis. L-ficolin, like MBL, activates MASP-1, 
which has similar proteolytic activity to thrombin on fibrinogen and factor XIII 
[280-282]. An association between MBL/MASP-1 enzymatic activity and the 
severity of fibrosis in HCV patients was previously demonstrated [279]. By such a 
pathway, L-ficolin may contribute to the pathogenesis of liver fibrosis and in this 
case serum L-ficolin level could be a marker of HCV-induced fibrogenesis. 
Although a higher level of anti-E1E2 antibodies (judged by measuring the 
reactivity to E1E2) was implicated as a protective modulator in HCV liver disease 
progression (previously described in section 4.3.5), there was no correlation 
between serum L-ficolin level and the level of anti-E1E2 in HCV-infected 
patients. This would suggest an independent effect of both anti-E1E2 and L-ficolin 
as immune mediators against HCV.
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6. General Discussion and Future Work
HCV infection is an important worldwide health problem, affecting 170 million 
people [3]. It causes acute and chronic hepatitis, and liver cirrhosis [2]. It 
represents an important risk factor for development of hepatocellular carcinoma 
[20]. Data suggest that it will continue as a major health burden, at least in the near 
future [6, 17]. The person-to-person variability in HCV outcome is subject to host 
and viral factors [27-29]. HCV envelope glycoproteins, E1 and E2, are 
glycosylated transmembrane proteins essential for host-cell entry [98, 99]. They
bind to receptors such as CD81 and SR-B1 and induce fusion with the host-cell 
membrane [101, 102]. They also provide a target for host immune recognition [56, 
106]. 
The host immune response plays contrasting roles in the pathogenesis of viral 
hepatitis by contributing either to viral control and clinical recovery, or to the 
development of liver cirrhosis [23, 173], which is the main complication of 
chronic liver disease in HCV-infected patients. This project represents an 
investigation into the role of two immune mediators; L-ficolin and anti-E1E2 in 
HCV liver disease. 
Chapter 6                                                         General Discussion and Future Work
164
6.1. L-ficolin Binding to HCV Glycoproteins
The main hypothesis before beginning this work was that L-ficolin could interact 
with HCV glycoproteins, that have multiple N-linked glycosylation sequons in the 
primary sequence, and thus may affect the course of viral infection. The binding of 
L-ficolin to target surfaces depends on the interaction of fibrinogen-binding 
domain with an array of carbohydrates across different N-glycans. L-ficolin has a 
preference for binding to N-acetyl glucosamine (GlcNAc) residues. Specific 
interactions between L-ficolin and HCV were demonstrated in terms of binding to 
HCV glycoproteins sE2 and ElE2 heterodimers by ELISA. This is the first 
biochemical analysis demonstrating the binding interaction of L-ficolin with HCV 
envelope glycoproteins. The ability of L-ficolin to bind to authentic HCV particles 
in patients’ sera was also demonstrated by immune precipitation of HCV particles 
containing viral RNA either with L-ficolin-anti L-ficolin GN5-coated beads or anti 
L-ficolin GN5-coated beads. This ex vivo interaction implies the presence of an 
accessible conformation of glycans with GlcNAc moieties on HCV particles 
circulating during infection and suggests that at least a fraction of circulating HCV 
may form complexes with L-ficolin in vivo. 
6.2. L-ficolin Functions in HCV Infection
6.2.1. Neutralisation Activity
As an innate immune molecule that binds to HCV glycoproteins, it would be 
expected that L-ficolin has a beneficial effect in limiting infection in the early 
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stages before the development of specific adaptive immunity. Thus, to evaluate the 
potential clinical relevance of L-ficolin binding to HCV glycoproteins, the 
functional consequence of this binding interaction was addressed by the inhibition 
of infection in the HCV pseudoparticles system. Recombinant L-ficolin resulted in 
neutralisation of HCV pseudoparticle infectivity of two strains of HCV (H77c and 
UKN2B1.1), in a dose-dependent manner, and completely inhibited infection of 
UKN2B1.1 at a concentration of 6 μg/mL. This concentration is slightly above the 
average level of L-ficolin in clinical samples of healthy blood donors examined in 
this study (4.4 μg/mL) or in other studies which reported an average serum           
L-ficolin level of 3.7 µg/mL [300] and 4.13 µg/mL [217] in healthy populations. 
This is the first study to demonstrate the in vitro neutralisation capacity of            
L-ficolin in the HCV pseudoparticles system.
6.2.2. Role in Disease Progression
The neutralising effect of circulating L-ficolin might reduce virus load and 
diminish the pathogenesis of HCV infection. In addition, L-ficolin binding to HCV 
might activate the complement system, assisting in viral clearance through 
activation of serine proteases that activate the lectin complement pathway.          
L-ficolin levels were measured in HCV and non-HCV patient serum samples. 
Patients with mild HCV liver fibrosis had a significantly higher level of L-ficolin 
compared to patients with severe HCV liver fibrosis. However, the reduction of    
L-ficolin level in patients with severe HCV liver fibrosis could be a result of 
Chapter 6                                                         General Discussion and Future Work
166
impaired hepatocyte productivity of L-ficolin, rather than a causal ability to 
modify HCV disease outcome. Further investigations with increasing the numbers 
of HCV-infected patients and control groups would provide more clear 
conclusions.
It may be difficult to draw a conclusion on the role of serum L-ficolin levels in the 
context of HCV liver disease, as the L-ficolin levels in this study were examined 
in clinical samples from patients with chronic HCV infection. The median duration 
of infection at time of sample collection was 18 years, range from 4-37 years. With 
determination of a neutralisation effect of L-ficolin in the HCV pseudoparticle 
infectivity assay, the effect of L-ficolin in HCV liver disease could be more 
relevant in the early phases of infection. Evaluation of the role of L-ficolin in the 
early stages of HCV infection requires the availability of samples from HCV 
patients with newly-acquired infection, who subsequently cleared the virus. 
Simultaneous measurement of serum L-ficolin and viral load in serum samples of 
acutely-infected HCV patients may indicate a correlation and allow exploration of
the implications of serum ficolin levels in the context of HCV disease. However, 
this will be difficult to achieve, as acute resolving HCV cases represent only 20% 
of newly infected patients and they are mostly asymptomatic and thus, undetected 
[18]. 
Chapter 6                                                         General Discussion and Future Work
167
6.2.3. Role in Liver Fibrosis
The development of liver cirrhosis is the main complication of chronic liver 
disease in hepatitis C virus infected patients and is the gateway for the genesis of 
hepatocellular carcinoma. Despite the neutralising effect of L-ficolin that might 
result in controlling viral infection, it is possible that the binding of L-ficolin to 
HCV particles plays a role in liver fibrosis. Ficolins activate MASP-1, which has 
similar proteolytic activity to thrombin on fibrinogen and factor XIII [280-282]. 
Thus, it can stimulate the conversion of fibrinogen into fibrin and promote fibrosis 
in the liver. An association between MBL/MASP-1 enzymatic activity and the 
severity of fibrosis in HCV patients has been previously demonstrated [279]. 
Based on the functional similarity between L-ficolin and MBL in activating the 
lectin pathway, it is possible to assume that L-ficolin may contribute to the 
pathogenesis of HCV-induced liver fibrosis and progression of disease pathology.
However, L-ficolin activity as an independent factor related to liver cirrhosis has 
not been examined in this study. This functional activity may augment the role of 
L-ficolin, as an innate immune mediator, in HCV liver disease to be effective not 
only in early stages (controlling circulating virus and neutralising infectivity), but 
also in late stages of HCV liver disease. Another potential pathway for 
development of fibrosis could be initiated by binding of L-ficolin to late apoptotic 
cells [301], in severe HCV infection where there is destruction of hepatocytes. The 
ficolin binding to hepatocytes and subsequent complement-coagulation cascade 
activation may result in the progression of liver fibrosis.
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6.3. L-ficolin as a Biotherapeutic
The ability of L-ficolin to neutralise HCV infectivity may be beneficial in terms of 
therapeutic vaccine development. Administration of L-ficolin as an adjuvant to an 
HCV vaccine may also increase uptake and antigen presentation for the 
development of an effective adaptive immune response. However, as L-ficolin 
may have potentially antagonistic roles in HCV infection, the possible role for      
L-ficolin in antiviral therapy in the future management of HCV-infected patients
must be cautiously considered. The possibility that L-ficolin may interact with 
MASP-1 and lead to an increase in activity makes L-ficolin therapy seem to be 
inappropriate during HCV infection.
6.4. Role of anti-E1E2 in HCV Liver Disease
The level of anti-E1E2 detected, using two different E1E2 constructs representing 
HCV genotypes 1 and 3, in HCV-infected patients was dependent on the genotype 
from which the E1E2 antigen preparation was derived. This result suggests that at 
least part of the antibody response is to genotype-specific antigens. Levels of anti-
E1E2 against homologous antigens were higher in patients infected with genotype 
3 (which is more associated with responsiveness to treatment) than genotype 1, 
which may impact on the differences between the genotypes in their clinical 
course and disease association. The level of anti E1E2 was inversely proportional 
to the viral load and the degree of liver fibrosis, which suggest a potential 
protective effect of anti-E1E2 against viral replication and disease progression.   
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6.5. Future Work
The functional activities of L-ficolin in controlling of a range of infectious 
diseases include opsonisation, neutralisation and complement activation. To date 
there have been no published studies on the interaction of L-ficolin with HCV. 
This study characterises the binding of L-ficolin to HCV glycoproteins. 
Neutralisation assay also showed that such binding is sufficient to prevent HCV 
pseudoparticles from infecting cells. It is an interesting field to be explored and it 
is quite clear that further studies are required to provide better understanding of the 
role of L-ficolin as an innate immune defence against HCV in HCV disease. 
As L-ficolin has similar activity to MBL, the role of L-ficolin/MASPs complexes
in the pathogenesis of liver cirrhosis through the complement and coagulation 
pathways could be further investigated. Studies to investigate the functional 
activation of MASPs on binding of L-ficolin to HCV glycoproteins are required. 
The L-ficolin associated functional activity could be examined by assays for         
L-ficolin/MASP-1 and MASP-2 activity upon binding to HCV glycoproteins. 
MASP-1 activity could be assayed using the Val-Pro-Arg-7-amino-4-methyl 
coumarin substrate. MASP-2 activity could be evaluated by testing of the ability of 
L-ficolin/EIE2 to cause C4 deposition. 
HCV genotypes differ in their nucleotide sequences by 31–34%, and in their 
amino acid sequences by ～30% [47, 64]. Some differences between HCV 
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genotypes in sequence may affect the glycosylation pattern of E1E2, and thus the 
binding ability to L-ficolin. Therefore, the binding of L-ficolin to E1E2 
heterodimers expressed from a representative panel of HCV genotypes could be 
tested.
As HCV glycoproteins provide a target for immune interaction by anti-E1E2 
antibodies, determination of the specific patterns of glycans required for L-ficolin 
binding would assist in understanding the role of L-ficolin in binding to HCV. 
E1E2 mutants with different glycosylation patterns could be tested for a potential 
effect on binding activity. For blocking with antibodies and competition assays, 
E1E2 could be captured by ALP98, then detection of ficolin binding could be done 
with biotinylated GN5. 
L-ficolin has functional polymorphic sites that regulate both expression as well as 
function. Single nucleotide polymorphisms (SNPs) in the promoter region of the 
L-ﬁcolin gene are associated with changes in the serum concentration [235]. 
Alternatively, SNPs reported in the exon 8, encoding the fibrinogen-like domain, 
are associated with change in GlcNAc binding ability [267]. Investigation of these 
polymorphisms in the context of HCV liver disease could be performed to assess 
the possible relationship with HCV liver disease severity and progression. 
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A further study to investigate the profile of reactivity of a particular serum to 
different E1E2 preparations from different genotypes in native and denatured 
states is required to determine the cross reactivity and epitope specificity of 
antibody response during chronic HCV infection. This would provide a better 
understanding of the regions of the HCV envelope glycoproteins recognized by 
antibodies.
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7. Appendix 
7.1. Publications
7.1.1. J Viral Hepatitis, 2008. vol 15 (5): p339-45.
Hamed MR, Tarr AW, McClure CP, Ball JK, Hickling TP, Irving WL.
“Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) 
with HCV disease”.
Hepatitis C virus (HCV) causes acute and chronic liver diseases in humans. Its two 
envelope glycoproteins, E1 and E2, provide a target for host immune recognition. 
To study the role of anti-HCV E1 and E2 (anti-E1E2) in HCV disease, the 
correlation between antibody level and viral load, genotype, disease severity and 
response to treatment was investigated. The levels of antibodies to HCV 
glycoproteins E1 and E2 antibodies were evaluated in 230 sera of patients with 
chronic hepatitis C by enzyme-linked immunosorbent assay. The antigens used 
were recombinant HCV glycoproteins derived from genotype 1 (H77c) and 
genotype 3 (UKN3A1.28). Seroreactivity was greater when sera were tested 
against antigen derived from their homologous genotype than against heterologous 
antigen. Reactivity against UKN3A1.28 in sera from patients infected with 
genotype 3 was significantly higher than corresponding reactivity between patients 
infected with genotype 1 and H77c. The seroreactivity was inversely proportional 
to the viral load and to the degree of liver fibrosis. The pre-treatment level of anti-
E1E2 was higher in sustained responders to combination therapy. These results 
demonstrate that seroreactivity against E1E2 depends upon the genotypic origin of 
the E1E2 antigens and the infecting genotype, and suggest a possible protective 
effect of anti-E1E2 against disease progression.
7.1.2. PLoS Pathogens, Submitted July 2009. 
Mohamed R. Hamed, Richard J. P. Brown, Anders Krarup, C. Patrick McClure 
Robert B. Sim, Jonathan K Ball, William L. Irving, Alexander W. Tarr & Timothy 
P. Hickling
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“The Human Soluble Lectin L-Ficolin Neutralises Entry of Hepatitis C Virus by 
Binding to the E1 and E2 Surface Glycoproteins”
Liver ficolin (L-ficolin) is a soluble pattern recognition molecule of importance in 
innate immune defence against microorganisms. Upon binding to specific 
pathogen-associated carbohydrates, L-ficolin activates the lectin complement 
pathway, resulting in opsonisation or lysis of pathogens. We hypothesised that      
L-ficolin might play a role in host defence against Hepatitis C Virus (HCV). In 
this study, both recombinant N-terminal FLAG-tagged L-ficolin and L-ficolin 
purified from serum were investigated for binding to the envelope glycoproteins 
E1 and E2 of HCV. Specific, dose-dependent binding of L-ficolin to HCV 
glycoproteins E1 and E2 was observed. This interaction was inhibited by soluble 
ligands for L-ficolin. The interaction between L-ficolin and HCV particles in 
infected sera was also demonstrated. Interaction between L-ficolin and HCV 
glycoproteins E1 and E2 potently neutralised entry of retroviral pseudoparticles 
bearing these glycoproteins. This is the first description of direct neutralisation of 
HCV entry by a soluble innate immune molecule. These results implicate L-ficolin 
as a previously undescribed element of the immune defence against HCV 
infection.
7.2. Presentations and Posters
7.2.1. Presentations
7.2.1.1. 160th Society for General Microbiology Meeting
University of Manchester, UK, 26-29 March 2007.
“Role of Antibodies to HCV Glycoproteins E1E2 in HCV Liver Disease”.
7.2.1.2. 5th UK Meeting on Biology and Pathology of HCV
Rydal Hall, Ambelside, UK, 27-29 April 2007.
“Role of Human Serum L-Ficolin in HCV Disease”
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7.2.1.3. 162th Society for General Microbiology Meeting
Edinburugh, Scotland, UK, 31 March - 3 April 2008.
“L-Ficolin/HCV Binding Interaction in HCV Disease”
7.2.1.4. Institute of Clinical Research Annual Meeting
University of Nottingham, UK, 10 June 2008.
“Association of Antibodies to Hepatitis C Virus Glycoproteins 1 and 2 (anti-E1E2) 
with HCV Disease”. 
7.2.2. Posters
7.2.2.1. 14th International Symposium on HCV and Related 
Viruses
Glasgow, Scotland, UK, 9-13 September 2007.
“Role of Human Serum L-ficolin in HCV Disease”.
 7.2.2.2. 15th International Symposium on HCV and Related 
Viruses
San Antonio, Texas, USA, 5-9 October 2008. 
“The Role of Soluble Lectin L-ficolin in HCV Immune Recognition”
7.2.2.3. 44th Annual Meeting of the European Association for 
the Study of the Liver
Copenhagen, Denmark, 22-26 April 2009.
“Role of Soluble Lectin L-ficolin in HCV Immune Recognition in Hepatitis C 
Virus Infection”.
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7.3. Prizes
7.3.1. 1st Runner Up, Best Poster Prize
Second Postgraduates Research Day, School of Molecular Medical Sciences, 
University of Nottingham, 25 June 2007.
“Humoral Immune Responses to HCV: Role of Anti-E1E2 and L-ficolin”.
7.3.2. Best Poster Prize (Peer Review)
Graduate School Poster Competition, University of Nottingham, 7 May 2008.
“A Potential Target for Vaccine Production against Hepatitis C Virus”.
7.3.3. European Association for the Study of the Liver 
Young Investigator Bursary Award.
Copenhagen, Denmark, 22-26 April 2009.
“Role of Soluble Lectin L-ficolin in HCV Immune Recognition in Hepatitis C
Virus Infection”.
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